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ABSTRACT
Acute kidney injury (AKI) and chronic kidney disease (CKD) are 
serious illnesses associated to high mortality and unsatisfactory 
therapeutic treatments. In search for new therapies, it has become 
evident that stem cells could be a possible option for patients with AKI 
and CKD.
The evidence of the renoprotective effect of bone marrow-mesenchymal 
stem cells (BM-MSCs) in experimental model of AKI, prompted us to 
study the effect of stem cells isolated from sources that are more 
accessible as cord blood (CB) and amniotic fluid. Infusion of hCB-MSCs 
in immunodeficient mice with AKI ameliorated renal function and 
tubular structure, prolonging survival. Moreover, transplanted hCB- 
MSCs localized in peritubular areas, limiting oxidative stress and 
apoptosis. By virtue of stem cell capacity to produce growth factors, 
hCB-MSCs were able to induce the pro-survival factor Akt in tubular 
cells and subsequently their proliferation.
Using the well-established model of AKI in immunodeficient mice, we 
studied the pro-regenerative effect of amniotic fluid stem (hAFS) cells. 
Infusion of hAFS cells in cisplatin-mice improved renal function and 
limited tubular damage, although not to control level, and prolonged 
animal survival. These cells engrafted injured kidney predominantly in 
peritubular region and through a paracrine mechanism are able to exert 
an anti-apoptotic effect, to activate Akt and stimulate proliferation of 
tubular cells. We enhanced the therapeutic potential of hAFS cells by 
cell pre-treatment with GDNF, which markedly ameliorated renal 
function and tubular injury by increasing stem cell homing to the 
tubulointerstitial compartment.
In AKI models, the renoprotective effect of BM-MSCs is well 
established, however the role of these stem cells in model of CKD is 
controversial and not demonstrated so far. Therefore, we tested the 
effect of BM-MSCs in a model of adriamycin-induced nephropathy. 
Repeated infusions of BM-MSCs limited podocyte loss, and normalized 
distribution of parietal epithelial cells along the Bowman's capsule, 
reducing glomerulosclerosis. Moreover, through the local release of 
growth factors as VEGF, BM-MSCs were able to provide a local pro­
survival environment that limited glomerular inflammation and 
microvascular rarefaction.
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CHAPTER 1
INTRODUCTION
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1.1 Acute kidney injury
Acute kidney injury (AKI), formerly known as "acute renal 
failure" (ARF) is a common clinical problem with increasing incidence, 
serious consequences, unsatisfactory therapeutic options, and an 
enormous financial burden to society (Devarajan et ah, 2006). AKI is a 
complex disorder that comprises multiple causative factors and occurs 
with varied clinical manifestations that range from minimal but 
sustained elevation in serum creatinine to anuric renal failure. AKI is 
classically characterized by the rapid deterioration of renal function, 
with at least a 50% decrease in glomerular filtration rate (GFR) that 
leads to accumulation of nitrogenous wastes such as blood urea 
nitrogen (BUN) and creatinine (Devarajan et ah, 2006).
The incidence of AKI in hospitalized patients has generally been 
reported to be in the 2 %-7% range, with an incidence of 5% to greater 
than 10% in the intensive care unit (ICU) patients (Lamiere N et ah, 
2006; Waikar S et ah, 2008). Despite advances in preventive strategies 
and support measure, over the last 20 years, the incidence of AKI has 
remained stable, probably due to the therapeutic use of new more 
aggressive nephrotoxic drugs, more invasive procedures and increasing 
age of the patient population. Moreover, AKI has remained associated 
with high morbidity and mortality, particularly in ICU, where mortality 
rates may exceed 50%. In addition to mortality rates, there are chronic 
consequences even in patients survive their acute illness, with a high
2
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risk to develop or exacerbate chronic kidney disease (Coca et al. 2009; 
Hsu et al. 2009).
Traditionally, the causes of acute kidney injury are classified as 
pre-renal due to inadequate perfusion, intrinsic, renal or parenchymatous 
due to injury to renal parenchyma, and post renal or obstructive due to 
obstruction of outflow (Figure 1.1). The pre-renal AKI occurs when there 
is a volume depletion caused by renal or extra renal losses, fluid 
sequestration, or inadequate perfusion pressure (Lattanzio et al 2009). 
Patients with pre-renal AKI can exhibit, at least at the beginning of the 
disease, intact glomerular and tubular structure. Among hospitalized 
patients, pre-renal AKI can be consequence of liver dysfunction, 
nephritic syndrome, intestinal obstruction, decreased cardiac output 
(cardiogenic shock, myocarditis, myocardial infarction, etc.); in surgical 
patients, pre-renal azotemia is a common cause of peri- and post­
operative renal dysfunction. Moreover, among the pre-renal causes of 
AKI, there are peripheral vasodilatation (hypotension, sepsis, 
hypoxemia, etc), renal vasoconstriction (prostaglandin synthesis 
inhibition, sepsis, hepatorenal syndrome, hypercalcemia) or efferent 
arteriole vasodilatation. If the underlying cause is corrected, the AKI is 
rapidly reversible.
In intrinsic AKI, the decrease in GFR is secondary to intrinsic renal 
damage mainly affecting tubules (acute tubular necrosis, ATN), 
interstitium (acute tubulointerstitial nephritis), glomeruli a n d /o r  
vessels (acute glomerulonephritis, vascular occlusion). Injury to the
3
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tubules most often is caused by ischemia or nephrotoxins, and ATN has 
composed by three phases: initiation, maintenance, and recovery. The 
classic course of "self-limited" ATN is the steady rise in serum 
creatinine levels (injury stage), followed by stabilization, and an 
eventual decline in those measures during 7 to 21 days. Acute 
interstitial nephritis is an interstitial disturbance that often results from 
an allergic reaction to drug. Symptoms include fever, rash, and serum 
and urine eosinophil counts may be elevated. Autoimmune disease, 
infection and infiltrative disease also can lead to interstitial nephritis 
(Lattanzio et al. 2009). Glomerulonephritis, an uncommon cause of AKI, 
has systemic manifestations as fever, rush and arthritis. Urine finding 
include red blood cell casts, haematuria, and proteinuria. Finally, 
vascular disease can occur on the micro- and macrovascular levels. 
Microvascular disease is commonly secondary to small-vessel 
thrombosis or occlusion. Macrovascular causes should include renal 
stenosis or thrombosis, aortic disease or acute dissection (Lattanzio et al. 
2009).
Post-renal causes of AKI result in obstruction of the outflow tracts of the 
kidney. It can be due to congenital anomalies, prostatic hypertrophy, 
retroperitoneal fibrosis and, less frequently, to bilateral renal calculi or 
to malignant conditions. Drugs and infections might also cause post- 
renal AKI. Approximately 10% of AKI cases are the result of post-renal 
causes that are readily reversible (Lattanzio et al. 2009).
AKI is usually treated by targeting the underlying causes. In
4
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certain situations, such as when a patient has glomerular disease, 
microvascular disease or obstructive disease, rapid diagnosis and 
treatment are necessary to prevent permanent renal damage. However, 
once AKI develops, supportive therapy is critical to maintain fluid and 
electrolyte balances, minimize nitrogenous waste production and 
sustain nutrition. Before the development of renal replacement therapy, 
many people with AKI died from severe electrolyte imbalance 
(hyperkalemia, acidosis) or from the uraemic toxins themselves. The 
treatment of AKI with renal replacement therapy has the objective to 
maintain fluid and electrolyte, acid-base, and solute homeostasis, to 
prevent further insults to the kidney and to promote healing and 
recovery. However, modern dialysis techniques, such as continuous 
renal replacement therapy, have had no significant impact on overall 
mortality. Over the last thirty years, despite advances in supportive 
care, very little clinical progress has been made for decreasing renal 
dysfunction and mortality. The quest for a pharmacological therapy 
that could improve survival after an AKI episode has been largely 
unsuccessful. Numerous pharmacologic agents have been tested with 
successful results in preventing or ameliorating experimental AKI (Star 
et ah, 1998). However, none of these substances have been translated 
successfully to clinical practice. Negative clinical trial experience with 
dopamine, furosemide, mannitol, calcium channel blockers, atrial 
natriuretic peptide and several other hormonal or pharmacological 
substances has been reported (Grino et al, 1994; Haug et al., 1993).
5
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Several studies have also evaluated the role of growth factors as 
epidermal growth factor (EGF), insulin growth factor-1 (IGF-1) and 
hepatocyte growth factor (HGF), possibly because their mitogenic and 
pro-survival activity (Nigam et ah, 2000; Toubeau et ah, 1994), but also 
because many types of renal cells express the receptor for this growth 
factors. In an animal model of ATN, EGF treatment enhanced renal 
tubule cell regeneration and accelerated the recovery of renal function. 
(Coimbra et al., 1990; Humes et ah, 1989; Norman et ah, 1990). The same 
was obtained with IGF-1. In ischaemic and toxic ATN, the pre­
treatment with IGF-1 or treatment within 24 hours of damage 
accelerated renal recovery (Ding et ah, 1993; Miller et ah, 1992). 
Administration of HGF in a mouse model of AKI induced by cisplatin, 
at the time of renal injury, accelerated renal recovery by reducing serum 
urea nitrogen and the severity of pathological changes (Kawaida et ah, 
1994; Miller et ah, 1994).
Although in animal models good results have been obtained, 
clinical trials in humans with AKI have failed to show substantial 
benefit of these growth factors as cure of a disease that contributes 
significantly to morbidity and mortality in severely ill patients. 
(Franklin et ah, 1997; Hirschberg et ah, 1999).
The failure of the pharmacological therapies tested, increasingly 
makes necessary to identify new treatments. At this purpose, a large 
body of literature reported an emerging role for stem cells, discussed 
later in this chapter, in the regenerative mechanisms of the kidney.
6
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1.1.1 Pathophysiology of acute kidney injury
The following part of the chapter will focus primarily on acute 
tubular necrosis (ATN), the most common cause of acute kidney injury. 
In the ischaemic and nephrotoxin ATN the straight portion of the 
proximal tubules is mainly damaged, however the proximal convoluted 
tubules are involved as well. ATN is characterized by a rapid loss of 
cytoskeletal integrity and cell polarity with shedding of the proximal 
tubule brush border, mislocalization of adhesion molecules and other 
membrane proteins such as sodium /potassium  ATPase, along with 
apoptosis and necrosis (Bonventre et al, 2003). Effacement of the 
tubular brush border, loss of proximal tubule cell microvilli, 
simplification of the basolateral surface of tubular epithelial cells, 
flattening of tubular epithelium and dilatation of tubular lumina also 
occurs (Figure 1.2).
Pigmented, granular or hyaline casts are present in the lumina of distal 
nephron segments in ATN. The major component of casts is the unique 
Tamm-Horsfall glycoprotein that is normally produced by the 
ascending thick limb of Henle and is present in the urine. Its 
polymerization within the renal tubules occurs under conditions of 
dehydration, and increasing sodium, calcium and hydrogen ion 
concentrations result in cast formation.
With severe injury, in many regions of the tubule the basement 
membrane remains the only barrier between the filtrate and the 
peritubular interstitium. Backleak of the filtrate can then occur,
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especially when the pressure in tubule is increased owing to 
intratubular obstruction (Zuk et ah, 2001). Biochemical pathways that 
lead to cell necrosis are activated by severe cell injury and include: cell 
energy (ATP) store depletion, increased concentration of reactive 
oxygen species, intracellular acidosis, increased activity of 
phospholipases, release of proteases from the tubular cell brush border, 
loss of lipid transmembrane protein polarity in the tubular-cell apical 
and basolateral surface membranes leading to relocation of 
sodium /potassium  ATPase to the apical cell membrane.
A more detailed description of the pathophysiological changes in 
nephrotoxic ATN is described for cisplatin induced renal damage as 
follows in this chapter.
1.1.2 Cisplatin nephrotoxicity
Acute kidney injury can be induced in experimental models by 
ischemia/ reperfusion, or by toxic insults like folic acid, cisplatin and 
glycerol. In this study, cisplatin-induced injury was chosen, because 
this animal model faithfully mimics the events leading AKI in human 
patients. So, this section of the introduction focuses on features of 
cisplatin nephrotoxicity and goes deeper inside the mechanisms 
underlying cisplatin toxicity.
Tubular cells of the kidney are particularly vulnerable to toxicant- 
mediated injury due to their exposure to circulating chemicals and
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transport processes that result in high intracellular concentrations. 
Drugs and chemicals may act at different sites in the kidney, and their 
nephrotoxicity is influenced by several factors like:
• direct toxic effect of drugs on cells of the nephron;
• pharmacologic activity of some substances and their effects on 
renal function;
• high metabolic activity of particular segments of the nephron;
• multiple transport systems, which can result in intracellular 
accumulation of drugs and chemicals;
• high intratubular concentration with possible precipitation and 
crystallization of some drugs.
Cisplatin (cis-diamminedichloroplatinum II), whose biological 
activity was discovered in the early sixties (Rosenberg et al., 1965; 
Rosenberg et al., 1967), is one of the most remarkable successes in "the 
war of cancer". Cisplatin and related platinum-based therapeutics are 
currently used in the treatment of neoplasia with a wide spectrum of 
efficacy against several solid tumours like testicular, head, neck, 
ovarian, cervical, nonsmall cell lung carcinoma and many other type of 
cancer (Pabla et ah, 2008; Madias et al., 1978). One of the major limiting 
factors in the use of cisplatin is the side effect in normal tissue, 
associated to ototoxicity, gastrointestinal toxicity, myelosuppression, 
allergic reactions and nephrotoxicity (Hartmann et al., 2003; Pabla et al., 
2008). The prevalence of cisplatin nephrotoxicity is high, occurring in 
about one-third of patient undergoing cisplatin treatment. For years,
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different approaches have been tried to minimize the side effects, one 
strategy used with some success is to hydrate the patients during 
cisplatin treatment (Pabla et al., 2008). Despite these efforts, the side 
effect of cisplatin, in particularly nephrotoxicity, remain a major factor 
that limits the use and efficacy of cisplatin in cancer therapy.
Following intravenous administration, cisplatin undergoes 
extensive protein binding (more than 90%). The unbound fraction, low 
in molecular weight and neutral in charge, is freely filtered at the 
glomerulus, not reabsorbed and appears unchanged in the urine. The 
mechanism of intracellular transport of cisplatin is not clear and may 
vary from on cell type to another, however, in the renal system, the 
organic cation transporters (OCTs) have been implicated in cisplatin 
uptake (Pabla et al., 2008; Ludwig et al, 2004). In particular, OCT2 is 
critical for cisplatin uptake in the kidney (Ciarimboli et al, 2005). 
Cisplatin is activated when the drug is inside the cell where the chloride 
ligands in the cis-position are replaced by water molecules forming a 
hydrated drug that can react with nucleophylic sites. The product is a 
highly reactive electrophylic molecule (Townsend et al, 2002).
The cytotoxicity of cisplatin is probably due to a combination of 
insults, including peroxidation of the cell membrane, mitochondrial 
dysfunction, inhibition of protein synthesis and DNA injury.
DNA injury and subsequent cellular events. Cisplatin binds to DNA, 
leading to the formation of inter- and intrastrand cross-links. Cross- 
linking results in defective DNA templates and arrest of DNA synthesis
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and replication (Wang et al, 2005; Heiger-Bernays et al, 1990; Jamieson 
et al, 1999). DNA damage may lead to p53 activation (Figure 1.3) by 
phosphorylation, and the protein accumulates in the nucleus to regulate 
the expression of numerous genes associated with cell cycle arrest, 
DNA repair and apoptosis as cyclin dependent kinase (CDK) inhibitor 
p21Wafi/api, growth arrest and DNA damage inducible gadd45a gene, 
and the pro-apoptotic bax gene (Morgan et al, 1997; Bullock et al, 2001; 
Delmastro et al, 1997; Hershberger et al, 2002).
Apoptosis and necrosis. Tubular cell death, in the form of both necrosis 
and apoptosis, is a common histopathological feature of cisplatin 
toxicity. Depending on the dose of cisplatin, renal tubular cells undergo 
either necrosis or apoptosis (Lieberthal et al, 1996). Necrotic cell death 
was observed when a high concentration of cisplatin (millimolar) was 
used, while lower concentration of cisplatin (micromolar) led to 
apoptosis (Lieberthal et al, 1996).
Several pathways of apoptosis have been implicated in cisplatin 
nephrotoxicity, including the intrinsic pathway focused on 
mitochondria, the endoplasmic reticulum (ER)-stress pathway and the 
extrinsic pathway mediated by death receptors.
Intrinsic or mitochondrial pathway has emerged as the major apoptotic 
pathway in cisplatin nephrotoxicity (Figure 1.4). Cellular stress 
activates Bax and Bak, the pro-apoptotic Bcl-2 family proteins, which 
form porous defect on the outer membrane of mitochondria (MOMP, 
mitochondrial outer-membrane permeabilization) (Jiang et al, 2006).
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MOMP leads to the release of apoptogenic factors, like cytocrome c, AIF 
(apoptosis-inducing factor), Smac/DIABLO, endonuclease G and 
others, from the organelles (Pabla et al., 2008; Green et al, 1998). 
Cytocrome c after being released into the cytosol, binds to apoptotic 
protease activating factor 1 (APAF1) causing oligomerization and 
apoptosome formation. The apoptosome, finally, recruits and activates 
pro-caspase 9, which after proteolytic processing activates downstream 
caspase-3 and-7 (Figure 1.4). These caspases are responsible for 
apoptotic hallmarks, such as chromatin condensation, plasma 
membrane asymmetry and cellular blebbing (Pabla et al, 2008; Green et 
a l , 1998).
Smac, after being released into cytosol, can bind and antagonize the 
caspase inhibitor proteins IAPs to further augment caspase activation. 
In contrast, AIF, once released from mitochondria, accumulates in the 
nucleous to induce apoptosis in a caspase-independent manner (Pabla 
et al., 2008; Green et al., 1998).
A direct involvement of the receptor-mediated apoptotic pathway, the 
extrinsic pathway, has also been demonstrated in renal tubular cells 
(Figure 1.4). In the extrinsic pathway, binding of the death receptors as 
Fas, TNFR-1 and 2 (tumor-necrosis factor-a receptor), by ligands at the 
plasma membrane leads to the recruitment and activation of caspase-8, 
which further activate downstream caspases to induce apoptosis 
(Figure 1.4). (Strasser et al., 2000).
It is important consider that although the classical apoptotic pathways
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activated by cisplatin involve caspase, not all the apoptosis is mediated 
by caspase. The mechanism of caspase-independent apoptosis is 
currently unclear, probably might involve AIF.
Mitochondrial dysfunction and oxidative stress. Oxidative stress has been 
recognized as an important factor that contributes to cisplatin 
nephrotoxicity (Baliga et al., 1999). Increase of various reactive oxygen 
species (ROS) occurs during cisplatin treatment in vitro (Brady et al., 
1990) and in vivo (Gordon et al., 1986; Davis et al., 2001; Satoh et al.,
2003). Once incorporated by the cells, cisplatin is converted into a 
highly reactive form, which induce depletion and inactivation of 
glutathione, a well-recognized cellular antioxidant, leading to the 
accumulation of endogenous ROS and oxidative stress within the cells 
(Pabla et al., 2008). Cisplatin may also induce mitochondrial dysfunction 
and increase ROS production via the disrupted respiratory chain (Pabla 
et al., 2008). Moreover, there is evidence that ROS increase p53 
(Nakamura et al., 2001) with subsequent activation of the cell death 
program.
In various experimental models, have been demonstrated the 
renoprotective effect of antioxidants as dimethylthiourea (DMTU), 
melatonin, selenium, vitamin E, N-acetylcysteine and many others 
(Ramesh et al., 2005; Jiang et al., 2007; Dickey et al., 2005; Tsuruya et al., 
2003; Sener et al., 2000; Naziroglu et al., 2004). However, whether these 
antioxidant chemicals are renoprotective in hum an patients during 
cisplatin-based chemotherapy is uncertain.
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Inflammation. In the case of cisplatin nephrotoxicity, several cytokines 
and chemokines as tumor necrosis factor-a (TNF-a), transforming 
growth factor p (TGF-P), RANTES, MIP-2, and monocyte chemotactic 
protein-1 (MCP-1) are significantly up-regulated in the kidney (Ramesh 
et al., 2002). In the inflammatory response trigger by cisplatin, TNF-a 
appears to be a key upstream regulator. Ramesh et al. showed that 
pharmacological inhibition of TNF-a afforded protection from cisplatin 
nephrotoxicity (Ramesh et al., 2002). Moreover, a significant up- 
regulation of the expression of ICAM-1, that serves as a ligand for the 
p2 integrins, LFA-1 and Mac-1 on leukocytes, was found in kidneys 
from cisplatin-treated rats and mice (Kelly et al., 1999; Ramesh et al., 
2002).
All this evidence suggests a pro-inflammatory role of cisplatin in its 
nephrotoxicity.
1.2 Repair and recovery in kidney disease
In a physiological setting, the kidney has been regarded as an 
organ with minimal cell turnover and limited capacity for repair. 
However, after injury, an increased cell proliferation is the driving 
event that directs towards tissue recovery. After ischemia/reperfusion 
injury, regeneration of tubules is evident on the third day, after ten days
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50% of the tubules have been regenerated (Ysebaert et al., 2000) and 
complete restoration of tubular structure is reached after 4 weeks 
(Humes et al., 1994; Witzgall R et al., 1994). This functional property of 
the kidney to regenerate supports the hypothesis that resident cells can 
be involved in restoring structure and function. What remains to be 
determined is whether reparative programme depend on (Figure 1.5):
- cells originating from de-differentiation of tubular cells
- stem or progenitor cells that reside in a specific niche in the kidney
- extrarenal stem cells that, recruited to the kidney following damage, 
exert a paracrine effect/ or differentiate into renal cells.
1.2.1 De-differentiation of terminally differentiated cells
Seemingly, terminally differentiated resident tubular cells may 
have a role in kidney repair during cell turnover or after damage. In 
fact, using healthy juvenile rats in which the kidney is fully developed 
but the nephrons still grow in length, Vogetseder et al. have 
demonstrated that mitotic cells (BrdU-retaining cells) displayed 
characteristic features of the epithelium (Vogetseder et al., 2005). 
Moreover, the same group has observed that the generation of new cells 
in the S3 segment of the proximal tubule was due to the division of 
differentiated, normally slow-cycling cells, suggesting that 
differentiated tubular cells are self-renewing (Vogetseder et al., 2007).
The cells that survive to damage might proliferate and generate
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identical cells or dedifferentiate and subsequently re-enter the cell cycle. 
The positive correlation between differentiated tubule markers and 
mitosis markers in healthy kidneys supports the idea that resident 
tubular epithelial cells could fuel regeneration. The de-differentiation 
hypothesis is also attractive due to the precedence set by nephron 
development, i.e. that the tubules arise from mesenchyme that is 
induced to become epithelium.
After the insult occurs, renal tubular cells rapidly lose their brush 
border and dedifferentiate into a more mesenchymal phenotype. This 
process seems to be followed by migration of the dedifferentiated cells 
into regions where cell necrosis, apoptosis or detachment have resulted 
in denudation of the tubular basement membrane (Figure 1.5). There, 
they proliferate and eventually redifferentiate into an epithelial 
phenotype, completing the repair process (Cantley et al, 2005). It is 
thought that the release, at the tubular sites of injury, of growth factors 
such as insulin-like growth factor 1 (IGF-1) and hepatocyte growth 
factor (HGF), coordinates this response of dedifferentiation, migration, 
proliferation and eventually redifferentiation (Schena FP, 1998).
Tubular cell dedifferentiation, which recapitulates in the patterns 
of gene and protein expression kidney development, was shown by the 
finding that tubular cells acquire an immature mesenchymal phenotype 
with re-expression of Vimentin, Pax-2 and neural cell adhesion 
molecule (NCAM) in post-ischemic recovery (Witzgall et al, 1994; 
Imgrund et al, 1999; Abbate M et al, 1999). A vimentin positive
16
C H A P T E R  1: I N T R O D U C T I O N - A K l
phenotype, normally not expressed in the mature nephron, is acquired 
by the proximal tubular cells during the recovery phase after 
ischaemia/reperfusion injury (Witzgall et al, 1994). NCAM, a 
dedifferentiation marker for renal cells, is expressed in post-ischaemic 
proximal tubular cells of the severely injured S3 segment (Abbate M et 
al, 1999). Moreover, it is implicated in the control of cell shape and 
migration and is rapidly down regulated during the conversion to a 
more mature phenotype. The loss of the highly specialized phenotype is 
reflected also by decreased expression of the apical brush border 
markers, gp330 and DPP-IV. While de-differentiating, these cells also 
express the transcription factors Pax-2, a factor involved in kidney 
development (Dressier, 1996), Egr-1 and c-fos (Ouellette et al., 1990). 
Cell adhesion molecules, such as integrins, also change their 
distribution: after ischaemia/reperfusion injury, pi-integrins are 
relocated to the lateral borders of the cell, like in immature epithelial 
cells where they are implicated in the control of cell migration (Zuk et 
al, 2001).
A great support for proximal tubular cell survival derives from 
distal tubular epithelial cells, which in response to 
ischemia/reperfusion injury, release reparative and prosurvival factors 
and protect the sensitive proximal tubules from injury (Gobe et al, 
2007).
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1.2.2 Renal stem /progenitor cells in the adult kidney
Stem cells of adult organs have traditionally been viewed as 
multipotent precursor cells capable of maintaining, generating and 
replacing mature cell types within their own specific tissue, as a 
consequence of physiological cell turnover or tissue injury (Blau et ah, 
2001). A stem cell is define as a cell that, upon division, can self-renew 
and give rise to a transit-amplifying progenitor, that acquires a more 
differentiated state, but exhibits a high capacity for growth. Adult stem 
cells support homoeostasis in tissue with high rates of turnover as 
blood, skin and intestine, but also in organs formerly believed to have 
no regenerative potential as the lung and brain (McCampbell et ah, 
2012).
Renal stem /progenitor cells in the adult kidney have been 
identified looking for cells expressing stem-cell markers or cells in the 
kidney with functional properties of stem cells, as that stem cells cycle 
infrequently. The search for renal stem / progenitor cells in adult kidney 
has not identified a multipotent cell able to self-renew and make more 
than 20 specialized renal cell type, but has revealed the presence of 
different population of stem /progenitor cells in distinct localizations 
within the nephron. These sites include the glomeruli, the tubuli, the 
renal papilla and the interstitium (Benigni et ah, 2010).
Multipotent progenitor cells expressing the stem cell markers 
CD24 and CD133 were immunoisolated from Bowman's capsules in 
adult human glomeruli (Sagrinati et ah, 2006). These parietal epithelial
18
C H A P T E R  1: I N T R O D U C T I O N - A K l
cells (PECs) exhibited clonogenic self-renewal and were able to generate 
podocytes and tubular cells in vitro. Moreover, in a mouse model of 
AKI, tubular regeneration occurred in animals that received an injection 
of CD24+CD133+ PECs (Sagrinati et al., 2006). Further molecular 
characterization of CD24+CD133+ hum an PECs revealed that this group 
is heterogeneous, and includes cells that express markers typical of 
differentiated podocytes, like nestin and podocalyxin (PDX) (Ronconi et 
al, 2009). Human PECs are spatially organized in a continuum along 
the Bowman's capsule, with CD24+CD133+PDX” cells present closest to 
the urinary pole, CD24+CD133+PDX+ cells (named transitional cells) 
localised between urinary and vascular pole, and differentiated 
podocytes negative for CD24 and CD133 and positive for PDX present 
near vascular pole (Ronconi et al, 2009). Only PDX” population of cells 
exhibited multipotency in vitro and were able to ameliorate renal 
function, reducing proteinuria, once injected into mice with 
adriamycin-induced renal injury (Ronconi et al., 2009). Genetic labelling 
has been used to mark the PECs and irreversibly track their progeny in 
newborn and adolescent mice, demonstrating that PECs migrate into 
the glomerular tuft and become podocytes. These finding provide 
evidence that these cells are responsible for podocyte renewal (Appel et 
al, 2009).
Similarly, multipotent progenitor cells expressing CD24 and 
CD133 were found in the tubular compartment of hum an kidneys. This 
population was first identified by searching for CD133+ cells in tubular
19
CHAPTER 1: INTRODUCTlON -AKi
fractions on the basis of the correlation between this antigen and the 
PECs (Sallustio et al., 2010). Moreover Sallustio et al, found that a subset 
of the CD133+ tubular cells co-expressed CD24 and, by clonogenic 
analysis, the CD24+CD133+ cells could differentiate into multiple cell 
types in vivo. This tubular population also had a similar gene signature 
to CD24+CD133+ glomerular cells by microarray (Sallustio et al., 2010). 
Tubular cells expressing both CD24 and CD133 were found in proximal 
and distal segments, although the frequency was not quantified. More 
recently, another research group discovered and characterized a human 
multipotent population of cells positive for CD24 and CD133 (Lindgren 
D et al., 2011). In this case, the isolation strategy was based on the high 
ALDH (aldehyde dehydrogenase) activity associated with sternness. 
Kidney cells with ALDH^s11 activity were isolated from the renal cortex 
and had an increased capacity to form sphere-like clusters of epithelial 
cells in culture, and were capable of anchorage-independent growth 
features seen in several types of multipotent stem cells. By whole- 
genome expression profiling, the ALDHhish cells showed high levels of 
CD24, CD133, vimentin and cytokeratins 7 and 19 (Lindgren D et al., 
2011). Cells expressing CD133 were also isolated from the tubular 
fraction of the healthy human renal cortex (Bussolati et al., 2005). These 
cells, that expressed PAX-2, demonstrated self-renewal capacity and 
were able to differentiate towards renal epithelium and endothelium in 
vitro. When injected into mice with glycerol-induced acute kidney 
injury, these cells homed the injured kidney and integrated in tubules
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(Bussolati et al., 2005).
Since a detailed repertoire of unique cell surface marker proteins 
expressed on renal stem /progenitor cells is unknown, an alternative 
strategy for identification has been based on the property that stem cells 
cycle infrequently to maintain the pool of cells for tissue turnover and 
repair. Slow-cycling cells can be identified by their retention of the 
proliferative marker bromodeoxyuridine (BrdU). On the basis of this 
concept, Maeshima et al. demonstrated the existence of label-retaining 
cells in proximal, distal and collecting tubules of normal rat kidneys 
(Maeshima et ah, 2003). Further studies showed the presence of these 
cells in the interstitium that were capable of re-expressing the 
mesenchymal cell markers Vimentin and e-cadherin after ureteral 
obstruction (Yamashita et al., 2005).
Based on the same method that uses BrdU incorporation, Oliver 
et al found that the interstitium of the renal papilla is a niche for kidney 
stem cells (Oliver et al, 2004). During recovery from ischaemia, BrdU- 
positive cells disappeared from papilla, suggesting that they can be 
involved in kidney repair. In vitro, renal papillary cells co-expressed 
epithelial (ZO-1) and mesenchymal (a-smooth muscle actin) markers. 
Under specific culture conditions, they gave rise to a heterogeneous cell 
population, with some cells expressing nestin, a marker of neuronal 
stem cells, and with other cells expressing class III P-tubulin, a marker 
of fully differentiated neurons, suggesting that isolated papillary cells 
were pluripotent. When injected into the renal cortex, papillary cells
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incorporated into parenchyma (Oliver et al., 2004).
Iwatani and co-worker have isolated from the kidney a stem cell- 
rich population termed side population (SP), using a method first set up 
by Goodell et al. (Goodell et al., 1996) that uses the high capacity of stem 
cells to extrude a Hoechst dye, and that therefore identifies these cells 
as Hoechstlow cells (Iwatani et al., 2004). In the kidney, side population 
cells have been found residing in the renal interstitial space and once 
systemically infused in experimental model, their therapeutic benefit 
has been modest. The beneficial effect of SP cells observed in animal 
models of kidney diseases as adriamycin nephropathy (Challen et al.,
2006), cisplatin-induced AKI (Hishikawa et al., 2005) and chronic kidney 
disease (Imai et al, 2007), is likely due to paracrine effect of SP cells.
For future application in the regenerative medicine field, it 
would be relevant to identify the factors regulating cell growth and 
differentiation of stem or progenitor cells. Isolation, in vitro expansion 
and transplantation of these cells could represent a new therapeutic 
approach.
1.2.3 Role of extra-renal stem cells in kidney repair
In the addition to the repair capabilities of the tubular cell itself,
and the possibility that endogenous renal stem cells participate in 
kidney repair, in the last few years it has become very clear that bone 
marrow-derived stem cells, contribute to turnover and regeneration 
after injury to several regions of the kidney (De Broe, 2005). Bone
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marrow-derived stem cells have remarkable plasticity to the extent that 
they can give rise to all type of blood cells but they can also differentiate 
into multiple lineages other than their tissue of origin (Wagers et al,
2004).
Evidence of the contribution of bone marrow-derived stem cells 
in the renal cell turnover and regeneration was obtained by Poulsom et 
al, examining kidney biopsies from male patients who have received 
kidney transplant from female donors (Poulsom et al, 2001). In men 
receiving a kidney transplant from female donors, Y chromosome 
containing tubular epithelial cells was observed in kidneys suffering 
damage as a consequence of acute tubular necrosis (Poulsom et al, 
2001). Similarly, in male patients with resolving ATN who had received 
a kidney transplant from a female donor, Gupta et al have 
demonstrated that extrarenal stem cells of bone marrow origin, can 
participate in the regenerative response following ATN, differentiating 
in renal tubular epithelial cells (Gupta et al, 2002).
The idea that bone marrow contains cells that home to the 
tubular epithelium has been further explored in mice. Poulsom et al 
found that female mice recipients of male bone marrow grafts showed 
co-localization of Y chromosomes and the tubular epithelial marker 
Lens culinaris lectins, in up to 8 % of tubular epithelial cells, indicating 
that bone marrow cells can traffic into the kidney and participate in the 
normal tubular epithelial cell turnover (Poulsom et al, 2001). More 
recently, the same group observed, in a mouse model of AKI-induced
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by folic acid, that bone marrow- derived stem cells contributed to 
regeneration. In female mice lethally irradiated and transplanted with 
male bone marrow cells, the authors determined that the number of Y- 
chromosome-positive tubular cells increases following folic acid- 
induced tubular injury in the recipient mouse, and that some of these 
cells undergo division within the tubule. They note, however, that most 
(90%) renal tubular regeneration came from female indigenous cells, as 
the cells involved in tubule repair seem to be Y-chromosome-negative 
(Fang et al., 2005). The finding that proliferation of endogenous tubular 
cells rather than influx of bone marrow-derived cells provides the bulk 
of cells involved in tubule repair is supported by the work of Lin and 
Duffield (Lin et al., 2005; Duffield et al., 2005). Moreover, Lin et al., have 
documented that transplantation of exogenous bone marrow-derived 
cells in mice w ith ischemia/reperfusion injury didn 't improve renal 
function (Lin et al., 2005).
It is not clear whether these cells, eventually coming from the 
bone marrow, are already present in the kidney prior to injury, 
functioning as resident stem cells, or whether they are recruited to the 
kidney at the time of injury (Poulsom et al., 2002). Conflicting results 
reported by different groups, have generated uncertainty as to whether 
cells from the bone marrow actually become tubular cells in vivo. On the 
basis of most current data, it seems that even if adult bone marrow- 
derived cells retain the capacity to differentiate into or fuse with renal 
tubular cells, it is an uncommon event and does not have a
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predominant role in the acute tubule regenerative process.
1.3 Stem cell therapy for kidney repair
As described above, the kidney shows an intrinsic capacity to 
repair as physiological cell turnover or after injury. However, if the 
damage has reached a certain point, renal repair is rather limited and 
the ability to recuperate from the injury may be compromised. For this 
reason, several groups have begun to explore the capacity of bone 
marrow-derived stem cells to promote tubule repair after injury, as cell 
therapy.
The bone marrow contains at least two populations of stem cells, 
haematopoietic stem cells (HSCs) from which all the cellular blood 
elements are derived, and mesenchymal stem cells (MSCs), which 
provide stromal support for haematopoiesis. Presently, MSCs are the 
preferred stem cell population for cellular therapy in experimental 
model of AKI (table 1), since HSCs failed to induce kidney repair in 
animal model of acute kidney damage and ischemia/ reperfusion injury 
(Morigi et al., 2004; Kale et al., 2003).
MSCs are undifferentiated adult stem cells of mesodermal origin 
that constitute only 0.001-0.01% of the total BM cell population. MSCs 
are progenitors of skeletal tissue components such as bone, cartilage, 
haematopoiesis-supporting stroma and adipocytes (Bianco et ah, 2001; 
Pereira et ah, 1995; Pittenger et al, 1999; Prockop et al, 1997). 
Experimental findings have shown the potential of MSCs to
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differentiate along multiple cell lineages including neuronal, myogenic 
and hepatocyte-like cells (Jiang et al., 2002; Kopen et ah, 1999; Schwartz 
et al, 2002; Toma' et al., 2002). Moreover, MSCs can be easily isolated 
and expanded. Our group has demonstrated that intravenous injection 
of murine BM-MSCs protected renal function and structure in mice 
with AKI induced by cisplatin, whereas HSCs had no protective effect 
(Morigi et al., 2004). Murine BM-MSCs minimized tubular damage and 
accelerated proliferation of tubular cells. Moreover, our group reported 
the presence of Y-chromosome-positive cells in the injured tubules of 
MSC-transplanted mice, although the percentage of MSCs-derived 
tubule cells was not stated (Morigi et al., 2004). The finding that MSCs 
can protect renal tubules from acute injury and might be directly 
incorporated into the regenerating tubule has been supported by a 
study from Herrera et al. in a glycerol-induced murine rhabdomyolysis 
model of acute renal failure (Herrera et al., 2004). However, follow up 
studies revealed that only 2-2.5% of the injected BM-MSCs showed 
engraftment, opposed to a previously reported 22% (Herrera et al., 
2007).
The renoprotective capacity of MSCs has been confirmed by two 
studies that have shown an important difference from the earlier 
findings (Duffield et al., 2005; Togel et al., 2005). In an experimental 
model of ischemia/reperfusion injury, neither Togel and colleagues nor 
Duffield et al. were able to detect direct engraftment of MSCs within 
renal tubules. The study by Togel et al. showed that intracarotid
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administration of MSCs either immediately or 24 h after renal ischemia 
resulted in significantly improved renal function. These MSCs were, 
however, only transiently present in the renal vasculature, and were not 
detected within the renal parenchyma for up to 3 days after infusion 
(Togel et al, 2005). Examination of gene expression in the MSC-treated 
kidneys revealed a decrease in pro-inflammatory cytokines and an 
increase in several growth factors, including basic fibroblast growth 
factor and transforming growth factor-a. So, these authors concluded 
that MSCs protected the kidney via paracrine an d / or endocrine effects 
rather than through direct engraftment in the renal tubules. Similarly, 
in the study of Duffield and colleagues, upon i.v. injection of MSCs, 
post ischemic functional renal impairment was reduced, but there was 
no evidence of differentiation of these cells into tubular cells of the 
kidney (Duffield et al., 2005). These authors found that proliferation of 
endogenous tubular cells, rather than engraftment of transplanted 
MSCs, accounted for the kidney repair.
Taken together, there is good evidence that administration of 
MSCs both protects against AKI in toxic and ischemic rodent models 
and accelerates recovery phase (Humphrey et al, 2008). Similar to 
rodent MSCs, our group has recently demonstrated the renoprotective 
effect of hum an MSCs in an immunodeficient mouse model of AKI 
induced by cisplatin (Morigi et al, 2008). Human BM-MSC infusion 
decreased proximal tubular epithelial cells injury and ameliorated the 
deficit in renal function, resulting in reduced recipient mortality
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(Morigi et al, 2008).
The mechanisms by which MSCs promote kidney remain unclear 
but an important aspect of the therapeutic effect of MSCs appears to be 
their ability to home to injured kidney. Several studies have explained 
the possible mechanism that regulate MSC homing, suggesting an 
increasingly involvement of inflammation in the MSC engraftment. Ip 
and co-workers have observed, using specific neutralizing antibody, 
that MSCs use |3-1 integrin to engraft in ischemic myocardium, 
suggesting that MSC recognition of the endothelial cell VLA-4 adhesion 
molecule via (3-1 integrin was required for engraftment (Ip et al, 2007). 
P-selectin and vascular cell adhesion molecule (VCAM-1), have been 
shown to be involve in the initial steps by which transplanted MSCs 
interact with the vessel wall in the course of extravasation. Using a 
parallel plate flow chambers and function-blocking antibodies against 
P-selectin and VCAM-1, Ruster et al. have observed a role of these 
adhesive molecules in the coordinated rolling and adhesion of MSCs on 
endothelial cells (Ruster et al, 2006). The central role of inflammation 
and VLA-4/VCAM-1 in MSCs-endothelial interaction has also come 
from studies of Segers and co-workers (Segers et al, 2006).
Chemotaxis of MSCs to sites of inflammation is also an area of 
interest. Several mediators have been identified and stromal cell- 
derived factor-1 (SDF-1) seems to be an attractive candidate. SDF-1 and 
its receptor CXCR4 are important mediators of leukocyte homeostasis. 
The post-ischemic kidney has been shown to recruit different leukocyte
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populations, including bone marrow-derived stem cells. Therefore, 
Togel et al. have investigated the SDF-1/CXCR4 system in the damaged 
kidney, and they observed that SDF-1 is expressed in the kidney and is 
upregulated after renal injury, mobilizing CXCR4-positive cells to the 
kidney after ischemic injury (Togel et al., May 2005). The role of SDF- 
1/CXCR4 system in the MSC engraftment in vivo was further 
investigated by Hung et al. (Hung et al, 2007). Short-term exposure of 
MSCs to low oxygen increased the expression of the chemokine 
receptors CX3CR1 and CXCR4, inducing an increased in vitro 
migration of MSCs in response to the fractalkine and SFD-1. Another 
candidate for MSCs homing is CD44, which is expressed on MSCs and 
required for renal localization of injected MSCs. Herrera and coworkers 
observed that CD44 and hyaluronic acid interactions recruited 
exogenous MSCs in a glycerol-induced mouse model of AKI (Herrera et 
al, 2007).
As commented above, there is increasing evidence that MSCs 
facilitate kidney regeneration predominantly by delivering growth 
factors and cytokines to the site of kidney injury instead of 
transdifferentiation into renal cells (Krause et al, 2005). The timing of 
renal epithelial cell proliferation, which is dramatically increased within 
24-48 h, appears to be too rapid to be explained by transdifferentiation 
of extrarenal cells type into epithelial cells. MSCs are able to secrete a 
broad array of growth factors and cytokines including granulocyte 
colony-stimulating factor (G-CSF), stem cell factor (SCF), leukemia
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inhibitory factor (LIF), macrophage colony-stimulating factor (m-CSF), 
IL-6 and IL-11, vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), monocyte-chemoattractant protein 
(MCP-1), hepatocyte growth factor (HGF) and insulin growth factor-1 
(IGF-1) (Haynesworth et al, 1996; Weimar et al, 1998). Togel and co­
workers observed that infusion of MSCs enhanced recovery of renal 
function in rats with ischemia/ reperfusion-induced acute renal failure 
(Lange et al, 2005). Examining MSC-conditioned medium, they found 
significant level of VEGF, HGF and IGF-1 and they determined that this 
conditioned medium was capable of enhancing endothelial cell 
proliferation and differentiation (Togel et al, 2007). Our group, using an 
in vitro cisplatin-induced proximal tubule cell culture model, have 
demonstrated that MSCs exert beneficial effects on tubular cell 
damaged by cisplatin, by producing the mitogenic and pro-survival 
factor IGF-1 (Imberti et al, 2006). Importantly, we observed that MSCs 
with IGF-1 knockdown failed to protect mice from cisplatin-induced 
AKI (Imberti et al, 2006). The Westenfelder laboratory performed a 
similar study in MSCs with knockdown of VEGF, showing that VEGF 
knockdown failed to protect the rats from AKI (Togel et al, 2009).
Recently, other than soluble factors, a new mechanism of 
communication among cells was proven: horizontal transfer of mRNAs 
contained within shed microvesicles. Bruno et al. found that 
microvesicles derived from human MSCs induced proliferation and 
inhibited apoptosis of tubular epithelial cells in vitro, while when
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injected in SCID mice with glycerol-induced AKI, accelerated the 
functional recovery of tubular cells (Bruno et ah, 2009). The effect of 
micro vesicles was RNA-dependent as microvesicles contained a specific 
subset of cellular mRNA, such as mRNA associated with proliferation, 
control of transcription and immunoregulation (Bruno et ah, 2009; Tetta 
eta l, 2011).
The therapeutic effect of MSCs can be ascribed not only to their 
ability to home to injured tissues and secrete trophic mediators, but also 
to their immunomodulatory roles. MSCs are immunologically 
privileged and allogenic MSCs do not induce a proliferative T-cell 
response. The mechanisms for this tolerance include low surface 
expression of both major histocompatibility complex (MHC) class I and 
II molecules, and major costimulatory molecules such as CD40, CD80 
and CD86 (McTggart et ah, 2007). MSCs also exert anti-inflammatory 
effect on T cells. T cells play an important role in immuno-mediated 
and ischemic kidney disease, therefore the ability of MSCs to regulate 
T-cell response is relevant for their therapeutic effect in AKI. Semedo et 
al. observed high level of anti-inflammatory cytokines in kidneys of 
MSC-treated animals after IRI (Semedo et ah, 2007,421).
Although bone marrow represents the most common tissue source 
of MSCs, harvesting these stem cells is invasive and their number, 
frequency, differentiation potential, and life span decline w ith the age 
of the donor. Therefore, in the clinical perspective to cure AKI, the 
search for new sources of MSCs, is of significant value. It has been
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reported that stem cells with similar surface expression patterns of 
MSCs can be isolated from alternative sources as umbilical cord blood, 
placenta, adipose tissue, amniotic fluid, peripheral blood, and other 
tissues (Liu et ah, 2009).
Since the first successful transplantation of umbilical cord blood in 
1988 (Gluckman et ah, 1989), cord blood has become an accepted source 
of haemopoietic stem cells for the treatment of leukaemia, 
haemoglobinopathy and for the repair of bone marrow following high- 
dose chemotherapy for solid tumours (Laughlin et al., 2004). However, 
recent research has revealed that the cord blood is an alternative and 
extremely rich reservoir contains not only haematopoietic stem cells but 
also neural and endothelial progenitors and mesenchymal stem cells 
(Flynn et ah, 2007; Sanchez-Ramos 2006; Erices et ah, 2000; Lee et ah, 
2009). Cord blood stem cells have many advantages over embryonic 
and other adult stem cells. Cord blood represents a potentially 
unlimited source of stem cells, and its collection is non-invasive and 
relatively simple to process and store (Seres et ah, 2010). Moreover, cord 
blood raises no ethical issues for basic studies and clinical applications. 
Based on these advantages, there is considerable interest in the use of 
cord blood stem cells in regenerative medicine.
On the other hand, in the last 10 years, the amniotic fluid, 
obtained from amniocentesis, has also been extensively studied as a 
non-controversial source of a population of stem cells with intermediate 
characteristics between embryonic and adult stem cells (De Coppi et ah,
32
C H A P T E R  1 : 1 N T R 0 D U C T I 0 N - A K 1
2007). Moreover, clonal hAFS cell lines had non-tumorigenicity at late 
passages, when injected into immunodeficient mice. Therefore, hAFS 
cells may represent a new pluripotential cell source for tissue 
regeneration without raising any ethical concerns associated with 
hum an embryonic stem cell research.
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Acute Kidney Injury
f v
Pre-renai causes Renal causes Post-renal causes
Vascular Glomerulo­ Tubular Interstitial-
disorders nephritis necrosis nephritis
Ischaemia Toxins Pigments
Figure 1.1: Classification scheme of acute kidney injury
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Figure 1.2: Tubular changes in the pathophysio logy  of ischaem ic acute 
tubu lar necrosis (M odified from  Lam eire at al., 2005)
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Figure 1.3: Main biological effects of cisplatin
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Figure 1.4: Pathways leading to cisplatin- induced apoptosis
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Figure 1.5: Possible mechanisms of renal cell regeneration (Modified from Cantley LG,
2005)
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Table 1.1. Summary o f studies using mesenchymal stem cells (MSCs) isolated from bone marrow to treat acute kidney injury
Injury model MSC source Administration I Features References
Glycerol-induced 
kidney injury
1 x 106 GFP+ mouse BM- 
M SC -fem ale C57BL/6J 
mice
i.v. injection
t proliferation, |  morphological 
recovery, f renal function
Herrera et al., 2004
Cisplatin-induced 
kidney injury
2 x 105 mouse BM-MSC -  
male C57BL/6J mice
i i.v. injection
t renal function, |  tubular 
proliferation, f morphological 
recovery
Morigi et al., 2004
40 min bilateral IR
1.5 x lO 6 rat BM-MSC-  
Sprague-Dawley rats
Infused into 
thoracic aorta 
via a carotid 
artery
t  renal function, 4 injury score, j 
preservation of proximal tubular 
brush border
Lange et al., 2005
40 min bilateral IR 1 x 106 rat BM-MSC
Intra-aortic 
delivery via left 
carotid artery
|  renal function, f proliferative 
indexes, 4 apoptotic indexes, J, 
renal injury, 4 IL-lp, TNF- a, IFN-y, 
iNOS, tIL-10, bFGF, TGF-a, Bcl-2
Togel et al., 2005
Cisplatin-induced 
kidney injury
2 x lO 5 mouse BM-MSC-  
male C57BL/ 6] mice
Tail vein or i.p. 
injection
t renal function, |  tubular cell 
proliferation, j tubular cell 
apoptosis
Bi et al., 2007
Glycerol-induced 
kidney injury
Cisplatin-induced 
kidney injury
1 x 106 mouse CD44+ or 
CD44-/-BM -M SC-  
C57BL/6J or 
Cd44tm lHbg/J mice
2 x 105 mouse IGF-1 gene 
silenced BM-MSC -  male 
C57BL/ 6J mice
Tail vein 
i.v. injection
CD44+ BM-MSC: t  morphological 
and functional recovery,CD44-/ - 
BM-MSC: no significant 
morphological or functional 
recovery
Limited protection of renal function 
(BUN) and tubular injury
Herrera et al., 2007 
Imberti et al., 2007
60 min bilateral IR
2 x lO 5 rat BM -M SC-male 
Wistar rats
i.v. injection
4 serum creatinine and plasma urea, 
t  PCNA nuclei in MSC treated 
kidneys, t IL-4, J, IL-ip
Semedo et al., 2007
30 min unilateral IR 1 xlO 5 rat MSC
Intra-arterially
infused
j apoptosis in kidney regions with 
MSC still present in 
microvasculature 24 h post-IR
Togel et al., 2007
Cisplatin-induced 
kidney injury
5 x 105 human BM-MSC Tail vein
t renal function, |  proliferative 
score, |  proximal tubular epithelial 
cell injury, J, apoptotic score, j 
mortality
Morigi et al., 2010
2 x 105 rat BM-MSC -  male 
Wistar rats
J. serum creatinine, t renal function,
60 min bilateral IR i.v. injection low  expression of IL-1 p, IL-6, TNF- 
a, high expression IL-4 and IL-10
Semedo et ah, 2009
Cisplatin-induced 
kidney injury
5 xlO 6 human BM-MSC i.p. injection
Prolonged survival, j urea nitrogen, 
|  apoptosis, |  proliferation
Eliopoulos et al., 2010
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1.4 Aim of the study
In literature is widely demonstrated the protective effect of MSCs 
isolated from bone marrow. However, the considerable amount of 
findings has highlighted the limits of adult stem cells, i.e. their number, 
frequency, differentiation potential, and life span that decline with the 
age of the donor. Therefore, in the clinical perspective to cure AKI, the 
search for new sources of MSCs, is of significant value. In the last 
decade, alternative sources of MSCs have been identified, and in 
particular cord blood (CB) and amniotic fluid (AF) are revealed as a 
non-controversial and rich reservoirs of fetal stem cells.
Based on this evidence, the aim of this study is to investigate the 
possible therapeutic effect of human CB-MSCs and human AFS cells in 
renal repair processes. The administration of stem cells will hopefully 
improve renal function, preserving renal structure, thus opening new 
perspectives for future therapies in acute damage. We aim to study the 
changes in renal function after stem cell injection but also stem cell 
engraftment into damaged tissue, their possible differentiation into 
renal epithelial cells and their effects on the tissue regeneration. 
Moreover, another important goal of this study is to clarify in vitro the 
mechanisms underlying the renoprotective effect of these different 
populations of stem cells.
40
CH A P TE R  2: M A T E R I A L S - A K I
CHAPTER 2
MATERIALS
41
C H A P T E R  2: MATER1ALS-AK1
2.1 Mice
NOD-SCID female mice were purchased from Charles River Italia 
s.p.a., Calco, Italy.
2.2 Cells
Hum an CB-MSCs. Human cord blood mesenchymal stem cells were 
kindly supplied from Dr. Lorenza Lazzari, Cell Factory, Fondazione 
IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, 
Italy.
Human BM-MSCs. Human bone marrow mesenchymal stem cells 
were kindly supplied from Dr. Martino Introna, Unit of haematology, 
Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy.
Hum an dermal fibroblasts were purchased from Istituto 
Zooprofilassico Sperimentale della Lombardia e dell'Emilia Romagna, 
Brescia, Italy.
HK2. Human papillomavirus 16 (HPV-16)-transformed proximal 
tubular cell line was purchased from ATCC (CTR-2190; American Type 
Culture Collection, Manassas, VA, USA).
Hum an AFS cells. Human amniotic fluid stem cells were kindly 
supplied from Dr. Paolo De Coppi, University College London, UK.
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2.3 Media, supplem ents and cell culture reagents
Penicillin-Streptomycin, liquid containing 10,000 units of penicillin and 
10,000 pg of streptomycin, GIBCO-Invitrogen, S. Giuliano Milanese (MI), 
Italy, was used at 1% (lml/lOOml).
L-Glutamine 200 mM, liquid, GIBCO-Invitrogen
"Growth m edium " for hCB-MSCs
Alpha MEM GlutaMAX™-I, Gibco-Invitrogen 
+ 20% FCS, selected lot purchased from Euroclone, Pero (MI), Italy 
+ 2 mM L-Glutamine,
+ 1 % penicillin -streptomycin,
"Growth m edium " for hBM-MSCs
DMEM, Sigma-Aldrich
+ 5% platelet lysate, supplied by Dr. Martino Introna 
+ 2 mM L-Glutamine,
+ 1 % penicillin -streptomycin,
"Growth m edium " for hum an dermal fibroblast
MEM, GIBCO-Invitrogen 
+ 10% FCS, selected lot, GIBCO-Invitrogen 
+ 2 mM L-Glutamine,
+ 1 % penicillin -streptomycin,
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"Growth medium" for HK2
Dulbecco's Modified Eagle's Medium (DMEM)/Ham's Nutrient Mixture 
F-12 (DMEM/F-12)
+1% penicillin -streptomycin
+ 5% Foetal Calf Serum (FCS), heat-decomplemented
+ 2 mM L-Glutamine
+ 5 p g / ml 3,3',5-Triiodo-L-thyronine
+ 5 n g / ml Hydrocortisone
+ 5 p g / ml Prostaglandin Ei
+ 5 pg/m l Insulin, 2.75 pg /m l Transferrin, 3.3 ng /m l Sodium selenite 
+ 10 ng /m l Epidermal growth factor
DMEM/F-12, supplemented with 3150 m g/L  glucose, 3574 m g/L  HEPES, 
55 m g/L  sodium pyruvate, without sodium bicarbonate and without L- 
glutamine, was purchased from Sigma-Aldrich, St Louis Missouri USA- 
Milan, Italy.
FCS, selected lot purchased from GIBCO-Invitrogen. 
3,3',5-Triiodo-L-thyronine sodium salt, powder, purchased from Sigma- 
Aldrich. To prepare a 400 n g / ml stock solution, the powder was dissolved 
in 1 ml of NaOH 1 N (Carlo Erba Reagenti, Milano, Italy) and 49 ml of 
sterile DMEM/F-12. A further dilution of 1/50 was done in DMEM/F-12.
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Hydrocortisone-water soluble/ powder, purchased from Sigma-Aldrich. A 
stock solution of 1 m g/m l was prepared in DMEM/F-12.
Prostaglandin Ei, powder, purchased from Sigma-Aldrich. A stock 
solution of 1 m g/m l was prepared by dissolving the powder in ethanol 
(Carlo Erba Reagenti) follewed by a dilution in PBS IX to reach the 
concentration of 10 ng/m l.
Insulin-transferrin-sodium selenite (ITS) 100X, liquid, was purchased from 
GIBCO-Invitrogen.
Recombinant hum an epidermal growth factor, powder, purchased from 
PeproTech Inc., Rocky Hill, New Jersey, USA. A stock solution of 1 pg /m l 
was prepared in PBS IX.
"Growth medium " for hAFS cells
Alpha MEM GlutaMAX™-I, Gibco-Invitrogen 
+15% ES-FBS, GIBCO-Invitrogen 
+ 2 mM L-Glutamine, GIBCO-Invitrogen 
+ 1% penicillin -streptomycin, GIBCO-Invitrogen 
+ 18% Chang B, Irvine Scientific, Santa Ana, CA,
+2% Chang C powder, purchased from Irvine Scientific. A stock solution 
was prepared reconstituted Chang medium C lyophilized in 50 ml 
distilled water.
"Test m edium " (for in vitro experiments)
DMEM, Sigma-Aldrich
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+ 2 mM L-Glutamine, GIBCO-Invitrogen 
+ 2% FCS, GIBCO-Invitrogen 
+ 1% penicillin -streptomycin, GIBCO-Invitrogen
"Inductive media" for hCB-MSCs
Adipogenic Induction and Maintenance Media, Cambrex, Walkersville, 
MD, USA.
Osteogenic Induction and Maintenance Media, Cambrex, Walkersville, 
MD, USA.
Chondrogenic inductive medium (0.5 ml, Cambrex) with TGF|3 (10ng/ml, 
Sigma-Aldrich).
"Inductive media" for hAFS cells
DMEM low-glucose m edium DMEM, Sigma-Aldrich 
+ 10% FBS, GIBCO-Invitrogen 
+ 2 mM L-Glutamine, GIBCO-Invitrogen 
+ 1% penicillin -streptomycin, GIBCO-Invitrogen 
Adipogenic supplements:
1 |iM dexamethasone, Sigma-Aldrich 
+1 mM 3-isobutyl-l-methylxanthine, Sigma-Aldrich 
+ 10 jig/ ml insulin, Sigma-Aldrich 
+ 60 jjM indomethacin, Sigma-Aldrich 
Osteogenic supplements:
100 nM dexamethasone, Sigma-Aldrich
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+ 10 mM beta-glycerophosphate, Sigma-Aldrich
+ 0.05 mM ascorbic acid-2-phosphate, Wako Chemicals, Richmont, VA, 
USA.
Trypsin
Trypsin for hCB-MSCs: Trypsin 0.25%/EDTA 50 pM was purchased from 
GIBCO-Invitrogen
Trypsin for HK2: Trypsin, 0.5% (10X) with EDTA«4Na was purchased 
from GIBCO-Invitrogen. A solution IX was aseptically prepared in 
balanced salt solution without Ca++ and Mg++.
Trypsin for hum an AFS cells: Trypsin 0.05% /EDTA 0.02% solution 
(w /v) in PBS IX without Ca++ and Mg++. Biochrom, Berlin, Germany.
2.4 Growth factors
Glial cell line-derived neurotrophic factor (GDNF) protein, Abeam Inc, 
Cambridge, MA, USA.
2.5 Chemicals
Acetone was purchased from Carlo Erba Reagenti, Rodano, Milan, Italy. 
Alcian Blue was purchased from Sigma-Aldrich.
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Alizarin Red S (sodium alizarin sulfonate) was purchased from Sigma- 
Aldrich. 2% Solution was prepared by dissolving the powder in distilled 
water. Solution was stirred and centrifuged at 4000 rpm  for 10 minutes. 
The supernatant was collected and filtered. pH was adjusted at 4.1 with 
0.5% ammonium hydroxide.
Cis-diaminedichloroplatinum (cisplatin) was purchased from Sigma- 
Aldrich or Ebewe Italia Sri, Roma, Italy, as indicated in the Methods. 
Dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich.
Ethanol (absolute) was purchased from Carlo Erba Reagenti, Rodano, 
Milan, Italy.
Eukitt was purchased from Bio Optica, Milan, Italy.
Formalin solution, ready to use was purchased from Bio-Optica.
Harris haematoxylin and eosin was purchased from Bio-Optica, Milan, 
Italy.
Hydrogen peroxide (H2O2) solution was purchased from Sigma-Aldrich. 
Isofluorane was purchased from Abbot, San Donato Milanese, Milan, 
Italy.
M ounting m edium  was purchased from DakoCytomation, Glostrup, 
Denmark.
Oil Red O was purchased from Sigma-Aldrich. We prepared a 0.5% 
solution in methanol. Solution was stirred and centrifuged at 4000 rpm  for 
10 minutes. The supernatant was collected and filtered.
Paraffin, Bioplast Plus, was purchased from Bio Optica. 
Paraformaldehyde was purchased from Electron Microscopy Sciences
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(Hatfield, PA, USA). In order to prepare a 4% solution, we diluted 8% 
aqueous solution in PBS 2X under a fume hood.
Periodic acid, Diapath, Martinengo, Bergamo, Italy.
Propylene oxide (1,2-epoxypropane), Electron Microscopy Sciences, EMS, 
Rome, Italy.
Schiff's reagent, Kaltek srl, Padova, Italy.
Sodium hyposolfite was purchased from Merck. A 5% solution was 
prepared by dissolving the powder in water.
Toluene was purchased from Sigma-Aldrich.
Trypan Blue (4% solution) was purchased from Sigma-Aldrich. This 
solution was diluted 1:2 with saline and filtered (0.4 pm filters).
Tissue-Tek Oct Compound was purchased from Sakura Finetek, 
Torrance, CA, USA.
Von Kossa was purchased from Bio-Optica.
2.6 Buffers and solutions
"Blocking buffer "
Bovine serum albumin (BSA; Sigma-Aldrich) was added to PBS IX to 
obtain a final BSA concentration of 1%. The solution was maintained on 
ice for few minutes to facilitate albumin solubilisation. The solution was 
then filtered with a 0.2 pm sterile filter.
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Citrate buffer 10% concentrated pH 6.0, was diluted 1:10 in PBS IX and 
was purchased from DiaPath.
Cacodylate buffer 0.2 M
Sodium cacodylate trihydrate 12.84 g, Sigma-Aldrich 
+ 300 ml of water
pH was stabilized at 7.4 w ith HC10.2 N (Merck).
Cacodylate buffer 0.1M pH 7.4
Prepared by diluting (1:1) in water cacodylate buffer 0.2 M, pH 7.4 
S^'-diam inobenzidine (DAB)
One tablet of DAB was put into 25 ml of distilled water. Solution was 
mixed and 6.5 pi of 30% H2O2 was added.
DAB was purchased from Merck.
Duboscq-Brazil solution ready to use, was purchased from DiaPath, 
Martinengo (BG), Italy.
Epon resin
Solution 1:
5 ml of Durcupam ACM, Fluka (Sigma-Aldrich)
+ 18 ml of Epoxy Embedding Medium, Hardener DDSA, Fluka 
Solution 2:
6 ml of Epoxy Embedding Medium, Fluka
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+ 300 pi of Epoxy Embedding Medium Accelerator, Fluka 
Finally, solution 1 and 2 were mixed.
2.5% glutaraldehyde in  0.1M cacodylate buffer
0.2 M cacodylate buffer, pH 7.4,19 ml 
+ 19 ml of water
+ 2 ml of glutaraldehyde solution at 50%, Fluka (Sigma-Aldrich)
Osmium tetroxide 2%
1 g osmium tetroxide crystalline, Electron Microscopy Sciences 
+ 50 ml water.
Freshly prepared working solution was used at concentration 1% in PBS. 
"Perm eabilizing solution"
TRITON X100 was purchased from Sigma-Aldrich and was diluted to a 
final concentration of 0.5%, 0.3% or 0.1% in PBS IX, as indicated in the 
Methods.
Phosphate buffer saline (PBS) 10X (for cell culture and 
immunohistochemistry) was purchased from Ambion-Invitrogen. Finally, 
PBS IX is prepared diluting 1:10 PBS 10X in water.
Paraformaldehyde-lysine-periodate (PLP) fixative
Solution A: 8% paraformaldehyde, purchased from Electron Microscopy 
Sciences (Hatfield, PA, USA).
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Solution B: 0.05 M Phosphate buffer Stock (pH 7.4)
- Dissolve 0.69 gr of Sodium Phosphate Monobasic Monohydrate in 100 ml 
of dH20 (solution I)
-Dissolve 4.45 gr of Sodium Phosphate in 500 ml of dH20 (solution II)
- Add 95 ml of solution I and 405 ml of solution II.
Solution C:
-Dissolve 9.13 gr of L-Lysine (Sigma-Aldrich) and 1.425 gr of Sodium m- 
Periodate (Sigma-Aldrich) in 500 ml of Solution B.
Solution D: PLP fixative
- Add 10 ml of solution A and 30 ml of solution C
2.7 Antibodies
For all antibodies, preliminary experiments were performed following 
manufacturer's suggestions in order to identify the most appropriate 
concentration.
Antibodies used for hCB-MSC study
- Mouse-anti human antibody CD45-PC7 (phycoerythrin-Cy7; IM3548) 
was purchased from Beckman Coulter, and used at the concentration of 
1:100.
- Mouse-anti hum an antibody CD34-PE (phycoerythrin; 550619) was 
purchased from Becton Dickinson, San Jose, CA, USA, and used at the
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concentration of 1:100.
- Mouse-anti hum an antibody CD146-FITC (fluorescein isocyanate; 5040- 
F100T) was purchased from Biocytex, Marseille, France, and used at the 
concentration of 1:100.
- Mouse-anti hum an antibody CD90-PE (CBL415P) was purchased from 
Chemicon, Temecula, CA, USA, and used at the concentration of 1:100.
- Mouse-anti hum an antibody CD44-FITC (555478) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse-anti hum an antibody VE-Cadherin-FITC (ABIN123940) was 
purchased from Bender MedSystems, Burlingame, CA, U.S.A, and used at 
the concentration of 1:100.
- Mouse-anti hum an antibody alpha SMA-FITC (F3777) was purchased 
from Sigma-Aldrich, and used at the concentration of 1:100.
- Mouse-anti hum an antibody NG2-PE (IM3454U) was purchased from 
Beckman Coulter, and used at the concentration of 1:100.
- Mouse-anti hum an antibody CD105-PE (5100-PE100T) was purchased 
from Biocytex, and used at the concentration of 1:100.
- Mouse-anti hum an antibody CD73-PE (550257) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse-anti hum an antibody CXCR4-APC (allophycocyanin; 555976) was 
purchased from Becton Dickinson, and used at the concentration of 1:100.
- Mouse-anti human antibody CD56-PE was purchased from Cymbus, 
Hampshire, UK, and used at the concentration of 1:100.
- Mouse-anti hum an antibody LNGFR-PE (557196) was purchased from
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Becton Dickinson, and used at the concentration of 1:100.
- Mouse-anti hum an antibody HLA class I-FITC (IM1838U) was 
purchased from Immunotech Beckman Coulter Company, Praha, Czech 
Republic, and used at the concentration of 1:100.
- Mouse-anti human antibody HLA class II (347360) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Unconjugated mouse-anti human antibody CK3/12 was purchased from 
Biodesign, Maine, USA, and used at the concentration of 1:100.
- Unconjugated mouse-anti hum an antibody CK19 was purchased from 
Biodesign, and used at the concentration of 1:100.
- Unconjugated mouse-anti hum an antibody BB9 (557813) was purchased 
from Becton Dickinson, and used at the concentration of 1:100.
- Unconjugated mouse-anti hum an antibody SSEA4 (MAB4304) was 
purchased from Chemicon, and used at the concentration of 1:100.
- Mouse anti-human HNA (MAB1281) antibody was purchased from 
Chemicon and used at the concentration of 1:50.
- Rabbit polyclonal anti-nitrotyrosine (06-284) antibody was purchased 
from Upstate Biotechnology, Billerica, MA, USA, and used at the 
concentration of 1:2000.
- Monoclonal mouse anti- PCNA antibody (clone PC10; P8825) was 
purchased from Sigma-Aldrich and used at the concentration of 1:250.
- Rabbit anti-phosphorylated Akt (Ser 473) (9271) antibody was purchased 
from Cell Signaling Technology, Danvers, USA, and used at the 
concentration of 1:100.
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- Biotinylated goat anti-rabbit IgG antibody (AP132B) was purchased 
from Chemicon, Temecula, CA, USA, and used at the concentration of 
1:50.
- Biotinylated sheep anti-mouse IgG antibody (AP302B) was purchased 
from Chemicon, Temecula, CA, USA, and used at the concentration of 
1:50.
- FITC-conjugated goat-anti-mouse antibody was purchased from 
Exalpha, Maynard, MA, USA, and used at the concentration of 1:50.
- PE-conjugated goat-anti-mouse antibody was purchased from Exalpha, 
and used at the concentration of 1:50.
- Isotype imm unoglobulins IgG l PE-FITC (FCMAB230P; FCMAB229F) 
was purchased from Chemicon, and used at the concentration of 1:50.
- Isotype immunoglobulins IgG l PC7 (6607099) was purchased from 
Beckman Coulter, and used at the concentration of 1:50.
- Isotype im m unoglobulins IgG l APC (554681) was purchased from 
Becton Dickinson, and used at the concentration of 1:50.
- Cy3-conjugated goat anti rabbit antibody (111-165-003) was purchased 
from Jakson Immunoresearch, West Baltimore, Pike, USA, and used at the 
concentration of 1:50.
- Cy3-conjugated goat anti-mouse antibody (115-165-146) was purchased 
from Jackson Immunoresearch, and used at the concentration of 1:50.
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Antibodies used for hAFS study
- Mouse monoclonal antibody anti-CD117 (c-Kit, SC53147, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), and used at the concentration of 
1:100.
- Mouse anti-human antibody CD29 FITC (610468) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD44 FITC (555478) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD73 PE (550257) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD90 FITC (555595) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD105 PE (560839), was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD80 FITC (557226) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody CD86 PE (557344) was purchased from 
Becton Dickinson, and used at the concentration of 1:100.
- Mouse anti-human antibody Oct-4 FITC (SC-5279) was purchased from 
Santa Cruz, and used at the concentration of 1:100.
- Mouse anti-human antibody SSEA-4 FITC (SC-21704) was purchased 
from Santa Cruz, and used at the concentration of 1:100.
- Mouse anti-human antibody HLA-ABC FITC (IM1838U) was purchased 
from Immunotech, Marseille, France, and used at the concentration of
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1:100.
- Mouse anti-human antibody HLA-DR PE (IM1639) was purchased from 
Immunotech, and used at the concentration of 1:100.
- Mouse anti-human CD105 antibody (M352701) purchased from 
DakoCytomation, Glostrup, Denmark, and used at the concentration of 
1:100.
- Rabbit anti-phosphorylated Akt (Ser 473) antibody (9721) was purchased 
from Cell Signaling Technology, Danvers, USA, and used at the 
concentration of 1:100.
- Mouse anti-Ki-67 antibody (NCL-L-ki67-MMl), was purchased from 
NovoCastra Laboratories Newcastle upon Tyne, UK.
- Mouse anti-human CD44 antibody (AB6124) purchased from Abeam, 
and used at the concentration of 1:100.
- Rabbit anti- hum an CXCR4 antibody (AB2074) purchased from Abeam, 
and used at the concentration of 1:100.
- Rabbit anti- hum an CX3CR1 (AB8021) antibody purchased from Abeam, 
and used at the concentration of 1:100.
- MicroBeads conjugated goat anti-mouse IgG antibody (11033) 
purchased from Dynal; Invitrogen, Carlsbad CA, USA.
- Cy3-conjugated goat anti rabbit antibody (111-165-003) was purchased 
from Jakson Immunoresearch, West Baltimore, Pike, USA, and used at the 
concentration of 1:50.
- Cy5-conjugated donkey anti mouse antibody (715-175-150) purchased 
from Jackson Immunoresearch and used at the concentration of 1:50.
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- Cy3-conjugated goat anti-mouse antibody (115-165-003) purchased from 
ackson Immunoresearch and used at the concentration of 1:50.
- FITC-conjugated goat anti mouse antibody (115-095-003) purchased 
from Jackson Immunoresearch and used at the concentration of 1:50.
- FITC-conjugated goat anti rabbit antibody (111-095-003) purchased 
from Jackson Immunoresearch and used at the concentration of 1:50.
2.8 Other reagents
Dapi: I'^ '-diam idino^-phenylindole dihydrochloride hydrate was 
purchased from Sigma-Aldrich.
FITC-labeled lectin W heat Germ Agglutinin (WGA) was purchased from 
Vector Lab., Burlingame, CA, USA, and used at the concentration of 1:400. 
Hum an IGF-I Quantikyne ELISA Kit purchased from R&D Systems Inc., 
Minneapolis, MN, USA.
Lympholyte-H purchased from Cedarlane; Ontario, Canada, and used at 
the concentration of 1.077 g/m l.
In Situ Cell Death Detection Kit, Fluorescein was purchased from Roche. 
M illiplex MAP purchased from Millipore, Billerica, MA, USA.
PKH-26: Red Fluorescent Cell Linker Kit for general cell membrane 
labeling was purchased from Sigma-Aldrich.
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Rhodamine-labelled Lectin Lens Culinaris Agglutinin (LCA) was 
purchased from Vector Laboratories Inc., and used at the final 
concentration of 25 pg/m l.
RosetteSep purchased from StemCell Technologies; Vancouver, Canada. 
Search Light proteome array, a multiplexed sandwich ELISA (Pierce- 
Endogen, Illinois, USA).
Vectastain ABC kit purchased from Vector Laboratories, Burlingame, CA, 
USA.
2.9 Disposable material
LiHeparinzed capillary pipettes, Hirschmann Laborgerate, Eberstadt, 
Germany.
Polyethylene labelled-cone shaped capsules purchased from Electron 
Microscopy Sciences.
Reflotron Urea test strips purchased from Roche Diagnostics GmbH, 
Mannheim, Germany.
2.10 Instrum ents
Bioplex 200 Suspension Array System purchased from Bio-Rad, 
Hercules, CA, USA.
Confocal laser-scanning microscope LS 510 Meta; Zeiss, Jena, Germany. 
Cytofluorimeters FACSCanto II was purchased from Becton Dickinson,
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BD Bioscience, Milan, Italy.
DynalBeads apparatus purchased from Dynal; Invitrogen.
Electron microscope Morgagni 268D was purchased from Philips, Brno, 
Czech Republic.
Real time-PCR: TaqMan ABI 7300 Sequence Detection System (PE 
Applied Biosystems, Monza, Italy).
Reflotron analyser purchased from Roche, Basel, Switzerland . 
Ultramicrotome purchased from LKB Instruments, Milan, Italy.
Nanodrop purchased from Celbio, Milan, Italy.
2.11 RNA isolation 
Total RNA (Trizol® Method)
Trizol® reagent was purchased as a ready-to-use solution (GIBCO- 
Invitrogen). It is an improvement to the single-step RNA isolation 
Methods, developed by Chomczynski and Sacchi (Chomczynski & Sacchi, 
1987) and consists of phenol and GITC (guanidine isothiocyanate). 
Chloroform was purchased from MERCK, Darmstad, Germany.
Isopropyl alcohol was purchased from Carlo Erba Reagenti
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2.12 DNase digestion of total RNA
The residual amount of DNA remaining after total RNA 
extraction/isolation was removed by digestion of the total RNA sample 
with DNase.
final concentration
RNA (?) pi (10 pg)
RNase-free DNase 10U/ pi 1 pi 10 U
DNase digestion buffer 10X 10 pi 1 x *
RNase Inhibitor 20 U / pi 1 pi 20 U
Distilled water to the final volume of 100 pi
Total volume 100 pi
# Stop Solution 10 pi
(?)Volume that depends on the initial RNA concentration 
*RQ1 RNase-Free DNase (Promega, Madison, USA) cointains RNase-free 
DNase, RNase Inhibitor DNase digestion buffer 10X (400 mM Tris-HCl pH 
8.0,100 mM MgSCh, 10 mM CaCh). Enzyme storage buffer is composed of 
10 mM HEPES pH  7.5, 50% glycerol v /v , lOmM CaChand 10 mM MgCl2). 
# Stop Solution 20mM EGTA.
To precipitate RNA final concentration
Distilled water 90 pi
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Sodium acetate (3 M) 20 pi 3 mM
Ethanol 500 pi
total volume 610 pi
2.13 RT-PCR
A DNA thermal cycler RT-PCR was used to carry out reactions.
RT reaction
RNA
*dNTPs (10 mM)
# RT primer (50 n g / ml)
Distilled water to the final volume
Total volume
*RT buffer 10 X 
*MgC12 (25 mM)
*DDT (0.1 mM)
’‘‘RNase inhibitor (40U /pl) 
Distilled water
Total volume
final concentration in 20 pi
? nl 2 ng
1 pl 0.5 mM
2 pi 5 n g / pi (=100 ng) 
of 10 pi
10 pi
2 pi 
2 pi
2 pi 
1 pi
3 pi
20 pi
IX
2.5 pM 
10 pM 
40 U
(?)Volume that depends on the initial RNA concentration 
§ Reverse Transcriptase (50 U / l  pi) 1 pi 50U
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^SUPERSCRIPT ™ First-Strand Synthesis System for RT-PCR (Gibco- 
Invitrogen) included: RT buffer 10 X (200 mM Tris-Cl pH8.4; 500 mM 
KC1); 25 mM MgCh; dNTP MIX (10 mM each dATP, dCTP, dGTP, dTTP); 
DTT (0.1 M); #Random hexamers (50 n g / pi); RNase OUT™ Recombinant 
Ribonuclease Inhibitor (40 un its/ pi); § Superscript ™ II RNaseH- Reverse 
Trancriptase (50 un its/ pi), Gibco-Invitrogen.
2.14 Real time RT-PCR (SYBR green methodology)
Target genes GAPDH
Volume Final in the reaction
SYBR Green PCR Master Mix 2X * 12.5 pi lx lx
Reverse primer 2.5 pi 300 nM 50 nM
Forward primer 2.5 pi 300 nM 50 nM
double distilled water 5 pi
template from RT reaction 2.5 pi (1:10) (1:100)
25 pi
* SYBR Green PCR Master Mix contains SYBR Green 1 Dye, AmpliTaq 
Gold DNA Polymerase, dNTPs with dUTP and optimised buffer 
components. It is supplied at a 2X concentration by Applied Biosystems, 
Foster City, CA, USA.
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CHAPTER 3
METHODS
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Methods for in vivo  and in vitro  experiments with hCB-MSCs
3.1 Isolation and characterization of hCB-MSCs
Human cord blood mesenchymal stem cells (hCB-MSCs) were 
kindly given by Dr. Lorenza Lazzari of the "Cell factory" at Fondazione 
IRCCS Ospedale Maggiore Policlinico, Magiagalli and Regina Elena, 
Milan, Italy. Briefly, hum an cord blood (CB) was collected after 
informed consent of the mother from full-term newborns and isolation 
of MSCs was performed within 12 hours. Cord blood was centrifuged, 
plasma discarded and UCB mononuclear cells were obtained by 
negative immunodepletion of CD3+, CD14+, CD19+, CD38+, CD66b+, 
and glycophorin A+ cells using a commercially available kit 
(RosetteSep; Materials, section 2.8) following manufacturer's 
instructions. Then the cells were laid on density gradient Lympholyte- 
H (Materials, section 2.8) and, following centrifugation, the low-density 
cell fraction was collected. After washing, cells were seeded at lxlO6 
cells/cm2 in the presence of "growth medium" (Materials, section 2.3). 
Medium was changed every 2-3 days, cells were detached using trypsin 
0.25%/EDTA 50 pM (Materials, section 2.3) when subconfluent (80%) 
and split 1:3. This technique allows reaching a 54% of isolation 
efficiency.
CB-derived cells obtained as described above were studied in 
order to verify their mesenchymal potential to differentiate towards
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osteoblasts, adipocytes and chondroblasts.
Adipogenesis: at confluence hCB-MSCs were incubated with hum an 
MSC Adipogenic Induction and Maintenance Media (Materials, section 
2.3) replaced every 2-3 days, for 3 weeks. Oil Red O (Materials, section 
2.5) incubated for 25 minutes at room temperature was used to detect 
the accumulation of lipid droplets in the vacuoles.
Osteogenesis: hCB-MSCs were grown for 2-3 weeks with human MSC 
Osteogenic Medium (Materials, section 2.3) replaced every 3-4 days. 
Subsequently the cells were washed with PBS and fixed in 10% 
formalin (Materials, section 2.5) for 20 minutes at room temperature. 
The presence of calcium rich hydroxyapatite of the extracellular matrix 
was assessed incubating the cells with 2% w /v  Alizarin Red S 
(Materials, section 2.5) solution for 20 minutes. A digital camera 
acquired images of mineral deposits.
Chondrogenesis: hCB-MSCs were centrifuged to form a pellet and 
cultured in differentiation chondrogenic medium (0.5 ml) with TGF|3 
(Materials, section 2.3) for 2 weeks. Cell clump was fixed in 
paraformaldehyde (Materials, section 2.5) and stained with Alcian Blue 
(Materials, section 2.5) to detect proteoglycans.
Human CB-MSCs were characterized by FACS analysis. Three 
independent evaluations of a pool of three different donors were 
performed. Stem cells ware incubated with "blocking buffer" 
(Materials, section 2.6) to block nonspecific sites for 15 minutes at 4°C. 
Cells were permeabilized with "permeabilizing solution" (0.1% Triton
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X-100, Materials, section 2.6) for 5 minutes at 4°C. Then, hCB-MSCs 
were incubated with conjugated mouse-anti human antibodies: CD45- 
PC7, CD34-PE, CD146-FITC, CD90-PE, CD44-FITC, VE-Cadherin-FITC, 
alpha SMA-FITC, NG2-PE, CD105-PE, CD73-PE, CXCR4-APC, CD56- 
PE, LNGFR-PE, HLA class I-FITC or HLA class II (Materials, section
2.7), for 30 minutes at 4°C.
Additional samples were stained with the primary unconjugated 
mouse-anti human antibodies: CK3/12, CK19, BB9 and SSEA4 followed 
by FITC-conjugated and PE-conjugated goat-anti-mouse antibodies 
(Materials, section 2.7). Isotype immunoglobulins IgGl PE-FITC, IgGl 
PC7, and IgGl APC (Materials, section 2.7) were used as negative 
controls. Subsequently, cells were rinsed in PBS IX, centrifuged and the 
pellet was suspended in 500 pi of PBS IX. Human CB-MSCs were 
analysed by flow cytometer.
3.2 M urine model of acute kidney injury
NOD-SCID female mice (Materials, section 2.1) two months of age 
at the start of the experiments were used. Animal care and treatment 
were conducted in conformity with the Institutional guidelines that are 
in compliance with national (D.L. n.116, G.U., suppl 40, 18 Febbraio 
1992, Circolare No. 8, G.U., 14 Luglio 1994) and international laws and 
policies (EEC Council Directive 86/609, OJL 358, Dec 1987; NIH Guide
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for the Care and Use of Laboratory Animals, U.S. National Research 
Council, 1996). Animals were housed in a constant temperature room 
(22-24 °C) with a 12-hour dark 12-hour light cycle and fed a standard 
diet.
3.2.1 Cisplatin preparation and injection
AKI was induced in female mice by subcutaneous injection of cis- 
diamminedichloroplatinum (cisplatin, Sigma-Aldrich) (Materials, 
section 2.5). To test the effect of hCB-MSCs, cisplatin was administered 
to mice, based on their weight, at a concentration (chosen by 
preliminary experiments) of 12.7 m g/kg. Cisplatin was freshly 
prepared as a stock solution of 1 m g/1  ml and dissolved in 0.9% sterile 
saline solution that was pre-warmed to 37°C. Cisplatin dissolved easily 
in saline as indicated by the disappearance of the yellow powder. 
Importantly, cisplatin needs to be protected from light and contact w ith 
metal (i.e aluminium) should be avoided.
To facilitate injection, mice were anesthetized for a few minutes in 
a container containing Isofluorane (Materials, section 2.5). A total 
volume of 400 pi was subcutaneously injected into female mice by 
using 1 ml syringe (needle 30Gxl/2").
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3.3 Cell administration
3.3.1 Human CB-MSC administration
Human CB-MSCs were administered to NOD-SCID female mice 
one day after receiving cisplatin. Cells were suspended in 500 pi of 
sterile saline. Before injection, mice were exposed to an infrared lamp to 
induce vasodilatation and facilitate injection into the tail vein. To 
investigate the effect of hCB-MSCs, female NOD-SCID mice were 
divided into two groups and intravenously (i.v.) injected as follows: 
group 1, saline (n=12); group 2, hCB-MSCs (5x 105 cells/mouse) (n=ll). 
Mice were sacrificed at 4 days after cisplatin and kidney samples were 
used for histology and immunohistochemistry evaluations. For survival 
studies seven animals for each groups (saline and hCB-MSCs) were 
used.
By additional experiments, we compared the effect of hCB-MSCs 
with that of hum an bone marrow (BM)-MSCs on renal function (at 4 
days) and animal survival. Human BM-MSCs (Materials, sections 2.2 
and 2.3) were isolated as previously described (Morigi et al.f 2008; 
Capelli et al., 2007). Mice were divided into three groups and i.v. 
injected 24 h after cisplatin as follows: group 1, saline (n=8); group 2, 
hCB-MSCs (5x105 cells/mouse) (n=10); group 3, hBM-MSCs (5x105 
cells/mouse) (n=10).
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3.3.2 Human fibroblast administration
To better explain the specificity of stem cell effect, we 
intravenously injected hum an fibroblast (Materials, sections 2.2 and 2.3) 
(5x105 cells/mouse) in mice 24 hours after cisplatin administration 
(n=9), in comparison with mice given saline (n=10). Three mice treated 
with hum an fibroblast and four saline-treated mice were sacrificed at 4 
days to assess renal function and histology. The remaining mice were 
followed during time for survival studies. Normal mice served as 
controls
3.4 Renal function measurement
To assess renal function, we measured blood urea nitrogen (BUN). 
Mice were bled from the retro-orbital plexus while they were 
anesthetized with Isofluorane. By means of disposable LiHeparinzed 
capillary pipettes (Materials, section 2.9), 32 pi blood was collected from 
the venous retro-orbital plexus. Blood was applied to test strips and 
BUN was read by a Reflotron analyser (Materials, section 2.10) in 180 
seconds. BUN levels exceeding 30 m g /d l were considered abnormal 
(normal range in our laboratory: 14-29 m g / dl).
Blood samples for BUN determination were collected at day 0 (basal 
BUN) and day 4, after cisplatin injection in mice administered with 
saline or receiving stem cells.
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3.5 Sacrifice and tissue collection
Mice were sacrificed by exposure to CO2 at 4 days after cisplatin 
or 24 h after cell administration. Kidneys were weighed and in order to 
take samples representative of the different structural components of 
the kidney, sections were cut in the axial coronal plane. Depending on 
the type of procedure that would have been applied (light microscopy, 
electron microscopy, immunohistochemistry), samples were differently 
fixed as described in each specific chapter.
Kidney samples were also taken from mice (n=3), which survived 
40 days after hCB-MSC injection to assess the possible presence of 
abnormal phenotype.
3.6 Renal morphology
3.6.1 Light microscopy
Immediately after collection, kidney fragments were fixed 
overnight in Duboscq-Brazil solution (Materials, section 2.6) and then 
dehydrated by ascending concentrations of ethanol (50, 70, 90,100% for 
5 minutes each). Once dehydrated, samples were dipped in toluene 
(Materials, section 2.5) for 1 hour, transferred to stainless steel base 
moulds and then paraffin (Materials, section 2.5) was added to cover 
the sample, subsequently incubated at 60°C for 2 hours. During this
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period of time paraffin can infiltrate the sample. Samples were then 
placed at room temperature to allow paraffin to solidify and embed the 
sample. A microtome was used to cut 3 pm thickness slices, which were 
placed at room temperature on glass slides. The sections were 
deparaffinised in toluene (a paraffin solvent) for 20 minutes and then 
rehydrated in decreasing concentrations of ethanol: (100% for 10 
minutes followed by 90, 70,50% for 5 minutes each) and water. In order 
to study renal morphology, samples were stained with haematoxylin 
and eosin (Materials, section 2.5). Glass slides were immersed in 
haematoxylin for 10 minutes followed by two quick rinses in distilled 
water and then in tap water for 5 minutes. Eosin was then added for 3 
minutes. After rinsing in water, samples were immersed in 100% 
ethanol followed by toluene and then m ounted with Eukitt (Materials, 
section 2.5).
To identify the basement membrane we stained the glass slides 
with periodic acid-Schiffs reagent (PAS-stain) (Materials, section 2.5). 
Samples were deparaffinized as already described, incubated for 10 
minutes with 1% periodic acid and were then washed under tap water 
for three minutes followed by a rapid wash in distilled water. Slides 
were stained with Schiff s reagent for 35 minutes and immersed three 
times for 5 minutes each in sodium hyposulphite (Materials, section 
2.5), rinsed in tap water for 5 minutes, and then in distilled water for 
another 5 minutes. Samples were then immersed in 100% ethanol 
followed by toluene and then mounted.
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Slides were scored for the following changes: luminal hyaline 
casts, tubular cell degenerative changes (cytoplasmic vacuolisation, 
swelling, cell flattening, PAS-positive droplets, nuclear fragmentation, 
cell debris) and cell loss (denudation of the tubular basement 
membrane). Non-overlapping fields of the entire section (up to 28 fields 
for each mouse) were analysed at high magnification using a 40x 
objective (high power field, HPF). Lesions were focal in distribution 
and the scores ranged from 0 to 3+ as follows: 0, no changes; 1+, very 
occasional tubular profiles (usually < 3 / section and < 2 /HPF) affected 
by lesions; 2+, more evident lesions affecting a minor percentage of 
tubules in each affected area; 3+, lesions in most tubules within affected 
areas. Sections were analysed in a single-blind fashion. Renal histology 
pictures were acquired and representative images are shown in the 
Results.
3.6.2 Electron microscopy
Small fragments of kidney tissue, not more than 0.5-1 mm 
thickness, were fixed for 4 h  in 2.5% glutaraldehyde in 0.1 M cacodylate 
buffer, pH 7.4 (Materials, section 2.6) and washed repeatedly in the 
same buffer in order to stabilize the sample and prevent degradation. 
Specimens were post-fixed in 1% OsC>4 (Materials, section 2.6) for 1 
hour. This step confers stability during the following steps of 
dehydration and embedding and provides electron contrast. Specimens 
were dehydrated through ascending grades of alcohol: 10% for 10
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minutes, 50% and 70% for 10 minutes each, 90% and 100% for 15 
minutes each. Samples were then placed in propylene oxide (1,2- 
epoxypropane) (Materials, section 2.5), a fluid miscible with both 
alcohol and epoxy resin, and embedded in Epon resin (Materials, 
section 2.6) overnight at room temperature that maintains the resin in a 
liquid state to better infiltrate the sample. Polyethylene labelled-cone 
shaped capsules (Materials, section 2.9) containing freshly prepared 
resin was used to contain the samples. Tissue fragments were placed at 
the tip of the truncated cone that was filled with embedding 
thermosetting synthetic resins. After 3 days during which time the 
samples were incubated at 60°C to allow polymerisation and 
solidification of the resin, the blocks of resin were cut by 
ultramicrotome (Materials, section 2.10). Ultrathin sections were stained 
with uranyl acetate and lead citrate and examined using a Philips 
Morgagni electron microscope (Methods, section 2.10) by Dr. Daniela 
Rottoli.
3.7 PKH-26 staining
To study intrarenal localization of stem cells, we labelled before 
injection, the cells with a red fluorescence cell linker (PKH-26) 
(Materials, section 2.8) as follows. A single cell suspension, obtained 
after stem cell detachment with Trypsin, was washed once using
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medium without serum. After centrifugation at 400xg for 5 minutes, the 
cells were incubated with 1 ml of Diluent C and then with 1 ml of 2X 
Dye Solution (4 pM) for 5 minutes with periodic mixing. An equal 
volume (2ml) of serum was added for 1 minute to stop the staining. 
After centrifugation at 400xg for 5 minutes, the cells were resuspended 
in complete medium and centrifuged at 400xg for 5 minutes, then the 
cells were washed 2 more time with serum free medium. Labelling 
efficacy was assessed to be >98% and viability evaluated by Trypan 
blue (Materials, section 2.5) exclusion was >96%. For in vivo 
experiments the PKH-26 positive cells were resuspended in saline 
(500 pi/mouse) and intravenously injected.
3.7.1 Quantification of PKH-26 labelled hCB-MSCs
After 4 days, mice were sacrificed and kidney samples were fixed 
in 4% paraformaldehyde (Materials, section 2.5) overnight at 4°C, then 
infiltrated with 30% sucrose/phosphate buffer saline (PBS), embedded 
in Tissue-Tek OCT Compound (Materials, section 2.5) and frozen in 
liquid nitrogen. Eight-micrometer-thick sections were stored at -80°C. 
Sections were fixed 10 minutes in acetone (Materials, section 2.5) and 
incubated for 10 minutes at room temperature with FITC-labelled lectin 
Wheat Germ Agglutinin (WGA, Materials, section 2.8), which binds 
membrane glycoproteins and sialic acid and was used to better identify 
tubular structure. Nuclei were stained with 4',6'-diamidino-2- 
phenylindole dihydrochloride hydrate for 15 minutes at room
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temperature (DAPI, Materials, section 2.8). Slides were analysed for 
PKH-26 positive cells. A number of twenty sections/mouse (n=4 mice) 
were analyzed and PKH-26 positive cells were counted. Data were 
expressed as number of PKH-26 positive cells/105 renal cells. The 
engraftment of hCB-MSCs-PKH-26 positive was also evaluated at 4 
days in other organs as liver, lung and spleen. Tissue samples were 
fixed as above and sections stained with DAPI. Six sections /m ouse 
(n=3 mice) were analysed for each organ, and PKH-26 positive cells 
were counted.
In order to confirm the human origin of hCB-MSCs, the stem cells 
were also identified for their positivity to the human nuclear antigen 
(HNA). Sections were fixed 10 minutes in acetone and then treated with 
"permeabilized solution" containing Triton 0.5% (Materials, section 2.6) 
for 10 minutes at room temperature. After washing in PBS IX 
(Materials, section 2.6), sections were treated with "blocking buffer" 
(Materials, section 2.6) for 15 minutes at room temperature, followed by 
incubation overnight with mouse anti-human HNA antibody 
(Materials, section 2.7) at 4°C. Subsequently, kidney samples were 
treated with an anti-mouse Cy3 antibody for 1 hour at room 
temperature as secondary antibody. Renal structure was evidenced by 
staining the sections with FITC-WGA lectin for 10 minutes, while nuclei 
were stained with DAPI for 15 minutes at room temperature.
Fluorescence was examined by an inverted confocal laser- 
scanning microscope (Materials, section 2.10).
77
C H A P T E R  3: M E T H O D S - A K I
3.8 Immunohistochemistry
3.8.1 Oxidative damage
To determine protein nitration of tyrosine residues, paraffin 
kidney sections (3 pm) were fixed with methanol and incubated with 
30% H 2O2 for 30 minutes at room temperature. Then sections were 
treated in citrate buffer (Materials, section 2.6) 10 m m ol/L  (pH 6.0) at 
boiling temperature for 20 minutes, followed by incubation with citrate 
buffer (20 minutes) at room temperature to enhance the reactivity of 
antibodies to antigens. Subsequently slides were treated with 
"permeabilizing solution" (0.3% Triton X-100) (Materials, section 2.6) 
for 15 minutes and "blocking buffer" (Materials, section 2.6) for 30 
minutes at room temperature. Then sections were incubated with rabbit 
polyclonal anti-nitrotyrosine (Materials, section 2.7), followed by 
biotinylated goat anti-rabbit antibody (Materials, section 2.7). Signal 
was developed using Vectastain ABC kit (Materials, section 2.8) and 
DAB reagents (Materials, section 2.6). Negative controls were 
performed omitting the primary antibody. At least 30-40 non­
overlapping sequential fields (n= 4 mice for each group) were analyzed. 
Each section was scored for intensity (absent, faint, moderate, intense: 0 
through 3).
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3.8.2 Apoptosis
Apoptosis was measured by a terminal transferase-mediated 
dUTP nick-end labelling (TUNEL) assay using an in situ cell death 
detection kit (Materials, section 2.8). Sections fixed in PLP (Materials, 
section 2.6) were treated in citrate buffer 10 m m ol/L  (pH 6.0) at boiling 
temperature for 20 minutes, followed by incubation with citrate buffer 
(20 minutes) at room temperature to enhance the reactivity of 
antibodies to antigens. To block nonspecific sites, sections were treated 
with "blocking buffer" for 15 minutes at room temperature and then 
incubated for 80 minutes at 37°C with TUNEL reaction mixture, that 
should be prepared immediately before use. The TUNEL reaction 
mixture was prepared add 50 pi of Enzyme Solution to 450 pi of Label 
Solution. As negative controls PLP-fixed slides were incubated only 
with Label Solution, while as positive controls, slides were treated with 
DNase I recombinant for 20 minutes at 37°C. Subsequently, sections 
were rinsed in PBS IX and then counterstained with Rhodamine- 
labelled lectin Lens Culinaris Agglutinin (LCA, Materials, section 2.8) 
and DAPI for 15 minutes. Slides were mounted with mounting m edium  
and analysed by confocal microscopy. To identify the anti-apoptotic 
effect of hCB-MSCs (ten fields/mouse; n=5 mice for each group) 
apoptotic nuclei and DAPI-positive cells per field were counted and the 
results were expressed as TUNEL positive cells/103 cells.
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3.8.3 Akt
To evaluate the effect of stem cells on the activation of the pro­
survival factor Akt, kidney samples were directly embedded in Tissue- 
Tek OCT Compound, frozen in liquid nitrogen, and stored at -80°C. 
Three-micrometer-thick sections of control, cisplatin-treated mice and 
cisplatin mice injected with PKH26-labeled hAFS cells, were fixed 10 
minutes in acetone at 4°C. The antigen retrieval was performed in 
citrate buffer at boiling temperature for 20 minutes, followed by 
incubation with citrate buffer (20 minutes) at room temperature. To 
block nonspecific sites, sections were treated with "blocking buffer" for 
30 minutes at room temperature, followed by incubation overnight with 
rabbit anti-phosphorylated Akt (Ser 473) antibody (Materials, section
2.7) at 4°C. Subsequently, kidney samples were treated with goat anti 
rabbit-Cy3 antibody (Materials, section 2.7) for 1 hour at room 
temperature. Renal structure was stained with FITC-WGA lectin for 10 
minutes, while nuclei with DAPI for 15 minutes at room temperature. 
Fluorescence was examined by an inverted confocal laser-scanning 
microscope.
Thirty fields per mouse (n=3 mice for each group) were analyzed and 
phosphorylated-Akt positive tubules were counted. Data were 
expressed as percentage of phosphorylated-Akt positive tubules per 
field.
80
C H A P T E R  3: M E T H O D S - A K I
3.8.4 Proliferation
The contribution of hCB-MSCs in the proliferation of tubular cells 
was evaluated by using an antibody identifying the proliferating cell 
nuclear antigen (PCNA) (Materials, section 2.7) as followed. Sections 
fixed in Dubosq-Brazil were deparaffinized and dehydrated. To obtain 
an adequate signal with PCNA antibody, the sections were microwaved 
twice for 10 min in citrate buffer, and incubated for 30 min with 0.3% 
H2O2 in methanol to quench endogenous peroxidases. To block 
nonspecific sites, sections were treated with 2% normal sheep serum 
and 1% BSA for 30 min at room temperature. Then the sections were 
incubated overnight with anti-PCNA antibody (Materials, section 2.7) 
at 4°C. After rinsing with PBS IX, sections were incubated with 
secondary antibody biotinylated sheep anti-mouse IgG (Materials, 
section 2.7), for 30 min at room temperature. PCNA signal was 
developed by Vectastain ABC kit using 3,3' diaminobenzidine (DAB) as 
substrate. Nuclei were counterstained with Harris hematoxylin. 
Evaluation was performed by counting PCNA positive cells in tubular 
profiles in at least 15 high power field (HPF, x400)/section (n=6 mice 
for each group).
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3.9 PCR and PCR-based techniques
These experiments were performed in collaboration with Dr. 
Lorena Longaretti of the "Gene Therapy unit" at the "Mario Negri" 
Institute for Pharmacological Research, Bergamo, Italy.
3.9.1 Preparation of total RNA
In order to isolate total RNA, Trizol® reagent (Materials, section 
2.11) was used. Trizol® reagent consists of a ready-to-use solution of 
phenol and GITC (Guanidine isothiocyanate). While disrupting cells 
and dissolving cell components, this solution has the function of 
maintaining the integrity of RNA. This method is an improvement to 
the single-step RNA isolation method originally developed by 
Chomczynski and Sacchi (Chomczynski & Sacchi, 1987). RNA was 
prepared by following the manufacturer's instructions.
Frozen kidney samples of cisplatin-mice given saline or hCB-MSCs 
were lysed with Trizol® reagent under a fumehood (1 m l/10 cm2). With 
the aim of separating the solution into an aqueous phase and an organic 
phase, 0.2 volumes (200 pi per 1ml Trizol) of chloroform were added. 
Chloroform (Materials, section 2.11) was incubated for 2-5 minutes at 
room temperature followed by centrifugation (12000 g, 15 minutes, 
4°C). Centrifugation separates the aqueous phase of the solution from 
the organic phase. Following centrifugation, RNA remained in the 
upper aqueous phase and this was carefully removed and transferred to
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a new tube. In order to precipitate RNA, isopropyl alcohol (Materials, 
section 2.11) was added to the recovered aqueous phase (500 pi 
isopropyl alcohol per 1 ml Trizol) and incubated for 10 minutes at room 
temperature. Following centrifugation for 15 min at 4°C at 12000 g, a 
gel-like pellet formed on the side and bottom of the tube and this was 
washed with 75% ice-cold ethanol (1 ml EtO H/m l Trizol). Ethanol at 
this concentration removed the excess of the remaining isopropyl 
alcohol and partially rehydrated the RNA pellet. After centrifuging at 
7500 g, for 5 minutes, at 4°C, RNA was allowed to air dry prior to 
resuspension in sterile water (about 20 pi, depending on the size of the 
pellet). RNA concentration was determined spectrophotometrically by 
Nanodrop (Materials, section 2.10). The calculation of the concentration 
of the nucleic acid in the sample was obtained by reading at a 
wavelength 260 nm. By using the formula here reported, we can easily 
calculate the pg /m l of RNA in the sample since 40 pg /m l of single­
stranded RNA approximately corresponds to an OD of 1:
RNA (pg/ pi) = OD 260nm x 40 x dilution (i.e. 100 =100 pi /  1 p i)/1000
To evaluate the purity of nucleic acid we can observe the ratio 
between the readings at 260 nm and 280 nm  (OD260/OD280 = nucleic 
acid and proteins/proteins) providing an estimation of the purity. The 
optimum value is between 1.8 and 2 (for RT-PCR it is better to have 2- 
2.1). If there is contamination of proteins the value will be lower, and 
the accuracy of the RNA quantisation will be impaired. In addition to
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control for phenol contamination, a reading at 320 nm  is performed and 
it should be equal to the blank.
3.9.2 DNA digestion of total RNA
For certain RNA applications that are sensitive to very small 
amounts of DNA, further DNA removal may be necessary. Indeed, in 
these cases, digestion with the enzyme DNase can remove the small 
residual amounts of DNA remaining after total RNA isolation. Total 
RNA (10 pg) was treated with RNase-free DNase (10 U DNase/10 pg 
RNA) in the presence of RNase Inhibitor (2 U /p g  of RNA) in a final 
volume of 100 ml with nuclease free water following the manufacturer's 
instructions (Materials, section 2.12). Samples were digested for 1 hour 
at 37°C and then the reaction was blocked by incubation (10 minutes at 
65 °C) with Stop Solution (Materials, section 2.12) (10 pi, same volume 
of the enzyme) containing 20 mM EGTA (pH 8.0) that blocks enzyme 
activity. At the end of incubation, RNA is precipitated by sodium 
acetate 3M pH 5.2 (1/10 of the volume) (Materials, section 2.12) and 
100% ethanol and centrifuged at 13800 rpm  for 30 minutes at 4°C. After 
washing with 70% ethanol (500 pi), air-drying for 5 minutes on ice and 
centrifuging for 10 minutes, the pellet was resuspended in 10 pi of 
sterile water.
A second quantification of the RNA was then performed by a 
spectrophotometer, as already described (Methods, section 3.23).
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3.9.3 Preparation of cDNA by RT-PCR
The purified RNA was reverse transcribed into cDNA. We 
prepared a solution containing 2 pg RNA, dNTPs, random  examer 
primers and sterile water to a final volume of 10 pi/sam ple (Materials, 
section 2.13). This solution was incubated in the thermal cycler for 5 
minutes at 65°C, quickly spun and pu t at 4 °C for primer 
annealing/hybridization. The following reagents were mixed and 
incubated for 2 minutes at 25°C: RT-buffer, Mg2+, DDT and RNase OUT 
(Materials, section 2.13). Samples to be retro-transcribed were added 
with Reverse Transcriptase (Materials, section 2.13). Negative controls, 
needed to verify if there was a genomic contaminant, consisted of 
* samples that had no enzyme added. Reaction was allowed to take place 
at 25 °C for 10 minutes in the thermal cycler followed by 50 minutes at 
42°C to start retro-transcription, 15 minutes at 70°C to terminate 
elongation. Finally samples were transferred to 4°C to stop the reaction.
3.9.4 Real time PCR for HGF gene
The cDNA obtained by RT-PCR was amplified by real-time PCR. 
Real-time PCR was performed by TaqMan ABI 7300 Real Time PCR 
System and PCR amplification reaction were by SYBR Green 
methodology with all the reagents supplied directly from Applied 
Biosystems and performed following the manufacturer's instructions as 
described in Materials, section 2.14. Template from RT reaction was 
mixed with SYBR Green PCR Master Mix and with forward primers
85
C H A P T E R  3: M E T H O D S - A K I
and reverse for hum an HGF or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (Materials, section 2.14). The primer 
sequence design was achieved by using the "Primer Express" dedicated 
software (Applied Biosystems) and were as follows:
HGF primers:
Forward: 5/-TCAAATGCCAGCCTTGGAA-3,
Reverse: 5'- GCAAAAAGCTGTGTTCATGGG-3,
GAPDH primers:
Forward: 5'-TCATCCCTGCATCCACTGGT-3'
Reverse: 5'-CTGGGATGACCTTGCCCAC-3'
After an initial hold of 2 minutes at 50°C and 10 minutes at 95°C, the 
samples were cycled 40 times at 95°C for 15 seconds and 60°C for 60 
seconds. The comparative Ct method normalizes the number of target 
gene copies to a housekeeping gene as GAPDH (ACt). Gene expression 
was then evaluated by the quantification of cDNA corresponding with 
the target gene relative to a calibrator sample serving as a physiologic 
reference (mouse with vehicle, A ACt). On the basis of exponential, 
amplification of target gene as well as calibrator, the amount of 
amplified molecules at the threshold cycle is given by: 2™°.
The identity of the amplification product was ensured by primer 
specificity for the HGF sequence, the presence of a single dissociation 
curve at a constant T melting, and the lack of genomic DNA
contamination or primer dimers in the RT" samples.
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3.10 In vitro  experiments
3.10.1 Cells and cell culture
HK2. Immortalized adult hum an proximal tubular cell line (HK-2) 
was purchased from ATCC (Materials, section 2.2). Originally, the HK-2 
cell line has been established by the group of Dr. Ryan (Ryan et al., 
1994) from normal adult male kidney unsuitable for transplantation. 
Firstly, cortical proximal tubular segments were isolated by 
microdissection and digestion with collagenase. The digested tissue 
was centrifuged after passing through a steel sieve. The pellet was then 
added to a 31% Percoll and viable proximal tubular cells (PTCs) were 
recovered at the bottom of the tube after centrifugation. Once obtained, 
PTCs were transferred in a tissue culture flask and maintained in 
selected medium until approximately 2 weeks to obtain the confluence. 
Secondly, in order to establish long-term culture, the cells were exposed 
for 48 hours to a replication-defective recombinant retrovirus 
containing the human papilloma virus (HPV) 16 E6/E7 genes. At 
molecular level, E6 binds to p53 inducing its degradation, and E7 
inactivates the retinobloastoma tumor-suppressor gene product, pl05- 
Rb. The elimination of these two negative regulators of the cell 
proliferation allowed for the development of the immortalized cell line. 
Transfected cells were then enzymatically detached, re-plated in flasks 
and growing cell clones were isolated. Only the clone, named HK-2, 
was grown for more than 30 passages for almost one year and has been 
characterized.
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HK-2 cells showed cuboidal morphology and dome formation, 
numerous surface projections consistent with microvilli and junctional 
complexes resembling those observed in primary cultured proximal 
tubular epithelial cells (PTECs). HK-2 cells stained positive for typical
i
brush border membrane (BBM)-associated enzymes (alkaline and acid 
phosphatase, gamma glutamyltranspeptidase and leucine 
amidopeptidase), for cytokeratin and vimentin -intermediate 
cytoskeletal filaments characteristic of epithelial cells- and they also 
express a3pi integrin with a pericellular pattern. The HK-2 cells did not 
express factor VIII, CALLA endopeptidase or 6.19 antigen, markers for 
endothelial cells, fibroblasts and adipocytes, respectively.
This cell line maintained functional characteristics similar to the 
primary PTECs, such as adenilate cyclase activity in response to 
parathyroid hormone (PTH) and Na+-dependent glucose uptake, 
suggesting that some receptor-mediated hormonal responses as well as 
sugar transport mechanisms are preserved.
In our laboratory, HK-2 cells were maintained in culture following the 
conditions allowing the maintenance of the described proximal tubular 
cell phenotype.
Medium. "Growth medium" (Materials, section 2.3).
Cell density. For routine cell culturing, HK-2 cells were seeded at the 
dilution of 1:2 (1:3 in the week-end) and maintained at 37°C in a 5% CO2 
humidified atmosphere. The cells were maintained at sub-confluence. The
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cells were subcultured every second day by using trypsin/EDTA 
(Materials, section 2.3) for 1 minute at room temperature.
Viability: Each time HK2 were detached, we evaluated the cell viability by 
Trypan blue. An aliquot of solution containing cells (20 pi) was mixed 
with the same volume of 2% Trypan blue solution. After a few seconds, 
the cells were seeded on Burker's chamber (Methods, Section 3.26) in the 
space within the glass of the chamber and the coverslip. Live (white) and 
dead (blue) cells were counted.
Cell storage. HK-2 cells were preserved for long-term storage in liquid 
nitrogen. Cell pellets were suspended in FCS plus 7.5% DMSO (Materials, 
section 2.5) in cryovials. To guarantee a gradual freezing, the vials were 
left in isopropanol-filled containers overnight at -80°C and then 
transferred to liquid nitrogen tanks for storage.
Thawing frozen cells. The cells were thawed rapidly by placing the vial in a 
water bath at 37°C with a gentle agitation. The cells were then slowly 
resuspended in 9 ml of complete medium and DMSO traces were remove 
by centrifugation at 1200 rpm  for 7 minutes.
hCB-MSCs. Human cord blood mesenchymal stem cells were kindly 
supplied from Dr. Lazzari as already described in Materials, section 2.2. 
Cells were maintained in culture in "growth medium" (Materials, section
2.3) then they were detached and used for in vivo and in vitro experiments. 
Cell storage. hCB-MSCs were preserved for long-term storage in liquid 
nitrogen. Cell pellets were suspended in "growth medium" plus 10%
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DMSO in cryovials. To guarantee a gradual freezing, the vials were left in 
isopropanol-filled containers overnight at -80°C and then transferred to 
liquid nitrogen tanks for storage.
Thawing frozen cells. The cells were thawed rapidly by placing the vial in a 
water bath at 37°C with a gentle agitation. The cells were then slowly 
resuspended in 9 ml of complete m edium and DMSO traces were remove 
by centrifugation at 1200 rpm  for 7 minutes.
3.10.2 Indirect co-culture experiments
For the experiments, HK-2 cells were seeded on 6-well transwell 
plates at the concentration of 46xl03 cells/cm2 (day -1). The day after (day 
0), HK2 that were about 70-80% confluent, have been washed with PBS IX 
and incubated with 8 pM of cis-platinum (Il)-diamine dichloride 
(cisplatin) (Materials, section 2.5) in pre-warmed "test medium"(Materials, 
section 2.3). Cisplatin was incubated for 6 hours and then was removed 
followed by rinsing with PBS IX. After drug withdrawal, hCB-MSCs 
(5x104 cells/well) were seeded on the top of the semipermeable Transwell 
polycarbonate tissue culture inserts (0.4 pm, diameter). Cell supernatants 
obtained by cisplatin-treated HK-2 cells alone or in co-culture with hCB- 
MSCs were collected at 24-72 hours after cisplatin.
3.10.3 Proteome assay
These experiments were performed in collaboration with Dr. 
Lazzari's group. Growth factors and inflammatory cytokines produced by
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indirect co-culture experiments were quantified by Search Light proteome 
array (Materials, section 2.8) in conditioned cell supernatants. 
Supernatants were analysed by Hum an Angiogenesis Array 1 (HGF, FGF, 
HB-EGF, VEGF) and the Hum an Inflammatory Cytokine 1 (IL-lb and 
TNFa) following manufacturer's instructions. ArrayVisionTM Software 
for data acquisition and management was used following manufacturer's 
instructions. In addition, serum levels of HGF were evaluated in cisplatin- 
mice given saline (n=10 mice) or hCB-MSCs (n=10 mice) at 4 day using the 
same multiplexed sandwich ELISA.
3.11 Statistics
The results are expressed as mean ± SE. Statistical analysis was 
performed using ANOVA followed by Tukey Cicchetti test for multiple 
comparisons, non parametric Kruskal-Wallis test or log-rank test, as 
appropriate. The Wilcoxon- based method was used to determine the 
significance of differences between independent groups. Statistical 
significance level was defined as p<0.05.
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Methods for in vivo  and in vitro  experiments w ith hAFS cells
3.12 Isolation and characterization of hAFS cells
Human amniotic fluid stem (hAFS) cells were kindly given by Dr. 
Paolo De Coppi of the "Stem Cell Processing Laboratory, Clinic of 
Paediatric Oncohematology" at University of Padova, Padova, Italy. The 
isolation was performed as previously described (De Coppi et ah, 2007). 
Briefly, back up samples of hum an amniocentesis were collected from 
consenting volunteer donors, according to guidelines from the Azienda 
Ospedaliera Padova (protocol number 451P/32887). The cellular content 
of the AF samples was pelleted by centrifugation, washed in PBS lx  and 
subjected to immunoselection. The cells were incubated with a mouse 
monoclonal antibody anti-CD117 (c-Kit, Materials, section 2.7) followed by 
goat anti-mouse IgG MicroBeads (Materials, section 2.7) and then selected 
on a DynalBeads apparatus (Materials, section 2.10). After 
immunoselection, c-Kit positive cells were seeded in "growth medium" 
(Materials, section 2.3). Human AFS cells were subcultured at a dilution of 
1:4 to 1:8 and expanded up to 70% of confluence. All the in vitro and in vivo 
experiments were performed with hAFS cells between passages 6-8. 
Differentiation of hum an AFS cells (2-7th passage) toward adipocytes and 
osteocytes was obtained by exposing cells to specific inductive media. 
Adipogenesis: cells were seeded at the density of 3,000 cells/cm2 and were 
cultured with "inductive media" with adipogenic supplements (Materials,
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section 2.3). Medium was replaced every 2-3 days, for 3 weeks. Oil Red O 
(Materials, section 2.5) incubated for 25 minutes at room temperature was 
used to detect the accumulation of lipid droplets in the vacuoles.
Osteogenesis: cells were seeded at the density of 3,000 cells/cm 2 and 
were cultured with "inductive media" with osteogenic supplements 
(Materials, section 2.3). Medium was replaced every 2-3 days, for 3 weeks. 
Von Kossa (Materials, section 2.5) staining was used to detect calcium 
deposition.
Immunophenotype of hAFS cells was evaluated by FACs analysis. 
Five independent evaluations of a pool of three different donors were 
performed. Stem cells were incubated with "blocking buffer" to block 
nonspecific sites for 15 minutes at 4°C. Then, hAFS cells were incubated 
with conjugated anti-human antibodies: CD29 FITC, CD44 FITC, CD73 PE, 
CD90 FITC, CD105 PE, CD80 FITC, CD86 PE, Oct-4 FITC, SSEA-4 FITC, 
HLA-ABC FITC or HLA-DR PE (Materials, section 2.7) for 30 minutes at 
4°C. Subsequently, cells were rinsed in PBS IX, centrifuged and the pellet 
was suspended in 500 pi of PBS IX. Hum an AFS cells were analysed by 
flow cytometer.
3.13 Murine model of acute kidney injury
Murine model of acute kidney injury was induced in NOD-SCID 
female mice by subcutaneous injection of cisplatin (Ebewe; Materials,
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section 2.5) described above (see section 3.2).
To test the effect of hAFS cells, we used a cisplatin already diluted, 
commonly used in patients undergoing chemotherapy, at a concentration 
of 15.5 m g/Kg. To facilitate injection, mice were anesthetized for a few 
minutes in a container containing Isofluorane (Materials, section 2.5). A 
total volume of 400 pi was subcutaneously injected into female mice by 
using 1 ml syringe (needle 30Gxl/2").
3.14 Stem cell adm inistration
To test the effect of hAFS cells, female NOD-SCID mice were divided 
into two groups and 24 h after cisplatin were intravenously injected as 
follows: group 1, saline (n=ll); group 2, hAFS cells (5x 105 cells/mouse) 
(n=ll). Mice were sacrificed at 4 days after cisplatin and kidneys used for 
histology and immunohistochemistry. Normal mice served as controls 
(n=ll).
To assess survival, cisplatin-treated mice given saline (n=7) and 
cisplatin-treated mice infused with hAFS cells (5x10s cells/mouse) (n=9) 
were used. By additional experiments the effect of hAFS cell infusion 
(5x10s cells/mouse) on survival of mice with AKI, was compared with that 
of hBM-MSCs (5x10s cells/mouse) and saline (n=6 animals for each 
group).
In addition, we compared the effect of hAFS cells with that of hAFS 
cells pre-conditioned with GDNF (100 ng /m l for 24 h Materials, section
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2.4) before injection. Twenty-four hours after cisplatin, mice were divided 
into three groups and i.v. injected as follows: group 1, saline (n=9); group 
2, hAFS cells (5x10s cells/mouse) (n=10); group 3, GDNF pre-conditioned 
hAFS cells (5x10s cells/mouse) (n=10). Animals were sacrificed at 4 days 
after cisplatin. For cell engraftment experiments, female mice were 
divided as follow (n=3 anim als/group): control mice injected with hAFS 
cells untreated (group 4) or treated with GDNF (group 5), cisplatin-mice 
infused with hAFS cells untreated (group 6) or treated with GDNF (group 
7). The animals were sacrificed 24 h after cell injection.
3.15 Renal function measurement
Blood samples for blood urea nitrogen (BUN) determination were 
collected as previously describe (section 3.4).
3.16 Sacrifice and tissue collection
Mice were sacrificed by exposure to CO2 at 4 days after cisplatin or 
24 h after cell administration. Kidneys were weighed and sections were 
cut in the axial coronal plane. Depending on the type of procedure that 
would have been applied (light microscopy, electron microscopy, 
immunohistochemistry), samples were differently fixed as described in 
each specific chapter.
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3.17 Renal morphology
3.17.1 Light microscopy
As described in section 3.6.1, kidney samples were fixed in Duboscq-Brazil 
and paraffin-sections were stained with hematoxylin and eosin, or 
periodic acid-Schiff's reagent (PAS). Luminal hyaline casts and tubular 
necrosis (denudation of tubular basement membrane) were assessed as 
reported in section 3.6.1 in non-overlapping fields (up to 28 for each 
section) (40x, high power field, HPF).
3.17.2 Electron microscopy
Fragments of kidney tissue were fixed for 4 h  in 2.5% glutaraldehyde in 0.1 
M cacodylate buffer, pH  7.4, and washed repeatedly in the same buffer. 
After post-fixation in 1% 0 s 0 4, specimens were dehydrated through 
ascending grades of alcohol and embedded in Epon resin. Ultrathin 
sections were stained with uranyl acetate and lead citrate and examined 
using a Philips Morgagni electron microscope by Dr. Daniela Rottoli and 
Dr. Mauro Abbate, Laboratory of Experimental Models of Kidney Disease, 
"Mario Negri" Institute, Bergamo. For more details, see section 3.6.2.
3.18 PKH-26 staining
To study intrarenal localization of stem cells, we labelled before 
injection, the cells with PKH-26 (Materials, section 2.8) as described in 
section 3.7. For in vivo experiments the PKH-26 positive cells were 
resuspended in saline (500 pi/mouse) and intravenously injected.
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3.18.1 Quantification of hAFS-PKH-26 positive cells
Hum an AFS cells, untreated or pre-conditioned with GDNF, were 
labeled with PKH-26. At different time points, hAFS cell-treated mice 
were sacrificed and kidney samples were fixed in 4% paraformaldehyde 
(Materials, section 2.5) overnight at 4°C, and embedded in OCT. Frozen 
kidney sections were stained with FITC-WGA lectin and DAPI. Ten to 
twenty sections/mouse (n=3-6 animals for each time point) were 
analyzed. Data are expressed as number of PKH-26 cells per 105 renal 
cells. The percentage of hAFS cells in tubular and peritubular areas was 
calculated as number of PKH-26 positive cells in each compartment per 
total PKH-26 cells. Human AFS cell engraftment in other organs as lung, 
liver, heart and spleen was also evaluated in control and cisplatin-treated 
mice (n=3). Nuclei were stained with DAPI.
To identify the hum an origin of hAFS cells, frozen kidney sections of 
cisplatin mice injected with PKH26-labeled hAFS cells, were stained with 
the anti-human CD105 antibody. Sections were fixed 10 minutes in 
acetone and then treated with "permeabilized solution" containing Triton 
0.5% (Materials, section 2.6) for 10 minutes at room temperature. After 
washing in PBS IX, sections were treated with "blocking buffer" 
(Materials, section 2.6) for 15 minutes at room temperature, followed by 
incubation overnight with mouse anti-human CD105 antibody (Materials, 
section 2.7) at 4°C. Subsequently, kidney samples were treated w ith an 
anti-mouse Cy5 antibody for 1 hour at room temperature as secondary 
antibody. Renal structure was evidenced by staining the sections w ith
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FITC-WGA lectin for 10 minutes, while nuclei were stained with DAPI for 
15 minutes at room temperature.
3.19 Immunohistochemistry
3.19.1 Apoptosis
Apoptosis was measured by TUNEL assay using an in situ cell 
detection kit (Materials, section 2.8) as previously described (see section 
3.8.2), followed by counterstaining with Rhodamine-labeled lectin Lens 
Culinaris Agglutinin (Materials, section 2.8) and DAPI (Materials, section
2.8) for 15 minutes. Slides were mounted with mounting medium 
(Materials, section 2.5) and analysed by confocal microscopy. To identify 
the anti-apoptotic effect and hAFS cells, apoptotic nuclei and DAPI- 
positive cells per field (ten fields/mouse; n=3 mice for each group) were 
counted and the results were expressed as TUNEL positive cells/103 cells.
3.19.2 Akt
Using the same procedure described in section 3.8.3, frozen kidney 
sections were fixed in acetone, incubated with anti-phosphorylated (p)Akt 
(Ser 473) antibody (Materials, section 2.7) followed by goat anti rabbit-Cy3. 
Slides were counterstained with FITC-WGA lectin and DAPI. Fifteen 
fields /m ouse (n=3 mice for each group) were analysed and pAkt positive 
tubules were counted and expressed as percentage of positive 
tubules/field.
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3.19.3 Proliferation
Proliferation of tubular cells induced by hAFS cells, was 
immunohistochemically identified by labeling with a monoclonal 
antibody against the cell-cycle associated protein Ki67 (Materials, section
2.7) as follows. Sections fixed in 4% paraformaldehyde (Materials, section 
2.5) overnight at 4°C, and subsequently embedded in Tissue-Tek OCT 
Compound, were treated with citrate buffer 10 m m ol/L  (pH 6.0) at boiling 
temperature for 20 minutes, followed by incubation with citrate buffer (20 
minutes) at room temperature. Then, sections were incubated w ith 
"blocking buffer" for 30 minutes at room temperature, followed by 
incubation overnight with mouse anti-Ki-67 antibody (Materials, section
2.7) at 4°C. Cy3-conjugated goat anti-mouse antibody was used for 1 hour 
at room temperature as secondary antibody. Slides were counterstained 
with FITC-WGA lectin and nuclei were visualized by DAPI. Evaluation of 
Ki-67 positive cells in tubular profiles was performed in at least 10 
HPF/section (n =3 mice for each group).
3.20 In vitro  experiments
3.20.1 Cells and cell culture
Hum an AFS cells. Human amniotic fluid stem cells were kindly 
supplied from Dr. De Coppi as already described in Materials, section 2.2. 
Cells were maintained in culture in "growth medium" (Materials, section 
2.3) seeded on special dishes (Optilux™) then they were detached by
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Trypsin (Materials, section 2.5) and used for in vivo and in vitro 
experiments.
Cell storage. Human AFS cells were preserved for long-term storage in 
liquid nitrogen. Cell pellets were suspended in "growth medium" plus 
10% DMSO in cryovials. To guarantee a gradual freezing, the vials were 
left in isopropanol-filled containers overnight at -80°C and then 
transferred to liquid nitrogen tanks for storage.
Thawing frozen cells. The cells were thawed rapidly by placing the vial in a 
water bath at 37°C with a gentle agitation. The cells were then slowly 
resuspended in 9 ml of complete medium and DMSO traces were remove 
by centrifugation at 1200 rpm  for 7 minutes.
3.20.2 Wound-healing assay
To study hAFS cell motility, confluent hAFS cells seeded on 
Optilux™ were cultured in "growth medium" for 24 hours with or 
without 100 ng /m l GDNF (Materials, section 2.4). After 24 hours, hAFS 
cells were scratched with a 200-pl pipette tip to create an artificial wound. 
Cells were washed with PBS1X to remove cell debris and fresh "growth 
medium" with or without GDNF was added. Images of wounded 
monolayer were obtained after 7 hours.
3.20.3 Cell viability assay
In order to study the capacity of hAFS to survive in a toxic 
environment, hAFS cells seeded 29.000/cm2, were exposed to "growth
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medium" alone or GDNF 100 n g / ml for 24 hours and then incubated with 
H2O2 (Materials, section 2.5) 200 mM for 24 hours. Morphology was 
analysed by light microscopy and then cells were detached by trypsin and 
counted after Trypan blue staining. Data were expressed as percentage of 
viable cells over the total number of untreated control cells (n=3 
experiments).
3.20.4 FACs analysis
Human AFS cells treated or not with GDNF 100 n g / ml for 24 hours, 
were detached by trypsin and a small aliquot was counted. After 
centrifuging at 1200 rpm  for 10 minutes, the pellet was incubated with 
"blocking buffer" for 15 minutes at 4°C. Cells were centrifuged and then 
suspended in 500 pi of mouse anti-CD44 or rabbit anti-CXCR4 or rabbit 
anti-CX3CRl antibodies (Materials, section 2.7) for 30 minutes at 4°C. 
Then the cells were incubated with goat anti-mouse or goat anti-rabbit 
FITC secondary antibodies as appropriate for 30 minutes at 4°C. Cells 
were rinsed in PBS IX and centrifuged. The pellet was suspended in 500 pi 
of PBS IX and cells were analysed by flow cytometer (Materials, section 
2.10).
3.20.5 M easurement of cytokines and growth factors.
These experiments were performed in collaboration with Dr. Aline 
Fabricio of Veneto Oncology Institute (IOV), Padova, Italy. Commercially-
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available hum an multiplex kits (Milliplex MAP; Materials, section 2.8) 
were used to quantify the production of Interleukin (IL)-6 and IL-10, as 
well as vascular endothelial growth factor (VEGF), fibroblast growth 
factor 2 (FGF-2), hepatocyte growth factor (HGF) and stromal cell-derived
factor-1 (SDF-l+p), in conditioned media of hAFS cells untreated or
treated for 48 h with GDNF 100 ng /m l (n=3 experiments). IGF-1 was 
measured using Human IGF-I Quantikyne ELISA Kit (Materials, section
2.8). IL-6, IL-10 and VEGF were measured using the MILLIPLEX MAP 
Human Magnetic Cytokine/Chemokine I Panel - 3 Plex Kit (Materials, 
section 2.8). FGF-2, HGF and SDF-1 were measured using the MILLIPLEX 
MAP Human Magnetic Circulating Cancer Biomarker Panel - 3 Plex Kit 
(Materials, section 2.8). Multi-analyte profiling was performed on the 
Bioplex 200 Suspension Array System (Materials, section 2.10). All 
samples were coded for a blinded analysis, and each sample concentration 
was determined in duplicate. Data were processed with Bio-Plex Manager 
5.0 software. Results were expressed as pg /m l/106 hAFS cells. Assay 
sensitivities (minimum detectable levels + 2 SD) were: IL-6, 0.2 pg/m l; IL- 
10, 0.5 pg /m l, VEGF < 5.8 pg/m l, HGF, 6.8 pg/m l; FGF-2, 3.2 pg/m l, 
SDF1, 33.9 pg/m l; IGF-1, from 7 to 56 pg/m l. The percentage of 
augmentation of IL-6, VEGF and SDF-1 production in GDNF-treated over 
untreated hAFS cells was also calculated as [GDNF/hAFS cells] -  [hAFS 
cells]/ [hAFS cells] x 100.
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3.21 Statistics
The results are expressed as mean ± SE. Statistical analysis was 
performed using ANOVA followed by Tukey Cicchetti test for multiple 
comparisons or Bonferroni post-hoc analysis, and unpaired t test using 
Sigmaplot software, version 11.0 (Systat Software, Inc. Chicago, IL, USA). 
Non-parametric Kruskal-Wallis test or Kaplan-Meier analysis and Log- 
Rank test were applied, as appropriate. Statistical significance was defined 
as p<0.05.
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Principles of the m ain techniques and instruments
3.22 Flow cytometer
Flow cytometry is a technique used for counting, examining and 
sorting microscopic particles suspended in a stream of fluid. In the flow 
cytometer any suspended particle or cell from 0.2-150 micrometers in size 
is suitable for analysis. This instrument allows simultaneous 
multiparametric analysis of the physical a n d / or chemical characteristics of 
single cells flowing through an optical/electronic detection apparatus. The 
properties measured include a particle's relative size, relative granularity 
or internal complexity, and relative fluorescence intensity. These 
characteristics are determined using an optical-to-electronic coupling 
system that records how the cell or particle scatters incident laser light and 
emits fluorescence. A flow cytometer is made up of three main systems: 
fluidics, optics, and electronics. The fluidics system transports particles in 
a stream to the laser beam for interrogation. For optimal illumination, the 
stream transporting the particles should be positioned in the centre of the 
laser beam. The flow of sheath fluid accelerates the particles and restricts 
them to the centre of the sample core. In addition, only one cell or particle 
should move through the laser beam at a given moment. To accomplish 
this, the sample is injected into a stream of sheath fluid within a flow 
chamber, that in a benchtop cytometer, is called flow cell whereas in a 
stream-in-air cytometer is called nozzle tip. Laser light of a single
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frequency hits the stream of fluid. The optic system consists of lasers to 
illuminate the particles in the sample stream and optical filters to direct 
the resulting light signals to the appropriate detectors. A num ber of 
detectors are aimed at the point where the stream passes through the light 
beam; one in line with the light beam (forward scatter or FSC) and several 
perpendicular to it (side scatter or SSC). Each suspended particle passing 
through the beam scatters the light in some way, and fluorescent 
chemicals in the particle may be excited into emitting light at a lower 
frequency than the light source. This combination of scattered and 
fluorescent light is picked up by the detectors, and by analysing 
fluctuations in brightness at each detector (one for each fluorescent 
emission peak) it is possible to deduce various indications about the 
physical and chemical structure of each individual particle. FSC correlates 
with the cell volume and is proportional to cell-surface area or size. FSC is 
a measurement of the most diffracted light and is detected just off the axis 
of the incident laser beam in the forward direction by a photodiode. FSC 
provides a suitable method of detecting particles greater than a given size 
independent of their fluorescence and is therefore often used in 
immunophenotyping to trigger signal processing. SSC depends on the 
inner complexity of the particle (i.e. shape of the nucleus, the am ount and 
type of cytoplasmic granules or the membrane roughness). SSC is a 
measurement of mostly refracted and reflected light that occurs at any 
interface within the cell where there is a change in the refractive index. 
SSC is collected at approximately 90 degrees to the laser beam by a
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collection lens and then redirected by a beam splitter to the appropriate 
detector. Correlated measurements of FSC and SSC can allow for 
differentiation of cell types in a heterogeneous cell population.
A fluorescent compound absorbs light energy over a range of 
wavelengths that is characteristic for that compound. The absorption of 
light causes an electron in the fluorescent compound to be raised to a 
higher energy level. The excited electron quickly decays to its ground 
state, emitting the excess energy as a photon of light. This transition of 
energy is called fluorescence. The range over which a fluorescent 
compound can be excited is termed its absorption spectrum. The range of 
emitted wavelengths for a particular compound is termed its emission 
spectrum. The argon ion laser is commonly used in flow cytometry 
because the 488-nm light that it emits excites more that one fluorochrome. 
One of these fluorochromes is fluorescein isothiocyanate (FITC). In the 
absorption spectrum of FITC the 488-nm line is close to the maximum 
absorption of FITC. If the fluorochrome was excited by another 
wavelength within its absorption spectrum, light emission of the same 
spectrum would occur but it would not be of the same intensity. More 
than one fluorochrome can be used simultaneously if each is excited at 488 
nm  and if the peak emission wavelengths are not extremely close to each 
other. When a fluorescent dye is conjugated to a monoclonal antibody, it 
can be used to identify a particular cell type based on the individual 
antigenic cell markers of the cell.
The optical system consists of excitation optics and collection optics.
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The excitation optics consist of the laser and lenses that are used to shape 
and focus the laser beam. The collection optics consist of a collection lens 
to collect light emitted from the particle-laser beam interaction and a 
system of optical mirrors and filters to address specified wavelengths of 
the collected light to designated optical detectors. The detected light 
signals are converted by an electronic system into electronic pulses that 
can be processed by the computer.
3.23 PCR based techniques
PCR
Polymerase chain reaction (PCR) is a method to create copies of 
specific fragments of DNA. PCR rapidly amplifies a single DNA molecule 
into many billions of copies. PCR is based on the enzymatic amplification 
of short DNA sequences (oligonucleotides) that are flanked by two 
"primers" (forward and reverse) defining the region to be amplified. 
Primers prime synthesis of the complementary DNA sequence by DNA 
polymerase. If primers are negligently designed, there may occur some 
unwanted structures. These can be prevented using specific programs, 
which calculate the possibility of those structures to form. One of this 
kind of structure is the hairpin structure. This happens when the primers 
3'end and 5'end pairs, or the other end pairs with the body. Another 
structure is primer dimers where the primers bind themselves. There may
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also be non-specific products because of false adhesion of primers. This 
can occur if few bases are wrong or temperature of annealing (Ta) is too 
low. The chain reaction is a three-step process: denaturation, hybridization 
or annealing, and extension that are repeated over several cycles (Figure 
3.1). At each cycle of the process, the number of copies is doubled. 
Denaturation is the process during which two strands separate from each 
other. Denaturation is carried on by heating up at a specific melting 
temperature, Tm (usually 95°C) that depends on the length of the primers 
(the longer the higher) and the number of guanine and cytosine bases (the 
more the higher temperature). During the denaturation, the double strand 
melts opening to single stranded DNA and all enzymatic reactions stop 
(for example: the extension from a previous cycle). After denaturation of 
the double stranded DNA (or RNA/cDNA from RT reaction), the primers 
are allowed to anneal to their 100% complementary sequence (one primer 
each strand) by lowering the temperature (down to Ta of the primers). Ta 
depends on the concentration of primers and on the composition of the 
oligonucleotide and is generally set about 5°C below Tm of the primers, Tm 
being the temperature at which 50% of the primer and its complementary 
sequence are present in a duplex DNA molecule. The elongation step 
involves the enzyme polymerase that derives from the bacterium Thermus 
acquaticus since this polymerase is heat-stable. Taq DNA polymerase 
performs the polymerisation reaction downstream of both primers. To 
allow exponential amplification of the target sequence comprised within 
the primers, these three steps " Denaturation-Annealing-Elongation" are
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then repeated for a number of times (cycles), at the end of one cycle, the 
region between the two primers has been copied once, producing two 
copies of the original sequence region. During PCR, the amount of product 
initially increases exponentially, but then the rate slows and eventually 
plateaus. Because a heat resistant polymerase is used, the reaction can be 
repeated continuously without addition of more enzymes. The reaction is 
carried out in a computer-regulated heating block, a thermal cycler, that 
permits rapid, controlled heating and cooling.
RT-PCR
RNA cannot serve as template for PCR, so first it m ust be reverse 
transcribed into cDNA and then amplified by PCR. The technique 
involves the reverse transcription of an RNA molecule to a 
complementary DNA strand (1st strand cDNA) and is known as RT-PCR. 
In the RT reaction the choice of reverse transcriptase enzyme (i.e. MMLV- 
RT or SuperScriptll RT) used to synthesize cDNA is important since 
enzymatic properties such as temperature optima, divalent ion 
requirement, specificity and sensitivity, can vary. The RNA is reverse 
transcribed in the presence of RT primers. Priming affects the size and 
specificity of the cDNA produced.
There are three types of primers that may be used for reverse 
transcription:
- 01igo(dT)i2-i8, which binds to the endogenous poly(A) tail at the 3' end 
of mammalian mRNA. This primer often produces a full-length cDNA;
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- Random hexanucleotides, which bind to mRNA at a variety of 
complementary sites and lead to partial length (short) cDNAs. Random 
hexanucleotides may be ideal for overcoming the difficulties presented 
by extensive secondary structure in the template. These primers may also 
transcribe more efficiently 5' regions of the mRNA;
- Specifc oligonucleotide primers, which selectively prime the mRNA of 
interest;
The RT reaction is carried out by reverse transcriptase enzyme for 45-60 
min at 37-42°C. Reactions are kept either at 4°C or at -20°C until further 
use.
Real time RT- PCR
Real-time reverse transcriptase (RT) polymerase chain reaction 
(PCR) is a widely specific, sensitive and reproducible used method to 
quantify the initial amount of the template (Real Time PCR). Two 
important findings made possible the discovery of real-time PCR: First, 
the Taq polymerase has, apart from its polymerase activity, a 5'-3' 
exonuclease activity. Second, dual labelled fluorogenic oligonucleotide 
probes have been created which emit fluorescence upon cleavage. The first 
real-time PCR created, the TaqMan assay, combines these two principles. 
The method is based on the 5-3' exonuclease activity of the Taq DNA 
polymerase, which results in the cleavage of fluorescent dye-labelled 
probes during PCR. The TaqMan® probe has a fluorescent dye usually on 
the 5' base called reporter dye (R), and a quenching dye (Q) typically at its
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3' base. While the probe is intact, the close proximity of the reporter and 
quencher prevents emission of any fluorescence (Figure 3.2). During 
reaction, TaqMan® probe bound to the template is cleaved by the TaqMan 
DNA polymerase 5' exonuclease activity and its degradation frees the 
reporter dye from the quenching activity. Fluorescence emitted by the 
reporter dye increases in each cycle proportionally to probe cleavage that, 
in turn, is proportional to the amount of formed PCR product (amplicon 
production, the amplified target sequence). The cleavage occurs only in 
the case the probe is annealed to the target therefore the origin of the 
detected fluorescence is specific amplification. At each PCR cycle, we can 
monitor the accumulation of amplified products by detecting the increase 
of reporter dye fluorescence. In real time RT-PCR, the amplicon formation 
is observed as the reaction goes on and during each PCR cycle with a 
continuous observation and not at the end of the reaction like in 
conventional PCR methods.
Reactions are characterized by the point in time during cycling when 
amplification of a PCR product is first detected rather than the amount of 
PCR product accumulated after a fixed number of cycles. The higher the 
starting copy number of the target sequence, the sooner a significant 
increase of fluorescence is detectable. A representative amplification plot, 
that is the plot of fluorescence signal against cycle number is shown in 
Figure 3.3. Initially, during the first cycles of amplification the 
fluorescence signal does not change much (baseline for amplification plot). 
An increase of fluorescence above the baseline indicates the detection of
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accumulated PCR product. A fixed fluorescence threshold can be set 
above the baseline. The threshold cycle (Ct) is the cycle at which exceeds 
the chosen fluorescence and the plot of the log of initial target copy 
number for a set of standards versus Ct is a straight line. Ct values are 
very reproducible in replicates when the threshold is picked in the 
exponential phase of PCR. Indeed, in the exponential phase, reaction 
components are not limiting and replicate reactions exhibit uniform and 
reproducible results. As the reaction components become limiting, the rate 
of target amplification decreases until a plateau is reached and there is no 
more increase (or little increase) in PCR product. On the other hand, the 
amount of PCR product observed at the end of the reaction is very 
sensitive to slight variations in the reaction components. In order to 
quantify the amount of target in unknown samples, Cts are measured and 
a standard curve is needed to determine a starting copy number. In each 
quantitative PCR method, specific errors are introduced due to minor 
differences in starting amount of RNA differences in efficiency of cDNA 
synthesis and PCR amplification Therefore, a reliable quantitative RT-PCR 
method requires correction of these experimental variations. At the 
present, this is most often performed by normalization to a housekeeping 
gene. However, the choice of the most suitable gene should be made for 
each experimental condition. In particular, the housekeeping gene should 
not be modulated in the experimental setting. For this reason GADPH, p- 
actin or ribosomal RNA (rRNA) (i.e. 18S rRNA) are used as housekeeping,
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indeed their expression is less likely to vary under conditions that change 
the levels of mRNA expression.
Because the 18S rRNA does not have a poly-A tail, cDNA synthesis using 
oligo-dT should not be used if such a transcript will be used as a 
normalizer. Normalization is performed by subtracting, for each reaction, 
the Ct value of the housekeeping gene, that is expected to be higher 
expressed than the target, from the Ct value of the gene of interest 
obtaining the "Delta Ct" or "ACt".
ACt = Ct(target) - Ct (normalizer)
For comparison among the samples and for relative gene expression 
comparisons, the ACt value of each experimental sample is compared to 
the ACt value of the control sample. The comparative "DeltaDeltaCt" 
calculation is:
AACt = ACt (experimental sample) - ACt (sample control)
The fold induction/reduction value is then determined by the following 
formula:
Fold difference = (2 -4ACt).
SYBR Green methodology. As the real time RT-PCR has become more 
used, other methodologies have been developed to directly measure PCR
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product accumulation by fluorescence emission. For example, minor 
groove binding dyes, such as SYBR Green 1. SYBR Green 1 is a non­
sequence specific fluorescent agent method that is based on double­
stranded DNA binding dye chemistry (Figure 3.4). Since SYBR Green 1 
does not bind to single stranded DNA and it is possible to quantify 
amplicon production. When in solution, SYBR Green exhibits little 
fluorescence but upon binding to double-stranded DNA it emits a strong 
fluorescent signal. During the amplification process, it is possible that a 
non-specific amplification takes place or that primer-dimer complexes are 
formed and in these cases a fluorescent signal may account for non­
specific amplification. Therefore, to verify the specificity of the PCR 
reaction, follow-up assays have been developed: identification of the 
melting point and the dissociation curve. Moreover, negative controls are 
included as well: No Amplification Controls (NAC, a minus-reverse 
transcriptase control) and No Template Controls (NTC, a minus sample 
control). In optimised conditions, a sharp peak at the melting temperature 
of the amplicon should be obtained, and the NAC and NTC should not 
generate significant fluorescent signal indicating that the products are 
specific, and that SYBR Green fluorescence is a direct measure of 
accumulation of the product of interest. In the presence of a dissociation 
curve with series of peaks it cannot be discriminated between specific and 
non-specific reaction products.
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3.24 Microscopy
3.24.1 Transmission electron microscopy
The transmission electron microscope is a type of microscope that 
uses beam of electrons to observe the specimen. The beam of electrons, 
emitted by a high voltage electron emitter situated at the top of the 
microscope column, pass through the sample and through a series of 
magnifying magnetic lenses, to finally reach the viewing screen where 
they are ultimately focused. To change the magnification and focal point 
of the image, different lenses can be used; the contrast and resolution of 
the image can be changed as well by operating through apertures-holes on 
the microscope column. The electron beam size that passes through the 
microscope column can be limited by one of these accesses. Another 
aperture serves to condense and maintain the coherence of the electron 
beam (condenser aperture). The objective aperture controls image contrast 
and is located below the sample just after the objective lens. In the column, 
a very high vacuum is created in order to reduce the electron beam 
interactions with air. Energy produced by an electric source (~2500K) 
superheats a tungsten wire that emits electrons. Liquid nitrogen is used to 
cool down the column for easier removal of water vapour. Electrons are 
sent down the microscope column, across the sample, lenses, and 
apertures. The lenses are magnetic coils that, set on a specific electron 
wavelength, focus and direct the electron beam. As it passes through the 
lens (three primary lenses) the electron beam is split. The topmost lens is
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the objective and it magnifies and focuses the image. Then there is the 
intermediate lens that controls the magnification of the image and the 
diffraction pattern. Finally, the projector lens that focuses and projects the 
image onto the imaging surface. The image can be visualized on a screen: 
where fewer electrons were transmitted through the sample, in thicker or 
denser zones, the image shows dark areas whereas areas where the 
sample was thinner or less dense more electrons are transmitted through 
and the image appears more light. The power of resolution of electron 
microscopy depends on the lens-systems and on sample preparation 
method. Usually, in m odern microscopes the resolution power ranges 
from 0.2 - 0.3 nm  and magnify up to 180,000x.
3.24.2 Light microscopy
A microscope is an instrument that allows observation of objects 
that are too small to be seen by the naked eye. In order to visualise objects, 
the light microscope uses light and magnifying lenses. Most microscopes 
in current use are known as compound microscopes, where a magnified 
image of an object is produced by the objective lens, and this image is 
magnified by a second lens system, the ocular, for viewing. Thus, final 
magnification of the microscope depends on the magnifying power of the 
objective lens times the magnifying power of the ocular lens. Objective 
magnification powers range from 4x to lOOx whereas ocular magnification 
ranges are typically 8x -12x. As a result, a standard microscope provides a 
final magnification range of 40x up to lOOOx. Each objective lens consists of
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six or more pieces of glass that combine to produce a clear image of an 
object. The use of lenses with a spatial curvature on their surface allows 
correcting spatial aberration due to the interaction of light with the glass 
(refraction). The objective lenses in most microscopes are achromatic, but 
for high resolution imaging with white light it is preferable to use totally 
corrected apochromatic lenses or fluorite lenses.
The light is an essential factor in producing good image. It should be 
bright and uniform across the field. The best way to illuminate the 
specimen is to use another lens, the condenser. The condenser sits directly 
beneath the specimen and focuses the light beam and maximizes the 
intensity and controls the uniformity of illumination. The condenser 
diaphragms, allows for an increase in contrast. After passing through the 
specimen on the stage the light enters the objective.
The fine detailed observation requires an imaging system capable of 
providing spatial details across a small distance. Resolution is defined as 
the ability to distinguish two objects as separate entities. Resolution is best 
when the distance separating the two tiny objects is small. Resolution 
depends on wavelength of the light, and the light gathering power of the 
objective (numerical aperture, NA) and condenser lenses.
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3.25 Immunofluorescence technique and confocal microscopy
Immunofluorescence is the labeling of antigens with fluorescent dyes. 
This technique is often used to visualize subcellular distribution of 
biomolecules of interest. Immunofluorescent labeled samples are studied 
using a fluorescence microscope or by confocal microscopy.
Most commonly, immunofluorescence employs two sets of antibodies: a 
primary antibody is used against the antigen of interest; a subsequent, 
secondary, dye-coupled antibody is introduced that recognizes the 
primary antibody. In this fashion, several primary antibodies recognizing 
various antigens but sharing a common constant region may be 
recognized by a single dye-coupled antibody. Typically this is done by 
using antibodies made in different species. This allows re-use of the 
difficult-to-make dye-coupled antibodies in multiple experiments. In some 
cases, it is advantageous to use primary antibodies directly labelled with a 
fluorophore. This direct labelling decreases the number of steps in the 
staining procedure and, more importantly, often avoids cross-reactivity 
and high background problems.
A fluorescence microscope is a light microscope used to study 
properties of organic or inorganic substances using fluorescence and 
phosphorescence instead of, or in addition to, reflection and absorption. In 
most cases, a component of interest in the specimen is specifically labeled 
with a fluorescent molecule called a fluorophore. The specimen is
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illuminated with light of a specific wavelength (or wavelengths), which is 
absorbed by the fluorophores, causing them to emit longer wavelengths of 
light (of a different color than the absorbed light). The illumination light is 
separated from the much weaker emitted fluorescence through the use of 
an emission filter. Typical components of a fluorescence microscope are 
the light source (Xenon or Mercury arc-discharge lamp), the excitation 
filter, the dichroic mirror (or dichromatic beamsplitter), and the emission 
filter (Figure 3.5 A). The filters and the dichroic are chosen to match the 
spectral excitation and emission characteristics of the fluorophore used to 
label the specimen.
The confocal microscope is an optical imaging technique used to increase 
micrograph contrast an d /o r to reconstruct three-dimensional images by 
using a spatial pinhole to eliminate out-of-focus light or flare in specimens 
that are thicker than the focal plane (Figure 3.5 B). The principle of 
confocal imaging was patented by Marvin Minsky in 1957. In a 
conventional (i.e., wide-field) fluorescence microscope, the entire 
specimen is flooded in light from a light source. Due to the conservation of 
light intensity transportation, all parts of specimen throughout the optical 
path will be excited and the fluorescence detected by a photodetector or a 
camera. In contrast, a confocal microscope uses point illumination and a 
pinhole in an optically conjugate plane in front of the detector to eliminate 
out-of-focus information. Only the light within the focal plane can be 
detected, so the image quality is much better than that of wide-field 
images. As only one point is illuminated at a time in confocal microscopy,
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2D or 3D imaging requires scanning over a regular raster (i.e. a 
rectangular pattern of parallel scanning lines) in the specimen. The 
thickness of the focal plane is defined mostly by the square of the 
numerical aperture of the objective lens, and also by the optical properties 
of the specimen and the ambient index of refraction.
3.26 Haemocytometer
The most practical method for routine determination of the number 
of cells that are in suspension is a direct count on a haemocytometer. 
Burker's chamber is a counting chamber that has been modified to a final 
single block of glass. This haemocytometer contains two chambers, each of 
which is divided into 9 squares of 1 mm2 (Figure 3.6). In use, a cover glass 
is supported 0.1 mm above the ruled areas. Thus, when the chamber is 
filled, the volume of cell suspension over each square is 0.1 mm3, lxlO4 
cm3 or about lxlO'4 ml. Therefore, the number of cells per 1 ml is 
calculated by multiplying the number of cells counted in the square by 104. 
The total cell number of the original cell suspension can be obtained by 
multiplying by the volume in ml and by the appropriate dilution factor.
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Figure 3.1 Schematic drawing of the PCR cycle
(1) Denaturation; (2) Hybridization; (3) Extension by Polymerase (P); (4) The first 
cycle is complete. The two resulting DNA strands make up the template DNA for 
the next cycle, thus doubling the amount of DNA duplicated for each new cycle.
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Figure 3.2 Schematic representation of the TaqMan principle
(A) Annealing of primers and probe to the target gene. The probe is still intact 
and fluorescence emission does not occur. (B) Extension phase of the PCR 
reaction. The probe is cleaved by the 5-3' exonuclease activity of the Taq 
polymerase, allowing fluorescence emission. FW, forward; RV, reverse; R, 
reporter dye; Q, quencher dye.
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Figure 3.3 Real time RT-PCR amplification plot
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Figure 3.4 SYBR Green dye assay chemistry
SYBR Green does not bind to single stranded DNA. It is a minor groove binding 
dye and emits strong fluorescence signal upon binding to double-stranded DNA.
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Figure 3.5 Schematic representation of a fluorescent (A) and a laser scanning (B) 
microscope
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4.1 Introduction
Acute kidney injury (AKI) is a common and costly complication of 
critical illness associated with adverse clinical outcomes. Recent studies 
have demonstrated that the incidence of AKI varies between 15% and 
80% in the intensive care unit (ICU) (James Seminar et al, 2011) and the 
mortality, associated with this syndrome, has remained unchanged 
worldwide during the past 30 years (Shah et al, 2006). To accelerate 
renal regeneration and to improve survival, several pharmacological 
strategies have been approached. However, translational research 
efforts have yielded disappointing results (Thadhani et al, 1996; Kelly et 
al, 2000; Grino et al, 1994; Haug et al, 1993). In the attempt to create 
innovative interventions for the cure of AKI, recent studies have tested 
stem cell-based treatment to repair acutely damaged organs by virtue of 
stem cell's peculiar properties of tropism and regenerative capability 
(Aejaz et al, 2007; Daley et al, 2008; Lindvall et al, 2006; Laflamme et al, 
2005; Little et al, 2006; Morigi et al, 2006). In this context, mesenchymal 
stem cells (MSCs) represent an attractive tool because of their beneficial 
effects on tissue repair in experimental models of myocardial infarction 
(Nagaya et al, 2004; Tang et al, 2006), neurologic disease (Lindvall et al, 
2006; Torrente et al, 2008) and more recently, in experimental acute 
kidney injury {Morigi et al, 2004; Imberti et al, 2007; Morigi et al, 2008; 
Herrera et al, 2004). MSCs were originally isolated from bone marrow 
(BM) (Pittinger et al, 1999; Bianco et al, 2008), but similar cell
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populations have been found to be harboured in other tissues including 
umbilical cord blood, placenta, adipose tissue, peripheral blood, dermal 
connective tissue, deciduous teeth, dermis and skeletal muscle (Liu et 
al, 2009). Studies by our group have documented that murine (Morigi 
et al., 2004; Imberti et al., 2007) and hum an (Morigi et al, 2008) MSCs of 
bone marrow origin infused in mice with cisplatin-induced AKI 
promoted renal functional and structural recovery by stimulating renal 
resident cells to proliferate, via local release of the growth factor IGF-1 
(Imberti et al., 2007). Consistently, studies in the ischemia/reperfusion 
rat model have documented that BM-MSCs were beneficial via 
paracrine production of mitogenic, anti-apoptotic and vasculotropic 
factors (Togel et al., 2005; Togel et al, 2007). To date, the most common 
source of MSCs has been the bone marrow, but collection of bone 
marrow from the patient is an invasive procedure and, in addition, it 
has been demonstrated that the number, differentiation potential and 
life span of these stem cells decline with age (D'ippolito et al, 1999). 
Therefore, the search for alternative sources of MSCs in the clinical 
perspective to cure AKI is of significant value. Recent studies have 
identified cord blood (CB) as an alternative reservoir, readily available 
and extremely rich of stem and progenitor cells (Flynn et al., 2007; 
Sanchez-Ramos et al, 2006; Erices et al, 2000; Lee O et al, 2004). Some 
studies have documented that hum an cord blood mesenchymal stem 
cells (hCB-MSCs) possess morphological characteristics, 
immunophenotypic markers and differentiation ability similar to hBM-
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MSCs {Kern et al., 2006; Panepucci et al, 2004; Wagner et al, 2005). With 
regard to the gene expression profile, the two MSC lineages share all of 
the most expressed transcripts, but hCB-MSCs express higher levels of 
genes involved in matrix remodelling and angiogenesis while hBM- 
MSCs express genes related to osteogenesis {Panepucci et al., 2004). 
Human CB-MSCs also deserve attention for their capability to 
synthesize growth factors (Flynn et al., 2007; Wagner et al., 2005; Liu et 
al., 2005) with anti-apoptotic and regenerative effects on renal tubular 
cells, the key target of AKI. Early clinical evidence documented safety 
and efficacy of CB progenitor cell infusion in humans for the treatment 
of haematological (Edwards et al, 2007; Pinto et al., 2008; Locatelli et al, 
2008) and neurological disorders (Sanchez-Ramos et al, 2006; Escolar et 
al, 2005) and Buerger's disease (Kim et al, 2006). So based on these 
evidences the aim of this study was to investigate whether hCB-MSCs 
could ameliorate acute renal dysfunction and attenuate tubular injury. 
To this aim, we set up an acute kidney injury model in 
immunodeficient mice, by using cisplatin, an anti-tumour drug 
accompanied by a high incidence of nephrotoxicity (Arany et al, 2003).
4.2 Murine model of acute kidney injury
In order to evaluate the renoprotective effect of CB-MSCs of 
hum an origin, we set up an experimental model of AKI induced by
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cisplatin in immunodeficient NOD-SCID mice. Renal function, assessed 
as blood urea nitrogen (BUN), and body weight were evaluated at 
different time intervals from cisplatin treatment. Previous experiments 
(Morigi et ah, 2008) indicated that subcutaneous injection of cisplatin 
(12.7 m g/kg) resulted in a significant increase in serum BUN at 2-3 
days, which peaked at 4-5 days and stabilized at high values until 
animal death (Table 1). In parallel, animals lost weight starting at 1 day 
from cisplatin treatment. Mice also invariably died within 5-7 days after 
receiving cisplatin (Table 1).
Renal injury was assessed by histological analysis. By light 
microscopy, no significant changes were detectable in the kidney taken 
1 day after cisplatin injection, the time at which hCB-MSCs were 
infused. Focal and severe tubular changes were observed at day 4 
(Figure 4.1 b). Changes in proximal tubules were revealed by the loss of 
brush border, cytoplasmic vacuolization, flattening and loss of the 
epithelial cells, PAS-positive droplets, nuclear fragmentation and 
luminal debris. Hyaline casts and cell loss were prominent. The most 
damaged tubules displayed areas of apparent denudation of the tubular 
basement membranes (Figure 4.1 b). Histology of kidney control mice is 
shown in Figure 4.1 a.
Electron microscopy analysis of all cisplatin treated mice revealed 
at day 1 after cisplatin, mitochondrial swelling, loss of brush border, 
and myelin figures in tubular epithelial cells. Necrotic epithelial cells 
with detachment from the underlying basement membrane were
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prominent in kidneys taken at day 4 after cisplatin injection (Figure 4.2 
b and c). Moreover, we observe peritubular capillary changes consisting 
of endothelial cell swelling, cytoplasmic vacuolisation, nuclear 
degeneration and detachment occasionally associated with 
polymorphonuclear (PMN) cell infiltration (Figure 4.2 c).
4.3 Characterization of human cord blood-mesenchymal stem cells
Eighty hum an cord blood (CB) units were processed and 54% 
generated MSC cultures. Human CB-MSCs isolated by lineage- 
depletion represented 1-2% of the initial cell population and grew up to 
10 passages maintaining their typically spindle-shaped morphology 
(Figure 4.3 a). The ability of hCB-MSCs to differentiate into osteocytes 
and chondrocytes, after exposure to appropriate inductive media, was 
observed by the extended area of mineralization and by secretion of 
cartilage-specific proteoglycans (Figure 4.3 b and c). At variance, hCB- 
MSCs were not able to differentiate into adipocytes as also previously 
described {Kern et al., 2006; Manca et al, 2008; Rebelatto et ah, 2008).
The expression of cell-surface antigens was evaluated by flow 
cytometry on all hCB-MSC cultures. As shown in Table 2, hum an CB- 
MSCs expressed mesenchymal stem cells markers as CD105, CD44, 
CD90, CD73, SSEA4 and HLA class I, while were weakly positive for 
CD56, desmin, CK3/12, CK19, BB9 and negative for HLA class II,
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LNGFR and VE-Cadherin. These cells also expressed CD146, alpha 
SMA (Table 2) but not CD34, CD45 and NG2, which altogether 
characterize a multipotent adult stem cell population consistent with a 
perivascular/pericyte-like phenotype (Crisan et al., 2008).
By RT-PCR analysis we observed that hum an CB-MSCs expressed 
some genes as RUNX1 and OCT4 that characterize the undifferentiated 
stem cell state (Figure 4.4), while the cells were negative for PPAR-2, 
VE-Cadherin, ABCG2, REX1, .FGF4, hTERT, SOX2, PAX7 and renal 
genes such as PAX2 and GATA3.
4.4 Human cord blood-mesenchymal stem cells protect cisplatin- 
treated mice from renal impairment
With the aim to study the renoprotective effect of hCB-MSCs, we 
injected 5xl05 cells into the tail vain of immunodeficient mice w ith AKI 
induced by cisplatin. We infused saline or hCB-MSCs in NOD-SCID 
mice, one day after cisplatin treatment, when tubular ultrastructural 
changes were already present. As reported in Figure 4.5, hCB-MSC 
treatment strongly protected renal function at 3 and 4 days, as reflected 
by the significant lower BUN values (hCB-MSCs 3d, 39.90+6.23 m g / dl 
and hCB-MSCs 4d, 50.83±8.09 m g/dl) in respect to cisplatin-treated 
mice injected with saline (saline 3d, 98.60±6.83 m g /d l and saline 4d, 
124.46±4.71 m g/dl).
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Subsequently, we studied whether renal function improvement 
induced by hCB-MSC treatment, was associated with the preservation 
of renal structure. Renal histology of mice with cisplatin-induced AKI 
on day 4, showed focal and severe tubular damage, characterized by 
tubules affected by necrosis and luminal casts (Figure 4.1 b and Table 3). 
Conversely, in kidneys of cisplatin-mice injected with hum an CB-MSCs, 
we observed an evident attenuation of renal tubular damage, as 
reflected by the significant reduction of necrotic tubules and casts 
(Figure 4.6 a and Table 3). Electron microscopy analysis at 4 days of 
kidneys of cisplatin-mice that received hCB-MSCs showed much less 
severe ultrastructural changes in proximal tubules and in peritubular 
capillaries (Figure 4.6 b).
Kunter et al. documented in a progressive model of 
mesangioproliferative nephritis, a long-term maldifferentiation of rat 
BM-MSCs into glomerular adipocytes. In order to exclude this side 
effect, we investigated in the renal tissue of cisplatin mice, whether 
hCB-MSCs were able to give rise to cell types of non-renal origin or 
adipocytes. (Kunter et al., 2007). Histological analysis of renal tissue of 
cisplatin-mice at 40 days, revealed no sign of abnormal phenotype.
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4.5 Localization of human cord blood-mesenchymal stem cells in
cisplatin-treated mice
To better explain the therapeutic effect of hCB-MSCs on renal 
tissue damaged by cisplatin, we evaluated whether the renoprotection 
was associated with recruitment of the injected stem cells into the renal 
parenchyma. For this purpose, hCB-MSCs were labelled, before their in 
vivo infusion, with a red fluorescence cell membrane linker, PKH-26. 
Sections of renal tissue of cisplatin-treated mice at 4 days were 
analysed, and the frequency of PKH-26-positive cells averaged 2 ±0.4 
/105 renal cells. Labelled hCB-MSCs were predominantly localized in 
peritubular areas (Figure 4.7 a), and only few cells were found in the 
context of tubular epithelium and glomeruli. The percentage (expressed 
as number of PKH-26 cells per total PKH-26 cells) in each compartment 
of PKH-26 positive CB-MSCs, averaged 83±11% in peritubular areas, 
5±5% in tubules, and 12±12% in glomeruli. The hum an origin and the 
ability of hCB-MSCs to engraft the damaged tissue were further 
confirmed by the positive staining for the hum an nuclear antigen HNA, 
in murine renal tissue (Figure 4.7 b).
We evaluated whether hCB-MSCs were able to engraft other 
organs, as liver, lung and spleen. Analysis of sections of these tissues, 
showed rare or absent PKH-26 positive hCB-MSCs suggesting a local 
recruitment of stem cells through renotroprism at site of injury.
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4.6 Human cord blood-mesenchymal stem cells prolong survival
of cisplatin-treated mice
The high responsiveness of NOD-SCID mice to cisplatin toxicity, 
allowed us to test whether hCB-MSC treatment could affect survival, 
the key clinical outcome in AKI. As shown in Figure 4.8, 14% of 
cisplatin-mice given saline was alive at 7 days, but all mice died within 
9 days (Figure 4.8). Human CB-MSC infusion remarkably prolonged 
animal survival (p<0.001), indeed at 9 days, when all mice died in the 
saline group, 86% of cisplatin-mice injected with hCB-MSCs were alive. 
The percentage of living animals given hCB-MSCs remained 
unchanged until 14 days, when the experiment was stopped.
We previously described in the same experimental model (Morigi 
et al., 2008), the effect of hBM-MSCs on lifespan of AKI mice. As shown 
in Table 4, we compared hCB-MSC efficacy to decrease animal 
mortality, with that of hBM-MSCs. Infusion of hCB-MSCs improved 
animal survival to a more significant extent than hBM-MSCs in respect 
to cisplatin mice given saline (hCB-MSCs, p<0.004 and hBM-MSCs, 
p<0.05 vs untreated cisplatin mice). By comparing renal function of 
mice infused with hCB-MSCs or hBM-MSCs, we found that serum BUN 
levels in cisplatin-mice treated with hCB-MSCs at 4 days were lower 
than those found in hBM-MSC-treated mice although a statistical 
significance was not achieved (hCB-MSCs, 58±7 and hBM-MSCs, 76±8
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vs saline, 122±7 m g / dl; hCB-MSCs, p<0.01 and hBM-MSCs, p<0.01 vs 
saline).
4.7 Human cord blood-mesenchymal stem cells prevent cisplatin- 
induced tubular damage and apoptosis
Oxidative damage, play a central role in cisplatin-induced renal 
injury because cisplatin generates active oxygen species such 
superoxide anion and hydroxyl radicals and stimulates renal lipid 
peroxidation (Matsushima et al, 1998). To assess oxidative damage we 
used nitrotyrosine staining because peroxynitrite, the reaction product 
of nitric oxide and superoxide anion, has been taken as key oxidant 
species involved in the direct nitration of tyrosine residues causing 
protein oxidation (Viappiani et al, 2006). As shown in Figure 4.9, 
cisplatin-mice with AKI exhibited at 4 days a high expression of 
nitrotyrosine in tubules of both the cortex and the medulla, in respect to 
control mice (Figure 4.9, Table 5). An evident reduction of nitrotyrosine 
staining within the tubules were detected in hCB-MSC transplant 
recipients (Figure 4.9, Table 5), indicating that human stem cells protect 
renal tissue from oxidative damage.
In vitro and in vivo models of cisplatin-induced toxicity, have 
demonstrated that apoptosis is partially responsible for tubular cell loss 
(Bonegio et al, 2002); therefore, we have studied whether hCB-MSC
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treatment could exert an anti-apoptotic action on renal cells in mice 
with AKI. Cells positive for TUNEL staining were quantified in kidney 
sections at day 4 by confocal laser scanning microscopy. In normal 
control kidneys, a low number of apoptotic cells were detected, while in 
renal tissues of mice treated with cisplatin we observed a significant 
increase (p<0.01) in the number of TUNEL-positive cells (Figure 4.10 a). 
Human CB-MSC infusion significantly (p<0.01) reduced apoptotic cells, 
compared to cisplatin-mice given saline (Figure 4.10 a), suggesting an 
anti-apoptotic effect of the stem cell therapy in mice with AKI. 
Representative images of kidney sections demonstrating TUNEL- 
positive cells are shown in Figure 4.10 b,c and d.
4.8 Human cord blood-mesenchymal stem cells induce Akt 
phosphorylation leading to tubular cell proliferation in cisplatin-
treated mice
Based on the evidence that the serine-threonine kinase Akt is a key 
enzyme involved in survival signals (Datta et al, 1999), we performed 
experiments to study whether the renoprotective effect of hCB-MSCs 
was mediated by an activation of Akt, represented by Akt 
phosphorylation (pAkt). Kidney sections of cisplatin-mice with AKI at 4 
days, showed a decrease of tubular phosphorylation of Akt in respect to 
control animals (Figure 4.11 a). Human CB-MSC treatment significantly
140
CHAPTER 4: RENOPROTECTIVE  EFFECT OF hCB-MSCs IN EXPERIMENTAL  MODE L OF AKI
increased the number of tubuli positive for pAkt at 4 days in respect to 
cisplatin-mice given saline (Figure 4.11 a), suggesting a role of stem cells 
in the activation of prosurvival pathways.
The effect of engrafted hCB-MSCs on tubular cell regeneration 
was explored by analysing the proliferation marker PCNA 
(proliferating cell nuclear antigen) in cisplatin-treated mice. The 
quantification of PCNA positive cells on renal tissues is shown in 
Figure 4.12. In normal control kidneys at 4 days, low number of PCNA 
positive cells was detected, reflecting a low level of tubular cell 
regeneration. In cisplatin-mice with AKI, the number of PCNA positive 
cells, slightly increased as compared to controls, indicating a 
spontaneous weak induction of the reparative process. The treatment 
with hCB-MSCs strongly induced the DNA synthesis suggesting a 
powerful induction of tissue recovery (p<0.01 vs control and p<0.05 vs 
saline).
4.9 In vitro expression of growth factors and cytokines by hum an 
cord-blood mesenchymal stem cells
In order to better explain the capability of hCB-MSCs to create a 
pro-regenerative environment able to promote tissue repair, we 
performed in vitro experiments, by co-culturing hCB-MSCs with 
cisplatin-treated proximal tubular cells (HK-2 cells) in a transwell
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system for 24 h. We focussed on the production of growth factors with 
vasculotropic, anti-apoptotic and renoprotective effect as FGF, HB-EGF, 
VEGF and HGF. In particular, we observed that HGF significantly 
(p<0.05) increased in the supernatants of co-cultured cells with respect 
to those of damaged HK-2 cells (FGF: 2-, HB-EGF: 7-, VEGF: 5- and 
HGF: 12- fold increase). Given the robust expression of HGF observed 
in in vitro experiments, we further studied the expression of this growth 
factor in vivo. The serum levels of HGF at 4 days in cisplatin-mice 
receiving hCB-MSCs, were significantly increased in respect to mice 
given saline (hCB-MSCs, 779±120 vs saline, 382+63 pg/m l, p<0.05). In 
parallel, kidneys of animals treated with human CB-MSCs showed a 
significant up-regulation of HGF mRNA expression at 4 days (hCB- 
MSCs, 1.8±0.1 fold increase vs saline, 1±0.03, p<0.0001).
Inflammatory cytokines produced by renal parenchymal cells, as 
IL-lp and TNFa, are responsible of cisplatin-induced renal toxicity 
(Ramesh et al, 2002; Zhang et al, 2007). To determine whether hCB- 
MSC ability to create a regenerative environment, is also due to anti­
inflammatory properties, proximal tubular cells pre-exposed to 
cisplatin were co-cultured with human CB-MSCs for different time 
intervals. We observed at 24 and 72h, a significant increase of the 
release of IL-ip and TNFa by proximal tubular cells exposed to 
cisplatin, as shown in Figure 4.13. Human CB-MSCs added to the co­
culture system, significantly inhibited the cytokine production during
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time (Figure 4.13), showing a modulator effect of stem cells on the 
production of inflammatory cytokines.
4.10 Conclusions
With the purpose to study the effect of hCB-MSCs, we first of all set 
up a model of acute kidney injury induced by the nephrotoxic drug, 
cisplatin. The results presented in Chapter 4 of this thesis can be 
summarized as follows. We found that:
• Injection of hCB-MSCs ameliorated both renal function and tubular 
cell injury prolonging animal survival.
• Transplanted hCB-MSCs localized in peritubular area acting though 
a paracrine mechanism.
• Human CB-MSCs markedly inhibited oxidative stress, apoptosis and 
inflammation, activating the pro-survival factor Akt and inducing 
proliferation of renal tubular cells.
• Human CB-MSCs produced a large amount of regenerative growth 
factors, inhibiting the release of inflammatory cytokines produced by 
damaged proximal tubular cells.
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4.11 Discussion
Mesenchymal stem cells have been most widely used in 
experimental models because of their plasticity, paracrine action and 
immunologic properties (Caldas et al., 2011). The most common and 
studied source of MSCs has been the bone marrow. We previously 
documented the renoprotective effect of human bone marrow derived- 
mesenchymal stem cells in the treatment of experimental AKI (Morigi et 
al., 2008). Data also demonstrated that stem cell transplantation could 
prolong animal survival and identified a suitable stem cell population 
for the possible use in future studies of cell therapy for human AKI 
(Morigi et al., 2008). However, aspirating bone marrow from the 
patients is an invasive procedure and it has been demonstrated that the 
number, the efficacy and the plasticity of these stem cells decrease with 
age of the donor (DTppolito et al., 1999). Therefore, the search for 
alternative sources of MSCs easily accessible is of significant value. 
Recent researches have revealed that cord blood is an alternative and 
extremely rich reservoir of stem cells with mesenchymal stem cell 
phenotype (Flynn et al., 2007; Sanchez-Ramos et al., 2006; Erices et al., 
2000; Lee et al., 2004). As cell therapy, MSCs of cord blood origin may 
be helpful in patients for whom the availability of autologous 
functional stem cells is limited, as patients treated with chemotherapy, 
which could compromise the availability of mesenchymal cells in bone 
marrow (Perry, 1969). Moreover, hCB-MSCs have many advantages
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partly related to the immaturity of newborn cells compared with adult 
stem cells and their being prone to escape immune rejection (Sanchez 
Ramos et al., 2006; Pinto et al, 2008; Locatelli et ah, 2008). For these 
reasons, human umbilical cord blood in the last years has been 'banked7 
and used as a source of marrow repopulating stem cells in patients with 
bone marrow deficit or inborn errors of metabolism (Sanchez Ramos et 
ah, 2006; Pinto F et ah, 2008; Locatelli et ah, 2008; Escolar et ah, 2005) 
resulting safe and efficacious. On this basis, we studied the capability of 
hCB-MSCs to regenerate the kidney in acute kidney injury.
We observed that hCB-MSCs expressed typical markers of 
mesenchymal stem cells, also expressed by hBM-MSCs. Moreover, we 
documented absence of adipogenic differentiation by hCB-MSCs (Kern 
et ah, 2006; Manca et ah, 2008; Rebellato et ah, 2008), while no differences 
in the osteogenic and chondrogenic differentiation capacity were 
detected between hBM-MSCs and CB-MSCs.
The transplantation of hCB-MSCs attenuated severe epithelial 
cell injury and improved renal function. Moreover, the present study 
shows for the first time, evidence that hCB-MSCs remarkably prolong 
animal survival to a more significant extent than hBM-MSCs.
Subsequently, once established the capacity of hCB-MSCs to 
repair renal injury, we then addressed the mechanisms possibly 
implicated in the renal reparative processes. Functional protection by 
hCB-MSCs can be the consequence of the capacity of stem cells to 
engraft the damaged kidney. Consistent with this possibility, the
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present data documented that hCB-MSCs were able to reach and 
survive in kidneys of NOD-SCID mice with AKI. We observed that in 
the renal tissue of cisplatin mice, hCB-MSCs almost exclusively 
localized in the peritubular areas and not in the context of the tubular 
epithelial lining, excluding that hCB-MSCs acted by transdifferentiation 
into proximal tubular cells. Rare or no cells were found in other organs 
including liver, lung and spleen. These data support the hypothesis that 
hCB-MSCs act through a paracrine effect once engrafted in the 
damaged kidney. This may happen via the local release of soluble 
factors (Imberti et al, 2007; Togel et al, 2005; Togel et al, 2007) and / or 
via the stimulation of target cells to produce growth factors with 
regenerative potential for renal cells. In this respect, some studies have 
documented that hCB-MSCs in culture constitutively produce pro­
survival, anti-inflammatory and mitogenic proteins (Liu et al, 2005; 
Kogler et al, 2005). Of interest, we have observed that growth factors as 
FGF, HB-EGF, VEGF, and particularly HGF, produced by hCB-MSCs in 
co-culture with cisplatin-damaged tubular cells, create a regenerative 
environment for tubular repair. We assume that the combination of 
several growth factors, locally produced by hCB-MSCs, could act in 
concert to create a proregenerative environment, in a more effective 
way than any single growth factor treatment.
Another significant finding of the present thesis was the 
identification of intracellular pathways of reno-protection conferred by 
hCB-MSCs. Oxidative damage induced by ROS and cell apoptosis, is
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consequence of renal tubular toxicity of cisplatin. Previous studies have 
demonstrated the favourable effect of anti-oxidants and ROS 
scavengers, in limiting programmed cell death (Lieberthal et al, 1996) 
and reducing tubular cell oxidative damage. Our data, that 
demonstrate an improvement of oxidative damage and cell apoptosis 
induced by hCB-MSC treatment, are consistent with idea that growth 
factors as HGF prevent oxidative stress in damaged tissues through 
their ability of normalizing anti-oxidant enzyme activity and 
mitochondrial function. (Garcia-Femandez et al, 2008; Okada et al, 
2004; Li et al, 2006; Ueda H 2001, 41}. On the other hand, the above 
growth factor together with VEGF have also the ability to activate the 
pro-survival factor Akt (Kumar et al, 200), a kinase that plays a critical 
role as mediator of the phosphoinositide-3 kinase (PI3K)-survival 
signals (Datta et al, 1999). Phosphorylated Akt counteracts cell 
apoptosis by phosphorylating and inhibiting the pro-apoptotic member 
of the Bcl-2 family, Bad (Zha et al, 1996) and the mitochondrial caspase- 
9 (Yang et al, 2001; Zhou et al, 2000). Recent findings have documented 
that blockade of PI3K-y-Akt pathway markedly accelerated renal 
tubular cell apoptosis and death leading to poor prognosis for mice 
with cisplatin-induced AKI (Kuwana et al, 2008). Our data confirmed 
the relevance of Akt in renal repair, showing that phosphorylation of 
Akt markedly decreased at 4 days, the time point with higher tubular 
damage and apoptosis, in renal tissue of cisplatin-mice. Conversely, 
treatment with hCB-MSCs, significantly increased pAkt positive tubuli
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and possibly activated downstream targets known to modulate cell 
proliferation and survival (Datta et al, 1999). All these protective effects 
were associated with a marked induction of proximal tubular cell 
proliferation as evidenced by the high number of cells positive for 
PCNA staining, after hCB-MSC injection.
Finally, we explored in vitro, the possible anti-inflammatory 
action of hCB-MSCs. Previous study in experimental and human AKI, 
have described an up-regulation of TNF-a and IL-1 |3 that are 
considered crucial in cisplatin-induced nephrotoxicity, as they act 
synergistically to stimulate the production of other cytokines and 
chemokines (Ramesh et al, 2002; Zhang et al, 2007; Devarajan et al, 
2006). Moreover, some researches have described an over-expression of 
E-selectin and ICAM-1, induced by TNF-a and IL-1 p, which promote 
inflammatory leukocyte migration (Takada et al, 1997). Here, we have 
documented the anti-inflammatory effect of hCB-MSCs co-cultured 
with proximal tubular cells damaged by cisplatin, which enhanced the 
production of these pro-inflammatory cytokines. We observed a 
marked reduction of TNF-a and IL-1 p when hCB-MSCs were co- 
cultured with proximal tubular cell damaged by cisplatin.
In summary, our findings indicate that hCB-MSCs promote 
kidney regeneration and prolong animal survival when transplanted in 
a mouse model of AKI. These effects seem to be mediated by a 
paracrine action of hCB-MSCs on tubular cells, which are able to 
proliferate as a result of activation of pro-survival and anti-apoptotic
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pathways. In the context of regenerative medicine, hCB-MSCs could be 
considered an option for autologous transplantation in hum an with 
AKI.
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Table 4.1: Time course of body weight, BUN and survival in NOD-SCID mice injected 
with cisplatin
0 1 2 3 4 5 7 days
Body Weight (g) 21±0.6 20±0.4 18±0.4 16±0.8 16±0.6 15±1 dead
BUN (mg/dl) 25±0.6 26±0.9 46±12 81±10
*
123±19
*
132±9 dead
Survival (%) 100 100 100 100 100 60 0
Data for body weight and BUN are expressed as mean ± SE (n=5). 
*p<0.01 vs day 0 (ANOVA, followed by Tukey Cicchetti test) 
BUN: blood urea nitrogen.
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Figure 4.1: Renal histology of NOD-SCID control mice (a) or cisplatin-treated mice 
sacrificed after 4 days (b). Original Magnification, x400.
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Figure 4.2: Ultrastructural changes in NOD-SCID mice 4 days after cisplatin 
injection.
(a) Ultrastructural analysis of normal proximal tubular cells, (b, c) Ultrastructural 
changes of tubular epithelium and peritubular capillaries in mice given saline at 4 
days after cisplatin treatment. Note the presence of PMN cell infiltration (*) in 
cisplatin mice at 4 days (c). Original magnification, X2,800.
PMN: polymorfonuclear.
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Figure 4.3: Human CB-MSC morphology and differentiation
(a) Representative image of hCB-MSCs with typical spindle shape morphology. 
Original magnification, xlO. (b) Differentiation of hCB-MSCs toward osteocytes 
evidenced by Alizarin Red staining, (c) Proteoglycans stained by Alcian Blue reveals 
chondrogenic potential of hCB-MSCs. Original magnification, x20.
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Table 4.2: Immunophenotype of hCB-MSCs
Antigens Percentage of fluorescent cells
CD105 55.3 ± 37.3
CD44 62.8 ± 35.1
CD90 90.4 ±6.9
CD73 98.8 ±1.9
SSEA4 3.9 ±4.1
HLA cl I 96.6 ±2.9
CD146 35 ± 18.1
aSM A 53.5 ±19.6
CD56 2.1 ± 1.4
DESMIN 0.4 ± 0.3
CK3/12 1 ± 0.7
CK19 2.6 ±1.7
BB9 0.2 ± 0.1
Data are expressed as mean ± SD
hCB-MSCs: human cord blood mesenchymal stem cells.
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Figure 4.4: Molecular profile of hCB-MSCs.
Human CB-MSCs were characterized for the expression of several 
adipogenic, endothelial, hepatic, receptor, embryonic and renal genes, 
lanel: negative control; lane 2: positive control; lane 3 hCB-MSCs; lane 
M: marker
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Figure 4.5: Effect of hCB-MSCs treatment in NOD-SCID mice with AKI
Cisplatin was administered to female NOD-SCID mice. Impairment of renal function 
was observed in cisplatin treated-mice injected with saline ( ♦  n=12). Human CB- 
MSCs treatment protected cisplatin treated-mice from renal damage (□  n=ll). 
°p<0.01 vs day 0 (basal); *p<0.01 vs cisplatin+saline at the same time (ANOVA, 
followed by Tukey Cicchetti test)
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Table 4.3: Effect of hCB-MSCs on renal histological changes at 4 days
Casts 
(n casts/HPF)
Tubular Necrosis 
(n necrotic tubuli/HPF)
Control (n=5) 0 0
Cisplatin+saline (n=12) 2.98±0.8 1.79±0.4
Cisplatin+hCB-MSCs (n=ll) 0.13 ±0.04* 0.09 ±0.03*
Data are mean ± SE. * p<0.01 vs Cisplatin+saline (Wilcoxon-Mann-Whitney test) 
HPF: high-power field
hCB-MSCs: human cord blood mesenchymal stem cells.
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Figure 4.6: Human CB-MSC infusion  protects mice w ith AKI from tubular injury.
(a) Renal histology of cisplatin-treated mice receiving hCB-MSCs at 4 days. Original 
M agnification, x400. (b) In cisplatin-treated mice injected w ith  hCB-MSCs, at 4 days, 
tubular cell and peritubu lar capillary injury is m arkedly attenuated. Original 
M agnification, x2800.
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Figure 4.7: Localization of hCB-MSCs in  renal tissue.
(a) Representative micrograph of kidney tissue from cisplatin-treated m ouse injected 
with PKH-26-labeled hCB-MSCs at 4 days. PKH-26 fluorescent hCB-MSCs were 
predominantly localized in peritubular area (arrow). Original magnification, x630.
(b) Representative micrograph of hCB-MSCs in a kidney section of cisplatin-mouse at 4 
days stained for human antigen HNA (red). Original magnification, x630.
159
CHAPTER 4: RENOP ROTECTIVE EFFECT OF hCB-MSCs IN EXPERIMENTAL  MODEL OF AKI
100 1
Cisplatin+hCB-MSCs
p<0.001po'
hJ
<>HH
Cisplatin+saline
75 9 11 140 4
Figure 4.8: Human CB-MSC treatment prolongs survival in mice with AKI.
All mice receiving saline (n=7) died within 9 days. At this time, 86% of NOD-SCID 
mice given hCB-MSCs (n=7) survived. p<0.001 vs Cisplatin+saline (Log Rank test)
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Table 4.4: Comparison between hCB-MSCs and hBM-MSCs on survival of cisplatin- 
treated mice
Od
SURVIVAL (%) 
4d 5d 7d 9d 14d
Cisplatin+saline (n=8) 100 100 50 0 0 0
Cisplatin+hCB-MSCs (n=10) 100 100 100 80 70 70*
Cisplatin+hBM-MSCs (n=10) 100 100 90 30 30 30**
**p<0.004 hCB-MSCs vs Cisplatin+saline;
*p<0.05 hBM-MSCs vs Cisplatin+saline (Kaplan-Meier analysis and Log-Rank Test) 
hCB-MSCs, human cord blood mesenchymal stem cells 
hBM-MSCs, human bone marrow mesenchymal stem cells
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Figure 4.9: Human CB-MSC treatment reduces renal oxidative damage in mice with 
AKI at 4 days.
Representative images of nitrotyrosine staining (dark brown), a marker of peroxynitrite, 
in renal tissue of control (a) and cisplatin-mice receiving saline (b) or hCB-MSCs (c). 
Representative image of negative control (d). Original magnification 400x.
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Table 4.5: Effect of hCB-MSCs on nitrotyrosine expression
Tubuli 
of Cortex
(score)
Tubuli of 
Medulla
(score)
Control (n=4) 0.60±0.06 0.39±0.03
Cisplatin+saline (n=4) 1.69±0.10° 1.29±0.08°
Cisplatin+hCB-MSCs (n=4) 0.98±0.21*° 0.54±0.11*
Data are mean ± SE. * p<0.05 vs Cisplatin+saline; ° p<0.05 vs Control 
(Kruskal Wallis test).
hCB-MSCs, human cord blood mesenchymal stem cells.
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Figure 4.10: Human CB-MSC treatment reduces tubular cell apoptosis in mice w ith  
AKI at 4 days.
(a) TUNEL positive cells quantified in kidney sections of control mice (n=5), cisplatin- 
treated mice given saline (n=5) or hCB-MSCs (n=5). °p<0.01 vs Control; *p<0.01 vs 
cisplatin+saline (ANOVA, followed by Tukey Cicchetti test), (b-d) Representative 
images of kidney sections labelled with TUNEL (green), rhodamine-labeled lectin LCA 
(red) and DAPI (blue). Original magnification 630X.
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Figure 4.11: Human CB-MSC treatment enhances Akt phosphorylation in m ice w ith  
AKI at 4 days.
(a) Percentage of pAkt positive tubules in control mice (n=3), cisplatin-treated mice 
receiving saline (n=3) or hCB-MSCs (n=3). °p<0.01 vs control; *p<0.01 vs cisplatin 
+saline (ANOVA, followed by Tukey Cicchetti test). (b-d)Representative images of p- 
Akt staining (red) with FITC-labelled lectin WGA (green) and DAPI (blue) in kidney 
sections of control, cisplatin-mice given saline or hCB-MSCs. Original magnification 
630X.
165
CHAPTER 4: RENOPROTECTIVE  EFFECT OF hCB-MSCs IN EXPERIMENTAL MODEL OF AKI
Control Cisplatin+ Cisplatin+
saline hCB-MSCs
Figure 4.12: Effect of hCB-MSCs at 4 days on tubular cell regeneration after cisplatin
Quantification of PCNA-positive tubular cells.°p<0.01 vs control; *p<0.05 vs cisplatin 
+saline (ANOVA, followed by Tukey Cicchetti test). Control (n=6), Cisplatin+saline 
(n=6), Cisplatin+hCB-MSCs (n=6).
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Figure 4.13: Anti-inflammatory effect of hCB-MSCs.
HK2 were incubated with cisplatin (8 pM) for 6 hours and after drug withdrawal, were 
co-cultured with hCB-MSCs for 24-72 hours *p<0.05 vs HK-2 cells +cisplatin (impaired t 
test). The experiments were performed in triplicate and repeated 3 times.
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CHAPTER 5
HUM AN AM NIOTIC FLUID STEM CELLS FOR THE 
TREATMENT OF ACUTE KIDNEY INJURY IN  MICE
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5.1 Introduction
Stem cell transplantation has been proposed as innovative and 
efficacious strategy for the treatment of acute organ injury (Choi et ah, 
2011; Shimada et al, 2011; Morigi et al, 2006; Iwatani et a l,2010). In this 
context, mesenchymal stem cells (MSCs) represent an attractive tool 
because of their regenerative effects in experimental model of 
myocardial infarction (Nagaya et al., 2004), in experimental acute 
kidney injury (Morigi et al., 2008; Herrera et al, 2004) and in neurologic 
disease like multiple sclerosis, amyotrophic lateral sclerosis and 
Parkinson (Torrente et al., 2008). The most common source of MSCs is 
the bone marrow (BM). Our group has documented that transplanting 
either murine or hum an BM-MSCs in mice with AKI improved tubular 
injury and ameliorated renal function through local release of growth 
factors as IGF-1. All resulted in such a protective effect by prolonging 
animal survival (Morigi et al, 2004; Imberti et al, 2007, Morigi et al, 
2008). Moreover, an alternative source of MSCs it has been identified in 
the cord blood (CB) (Flynn et al.,2007; Sanchez-Ramos et al, 2006; Erices 
et al, 2000; Lee et al, 2009). Human CB-MSCs share with human BM- 
MSCs morphological characteristics, immunophenotypic markers and 
differentiation ability (Kern et al, 2006; Panepucci et al, 2004; Wagner et 
al, 2005). Human CB-MSCs also displayed renoprotection, which 
resulted in prolonged animal survival as compared to hBM-MSCs 
(Morigi et al, 2010).
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Possible restrictions to using hum an BM and CB-MSCs may rest 
on both their limited capacity to grow in culture and difficulties to 
isolate enough cells from different cord blood samples. Finally, the 
capacity of MSCs to differentiate toward renal phenotype during 
kidney repair seems to be very confined (Togel et al., 2005; Morigi et al., 
2008; Duffield et al., 2005). Alternative sources of stem cells with higher 
plasticity would add value to the employment of cell therapy in terms 
of supporting tissue regeneration via direct cell replacement.
Embryonic stem cells are the most plastic stem cell population 
with unlimited capacity for self-renewal, however their employment is 
limited by ethical and safety issues (Hyun et al, 2010; Odorico et al.,
2001). Similarly, induced-pluripotent stem cells derived from de­
differentiation of somatic cells, still have limitations in regard to their 
clinical applicability because of teratogenic potential (Takahashi et al.,
2006).
On the other hand, in the last 10 years, the placenta, the fetal 
membranes (i.e. amnion and chorion) and amniotic fluid have also been 
extensively investigated as a non-controversial source of stem cells with 
multilineage differentiation potential and immunomodulatory 
properties (De Coppi et al., 2007; Cananzi et al., 2009). In particular, in 
the amniotic fluid, a population of stem cells with intermediate 
characteristics between embryonic and adult stem cells has been 
isolated (De Coppi et al., 2007). Indeed, hum an amniotic fluid stem 
(hAFS) cells, immunoisolated for c-Kit, express embryonic and
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mesenchymal stem cell markers including Oct-4 and SSEA-4, CD29, 
CD44, CD73, CD90 and CD105 (De Coppi et al., 2007). Human AFS cells 
can be readily expanded and reach 250 population doubling - 
characteristics of embryonic cells- while at the same time retaining 
stable telomerase length and normal karyotype between early and late 
passages (De Coppi et al., 2007). Clonal hAFS cell lines can differentiate 
into cells of the three embryonic germ layers and possess advantageous 
behaviours including the feeder independence and non-tumorigenicity 
at late passages, when injected into immunodeficient mice (De Coppi et 
al., 2007). For all these reasons, hAFS cells with high differentiation 
potential would be extremely valuable for cell therapy.
Because of the recent identification of hAFS cells few papers, 
exploring their differentiation potential, have been published. 
However, some studies have documented the capacity of hAFS cells to 
integrate and differentiate into damaged tissues. In an experimental 
model of naphthalene-induced lung damage, hAFS cells integrate in 
bronchio-alveolar position and differentiate into Clara cells (Carraro et 
al., 2008). Long-term experiments, up to 7 months, excluded tumor 
formation arising from hAFS cells (Carraro et al., 2008). Murine and 
hum an AFS cells displayed strong hematopoietic potential in sub- 
lethally irradiated RAG-1 deficient mice (Ditadi et al.,2009). Recently, 
hAFS cells showed high ability to differentiate into cardiomyocytes in 
rats with infarcted myocardium (Tsuji et al., 2010). Moreover, GFP- 
transfected hAFS cells incorporated into primordial kidney structures
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and expressed the early renal markers ZO-1, glial cell line-derived 
neurotrophic factor (GDNF) and claudin thus contributing to the 
development of renal vesicles, C- and S-shaped bodies (Perin et al,
2007).
Based on these evidences, the aim of this chapter is to study the 
potential of hAFS cells to regenerate renal tissue and to prolong 
survival of mice with cisplatin-induced AKI. Considering the plasticity 
of hAFS cells, we have investigated whether these cells afford 
protection through differentiation into renal cells or through local 
paracrine effect.
Moreover, we evaluated whether preconditioning of hAFS cells w ith a 
factor able to enhance their migration, engraftment and survival could 
maximize the regenerative potential of a stem cell-based therapy.
5.2 Isolation and characterization of human amniotic fluid stem
cells
Human AFS cells were isolated from human amniocentesis 
specimens by immunoselection of cells positive to c-kit (CD117) as 
previously described (De Coppi et al., 2007). As shown in Figure 5.1 a, 
amniotic fluid cells, seeded immediately after amniocentesis, displayed 
different morphologies, whereas after immunoselection for c-kit (Figure 
5.1 b), hAFS cells presented a small oval shape. Immunofluorescence
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analysis of hAFS cells, at first passage, showed positivity for HLA-ABC, 
SSEA4 and Vimentin (Figure 5.2 a-c).
Immunophenotype of hAFS cells were evaluated by FACs 
analysis. As shown in Tablel, hAFS cells stably expressed CD29, CD44 
and stromal cell markers as CD90, CD105 and CD73 at 4th and 8th 
passage (Table 1). The expression of c-kit was progressively lost after 
passaging whereas human AFS cells expressed embryonic stem cell 
markers Oct-4 and SSEA-4 after 8 passages of culture (Table 1). Human 
AFS cells also expressed HLA-ABC but not HLA-DR (Table 1), 
suggesting a low immunogenicity profile. This was further confirmed 
by absence of detectable CD80 and CD86 (data not shown). The ability 
of human AFS cells to differentiate into osteocytes and adipocytes, 
upon incubation with the appropriate inductive media, was observed 
by the extended area of mineralization and by lipid droplet formation 
(Figure 5.3 a and b).
5.3 Therapeutic effect of human amniotic fluid stem cells
In order to evaluate whether hAFS cells could exert a 
renoprotective effect, we set up an immunodeficient mouse model of 
cisplatin-induced AKI (see section 4.2). We observed that 
immunodeficient NOD-SCID mice injected with cisplatin developed 
renal function impairment characterized by high serum levels of BUN
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starting at 3 days after disease induction (basal, 23.1±1; 24 h, 24.4±1 and 
3 days, 98.7±9 m g/dl) that further increased at 4 days (133±4 m g/dl). 
By light microscopy, no structural changes were found in kidneys at 24 
h after cisplatin injection, the time of hAFS cell administration (Figure
5.4 b). Conversely, ultrastructural analysis at 24 h revealed focal 
changes consisting of swelling of mitochondria, loss of brush border, 
and myelin figures in tubular epithelial cells (Figure 5.5 b), as 
previously described (see section 4.2).
After identifying an experimental model of AKI suitable to test the 
effect of hAFS, we injected saline or stem cells (5xl05 cells) into the tail 
vein of NOD-SCID mice, one day after cisplatin treatment. As reported 
in Figure 5.6, hAFS significantly decrease (p<0.01) BUN levels at 4 days, 
as compared to cisplatin-treated mice given saline. Subsequently, we 
studied whether renal function improvement reflected an equally 
preserved renal structure. At 4 days, renal histology of cisplatin-treated 
mice showed focal and severe tubular cell degenerative alterations 
(Table 2, Figure 5.7 a) including nuclear fragmentation, loss of tubular 
epithelium and hyaline casts. Extended areas of necrosis affected the 
injured tubules (Table 2). Human AFS cells markedly attenuated renal 
tubular damage, as reflected by the significant reduction (p<0.01) of 
necrotic tubules and casts (Table 2, Figure 5.7 b).
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5.4 Distribution of human amniotic fluid stem cells
To study whether the renoprotective effect of hAFS cells was 
associated with their localization into renal parenchyma of cisplatin- 
treated mice, we labelled hAFS cells with PKH-26, a red fluorescence 
cell membrane linker before injection. As shown in Table 3, 24 h after 
PKH26-labeled-hAFS cell infusion, we quantified 2.9±0.2 cells/105 renal 
cells in the injured renal tissue. The frequency declined during time as 
assessed at 4 and 31 days (0.9±0.3 and 0.2±0.2 PKH-26+ cells/105 renal 
cells, respectively). The localization of PKH-26 labelled hAFS cells into 
the renal parenchyma was mainly in peritubular areas (Table 3, Figure 
5.8 a) and rarely within tubular epithelium, suggesting a differentiation- 
independent mechanism of action. To further confirm the hum an origin 
of PKH-26-labeled hAFS cells and the ability of these stem cells to 
engraft the damaged kidney, we co-stained kidney sections with anti­
hum an CD105 antibody (Figure 5.8 b and c).
In support of the concept that hAFS cells contributed to renal 
regeneration via a paracrine action and not through differentiation 
toward tubular cell phenotype, we performed immunofluorescence 
studies. Kidney sections of cisplatin mice treated with hAFS cells at 31 
days were incubated with hum an markers of epithelial tubular cells as 
cytokeratin and aquaporin-1. The results indicated that hAFS cells do 
not acquire renal phenotype in the long-term (Figure 5.9).
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The fate of hum an AFS cells in cisplatin-mice was also evaluated 
in liver, heart, spleen and lung at different times. As shown in Table 4, 
we didn 't find at 24h hAFS cells in organs other than kidney. At 4 days, 
no hAFS cells were detected in liver, heart and spleen, while few PKH- 
26 positive cells were found in the lung (Table 4). In control animals 
infused with hAFS cells, no engraftment was observed in the kidney 
and in the other organs at 24h.
5.5 Human amniotic fluid stem cell treatment inhibits apoptosis
In vitro and in vivo models of cisplatin-induced toxicity have 
demonstrated that renal tubular cells die by apoptosis. (Bonegio et al,
2002). Based on this evidence, we have studied whether hAFS cell 
transplantation could exert an anti-apoptotic effect on renal cells in 
mice with AKI. Apoptotic cells, evaluated as TUNEL positive cells, 
were quantified in kidney sections at day 4 by confocal laser scanning 
microscopy. As reported in Figure 5.10, kidney sections of control mice 
shown few apoptotic cells, while in renal tissue of cisplatin mice, we 
observed in damaged tubuli a significant increase (p<0.01) in the 
number of apoptotic TUNEL-positive cells (Figure 5.10 a,c). Infusion of 
hAFS cells led to a significant (p<0.01) decrease of TUNEL-labelled cells 
in respect to cisplatin-mice given saline (Figure 5.10 a,d), indicating their 
anti-apoptotic activity.
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5.6 Human amniotic fluid stem cells activate pro-survival pathways,
leading to renal regeneration
The serine-threonine kinase Akt is a mediator of survival signals 
that activates mitogenic pathways and counteracts apoptosis, through 
the phosphorylation of multiple substrates (Datta et al., 1999; Chang et 
al, 2003). Starting from this evidence, we studied whether the 
renoprotective effect of hAFS cells could pass through the activation of 
Akt, represented by its phosphorylation. As indicated in Figure 5.11, 
kidney sections of control mice showed a high number of tubuli 
positive for phosphorylated (p) Akt, while in mice with AKI the 
expression of phosphorylated (p) Akt declined at 4 days (Figure 5.11 
a,c). Treatment with hAFS cells significantly (p<0.01) increased the 
number of tubules positive for pAkt (Figure 5.11 a,d) suggesting a role 
of stem cells as activators of pro-survival pathways.
All these protective effects resulted in the induction of tubular cell
proliferation that reflected renal regeneration. We used the nuclear
marker of cycling cells, Ki-67, to quantify the number of proliferating
cells. In section 4.8 we used PCNA as marker of proliferation, but given
that PCNA has a role in DNA replication but also in DNA repair, we
prefered to use a marker strictly associate with cell proliferation. Ki-67
is a protein present during all active phase of the cell cycle (Gl, S, G2)
♦
but is absent in resting cells (GO) (Scholzen et al. 2000). In control mice at 
4 days, we observed weak spontaneous tubular cell regeneration, while
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in cisplatin mice the number of proliferating cells decreased (control, 
5±1.5 and saline 2±0.4 Ki-67+ cells/HPF). Hum an AFS cell treatment 
significantly (p<0.01) increased the number of Ki-67 positive cells in 
respect to cisplatin mice (hAFS cells, 16±1.3 Ki-67+ cells/HPF).
5.7 Human amniotic fluid stem cells prolong survival of mice
with AKI
Survival is the key clinical outcome in AKI, so based on the high 
sensitivity of NOD-SCID mice to cisplatin toxicity we investigated 
whether hAFS cell treatment could exert a protective effect also on 
survival. As shown in Figure 5.12, NOD-SCID mice with AKI started 
dying from day 5 and all animals receiving saline died within day 7 
(Figure 5.12) with high BUN levels (>140 m g/dl). Infusion of hAFS cells 
significantly (p<0.005) increased the lifespan of mice with AKI. All 
animals receiving hAFS cells were alive at 5 days, 56% of animal 
survived at 7 days and 33% of animals were still alive at the end of the 
study at 31 days.
In the same experimental model, we also compared the ability of 
hBM-MSCs and hAFS cells to prolong animal survival. As shown in 
Table 5, survival of cisplatin-mice treated with hAFS cells or hBM- 
MSCs was prolonged in respect to mice receiving saline (p<0.009). The
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effect on animal lifespan observed with hAFS cells and hBM-MSCs was 
comparable (Table 5).
5.8 Human amniotic fluid stem cells preconditioned with GDNF 
enhance their regenerative potential
Glial cell line-derived neurotrophic factor (GDNF), a member of 
the transforming growth factor family, is known to be a survival factor 
of dopaminergic and noradrenergic neurons and spinal motoneurons 
(Sariola et al., 2003). Moreover, recently, GDNF has been described to be 
necessary for migration an d /o r survival of renal resident MSCs (Shi et 
al., 2008). In the attempt to enhance the therapeutic potential of hAFS 
cell treatment, we tested the effect of hAFS cells pre-exposed to GDNF.
First, we evaluated whether hAFS cells preconditioned with 
GDNF for 24 h before their in vivo infusion, exhibited an increased 
capacity to engraft and survive in the damaged renal tissue in respect to 
untreated hAFS cells. At 24 h, we observed in the renal tissue, a higher 
number of GDNF-treated hAFS cells compare to unstimulated cells 
(GDNF/hAFS 24h, 4.9±0.3 vs hAFS 24h, 2.9±0.2/105 renal cells, p<0.05), 
suggesting a role of GDNF in stem cell migration. Moreover, we 
observed at 4 days that GDNF-treated hAFS cells were present in the 
renal tissue to a more significant extent than untreated hAFS cells 
(GDNF/hAFS 4 days, 3.6±0.5 vs hAFS 4 days, 0.9+0.3/105 renal cells, 
p<0.01). Both cell populations were predominantly localized in
180
C H A P T E R  5: H U M A N  A F S  CELLS FOR THE T R E A T M E N T  OF A K I  IN  MICE
peritubular areas (Figure 5.13 a and b). When infused in control NOD- 
SCID mice, preconditioned hAFS cells did not migrate in the kidney 
and in the other organs.
Subsequently, we studied whether GDNF-increased capacity of 
hAFS cells to migrate and survive in damaged renal tissue, was 
accompanied by an even greater effect on renal function and renal 
structure. As shown in Figure 5.14, GDNF-treated hAFS cells further 
ameliorated BUN levels of AKI mice compared to untreated cells 
(Figure 5.14). Moreover, tubular alterations like casts and tubular 
necrosis were significantly (p<0.01) reduced in cisplatin-mice 
transplanted with GDNF-treated hAFS cells in respect to AKI mice 
receiving untreated hAFS cells (Figure 5.15). The increased protective 
effect of GDNF-treated hAFS cells on renal function and structure was 
accompanied by a markedly enhancement of hAFS cell ability to induce 
tubular cell proliferation (Figure 5.16 a-d).
5.9 GDNF improves in vitro human amniotic fluid stem cell
motility,
chemokines/adhesive receptors and survival
Starting from evidence reported in literature (Shi et al, 2008) and 
from our in vivo results, we studied the mechanisms underlying the 
protective effect induced by GDNF-treated cells in AKI mice. Using a
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wound healing assay, we tested whether GDNF incubation for 24 h 
could enhance hAFS cell motility. As shown in Figure 5.17, hAFS cells 
treated with GDNF rapidly reduced the surface area of the wound at 7 
h in respect to untreated cells (Figure 5.17 a and b). In support of this 
result, we evaluated whether GDNF treatment could enhance the 
surface expression of receptors known to be involved in cell 
mobilization and engraftment within damaged tissue (Herrera et a\., 
2007; Shi et ah, 2007, 897; Ji et ah, 2004). As shown by flow cytometry 
histograms, hAFS cells constitutively expressed CD44, CXCR4 and 
CX3CR1 receptors, which were markedly enhanced by pre-conditioning 
with GDNF (Figure 5.18).
Next, to evaluate whether GDNF treatment could enhance hAFS 
cell survival in an oxidative environment like damaged tissue, we 
studied the effect of GDNF on hAFS cells exposed to hydrogen 
peroxide-induced cytotoxicity. Hydrogen peroxide (200 mM for 24 h) 
significantly reduced hAFS cell viability in respect to untreated cells 
(45.8±2% vs 95.2±0.7%, p<0.05). GDNF markedly (p<0.05) decreased 
hAFS cell susceptibility to hydrogen peroxide (72.9±5.7%).
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5.10 Human amniotic fluid stem cell production of pro-regenerative
factors
The potential of hAFS cells to create a pro-regenerative 
microenvironment was investigated by studying hAFS cell production 
of factors with mitogenic and prosurvival activities, comparing with 
that produced by GDNF-treated hAFS cells. By multi-analyte profiling 
assay, we observed that hAFS cells released in 48 h conditioned 
medium considerable amounts of IL-6, VEGF, SDF-1 and IGF-1 
(350.3±16.8, 369.2±4.6, 469.3±10.1 and 61±1 p g /m l/1 0 6 cells,
respectively). The levels of IL-10, FGF-2 and HGF were below the 
detection limits. When hAFS cells were exposed to GDNF, a markedly 
increased production of IL-6, VEGF and SDF-1 was detected (416.4±5.5, 
493.7±19.8 and 618.7±31.8 p g /m l/1 0 6 cells). At variance, IGF-1 secreted 
by GDNF preconditioned cells was not increased (67±7 p g /m l/1 0 6 
cells). In Figure 5.19 is shown the percentage of IL-6, VEGF and SDF-1 
production by GDNF-treated hAFS cells compared to untreated cells.
5.11 Conclusions
The results presented in Chapter 5 of this thesis, can be summarized 
as follows. We observed that:
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• Transplantation of hAFS cells ameliorated renal function and tubular 
structure prolonging animal survival.
• Mechanisms underlying tissue repair by hAFS cells operate through 
local activation of paracrine signals rather than cell differentiation.
• Human AFS cells blocked apoptosis activating pro-survival 
pathways.
• Preconditioning of stem cells with GDNF before their in vivo injection 
can enhance hAFS cell tropism and survival in damaged tissue, 
improving their regenerative capacity.
5.12 Discussion
Many stem cell populations (e.g. embryonic, adult and fetal stem 
cells) have been described and characterized to date. All of them show 
advantages and disadvantages, and seem to be possible candidates for 
cell therapy. However, the search of an easily accessible source of stem 
cells with high plasticity and without ethical concerns would add value 
to the employment of cell therapy in terms of supporting tissue 
regeneration.
Recently, hum an amniotic fluid has been identified as a source of 
multipotent stem cell population with remarkable plasticity, high 
expansion potential and a low risk for tumor development (De Coppi et 
al, 2007; Carraro et al., 2008). Some papers have explored the
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differentiation potential of hum an AFS cells, highlighting the capacity 
of these stem cells to differentiate towards cardiac, neural, and 
pulmonary lineages (Bollini et al, 2011; Tsai et al., 2006, 545; Carraro et 
al, 2008).
In the present study, we tested whether hAFS cells were able to 
trigger a regenerative process in a model of cisplatin-induced acute 
kidney injury. Recent evidence documented the efficacy of hAFS cells in 
a mouse model of AKI induced by glycerol. Human AFS cells were 
injected into the renal cortex of n u /n u  mice, 2 h  after intramuscular 
glycerol injection when the damage in the kidney has not yet been 
established (Perin et al., 2010). Furthermore, Hauser et al. demonstrated 
in the same experimental model of glycerol-induced rhabdomyolysis, 
that hAFS improve renal regeneration, but at a comparable extent as 
hBM-MSCs (Hauser et al., 2010). However, in both studies no data on 
animal survival, a critical outcome of AKI, were provided. Here, we 
have documented in NOD/SCID mice with established cisplatin- 
induced AKI, that hAFS cell treatment ameliorated tubular damage and 
limited renal function impairment prolonging animal lifespan. We 
compared the effect of hAFS cells and hBM-MSCs on survival of mice 
with AKI, and we obtained a comparable result between hAFS cells and 
hBM-MSCs but lower than that previously reported for hum an CB- 
MSCs (Morigi et al., 2010).
Another significant finding of the present thesis regards the 
capacity of hAFS cells to accelerate renal recovery in mice w ith AKI
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through a differentiation-independent mechanism. Indeed, we 
observed that, upon infusion, hAFS cells specifically engrafted the 
damaged kidney and predominantly localized in peritubular 
compartment rather than within the tubular epithelium, without 
differentiating in renal cells. This result is in contrast with the capacity 
of hAFS cells to develop and differentiate into de novo kidney structure 
when injected into kidney rudiments (Perin et al., 2007). Moreover, 
when hAFS cells were infused into damaged renal parenchyma of adult 
mice with AKI, their renal differentiation capacity was modest (Perin et 
al, 2010). These observations would suggest that only an embryonic 
microenvironment is able to create the appropriate condition for 
driving hAFS cells toward renal commitment. In our model, the 
regenerative effect of hAFS cells on damaged kidney was mediated 
through a local paracrine action due to the secretion of cytokines and 
growth factors with mitogenic and pro-survival effects like IL-6, VEGF, 
SDF-1 and IGF-1 that were found in the conditioned medium of hAFS 
cells.
Subsequently, once established the capacity of hAFS cells to 
induce renal regeneration, we studied the mechanisms involved in this 
reparative process. We previously demonstrated that renal toxicity 
induced by cisplatin was due to an increase of tubular oxidative 
damage responsible for cell apoptosis and reduction of the prosurvival 
factor Akt (Morigi et al, 2010). Moreover, Kuwana et al. have observed 
that blocking PBKy-Akt pathway, tubular cell apoptosis and necrosis
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were markedly accelerated, leading to a worse prognosis of cisplatin- 
treated mice (Kuwana et al., 2008). Here, we have documented that 
treatment with hAFS cells significantly reduced tubular cell apoptosis 
in respect to cisplatin-mice given saline. The capability of hAFS cells to 
create a regenerative environment was supported by the increased 
tubular expression of pAkt and proliferation at 4 days, the time point at 
which untreated mice exhibited higher tubular injury and apoptosis.
Another significant point of the present thesis has been to study 
an additional way to maximize hAFS cell regenerative potential by 
preconditioning of cells before their in vivo injection. Data are already 
available that gene modification (Hagiwara et al., 2008; Mangi et al., 
2003) or stem cell preconditioning with growth factors, cytokines, 
hypoxia or other factors (Shi et al, 2008; Mias et al, 2008; Schmidt et al, 
2006; Hung et al, 2007) can optimize in vitro and in vivo stem cell 
migration, engraftment, survival and efficacy. Here, we focussed on 
GDNF, a growth factor known to be a survival factor of dopaminergic 
and noradrenergic neurons and spinal motoneurons (Sariola et al, 
2003), besides being necessary for migration a n d / or survival of renal 
resident MSCs as recently described (Shi et al, 2008). Moreover, GDNF 
is known to participate to early nephrogenesis (Constantini et al, 2006) 
and to induce adult stem cells toward renal commitment (Yokoo et al, 
2005). Based on these evidences, we preconditioned hAFS cells with 
GDNF. We observed an increase of hAFS cell migration and homing in 
damaged kidney and a reduction of their susceptibility to the hypoxic
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environment, as reflected by the high number of GDNF-treated hAFS 
cells engrafting the renal tissue at 24 h that was also stably detectable at 
4 days. However, GDNF exposure did not commit hAFS cells toward 
renal phenotype, as supported by cell engraftment limited to the 
peritubular site. The increased engraftment and survival of 
preconditioned hAFS cells into the injured tissue, was associated with 
further amelioration of renal function, tubular injury and proliferation.
In vitro experiments allowed to batter explain the mechanisms 
underlying the protective effect of GDNF on hAFS cells. We observed 
that GDNF enhanced the motility of cultured hAFS cells, up-regulated 
the expression of surface receptors involved in chemotaxis and homing 
and increased the constitutive production of mitogenic and angiogenic 
factors. Moreover, enhanced survival of GDNF-treated hAFS cells, in 
response to a toxic concentration of hydrogen peroxide, suggests that 
GDNF can activate stem cell cytoprotective and anti-oxidant pathways 
capable to protect hAFS cells from oxidative stress occurring in 
damaged tissue.
In summary, our findings indicate that amniotic fluid could be 
considered a new potential stem cell source for organ regeneration. The 
renoprotective effect of hAFS cells seems to be mediated by local 
activation of paracrine signals rather than cell differentiation. A new 
approach to enhance hAFS cell tropism and survival in damaged tissue 
has been proposed by preconditioning of stem cells with GDNF before 
their in vivo use.
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Figure 5.1: Morphology of human AFS cells.
(a) Phenotypic appearance of the amniotic sample after amniocentesis: cells 
show different shape and volume. Original magnification 20X. (b) Human 
AFS cells after 5 days of selection for c-kit, receptor of the Stem Cell Factor 
(SCF). Selected cells showed a characteristic morphology: small oval shape 
that during maturation in culture becomes bigger. Original magnification 
20X; inset 40X.
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Figure 5.2: Immunophenotype of human AFS cells.
Representative images of hAFS cells (first passage) showing positive staining 
for HLA-ABC (a), SSEA-4(b) and vimentin (c). Original magnification 20X.
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Table 5.1: Phenotypic analysis of hAFS ckit+ cells
Antibody P4 P8
CD29 99.95% 82.94%
CD44 99.81% 82.77%
CD90 90.55% 77.51%
CD105 99.27% 90.70%
CD73 99.85% 95.80%
CD117 4.41% 2.10%
OCT4 69.50% 50.50%
SSEA-4 38.26% 33.21%
HLA-ABC 42.50% 28.01%
HLA-DR 0.58% 0.12%
Standard deviation was £ 10%
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Figure 5.3: Differentiation of human AFS cells
(a) Osteogenic differentiation of hAFS cells was evidenced by Von Kossa 
staining with area of mineralization, (b) Adipogenic differentiation of hAFS 
cells was visualized by Oil Red O staining. Original magnification 20X.
CHAPTER 5: H U M A N  AFS CELLS FOR THE T R E A T M E N T  OF AKI IN MICE
%
I V  »
#  *;•
e* o 7* r£ACwj/rj / # r £, ' *Uy i i" '
*
I  Sym ■ IbKifl
i  * f#
Figure 5.4: Representative light micrographs of PAS-stained-sections of 
kidneys taken from a control mouse (a) or from mice at 24 h (b, the time of 
hAFS cell infusion). Original magnification 400X.
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Figure 5.5: Ultrastructural changes in NOD-SCID mice 1 day after cisplatin 
injection
Electron micrographs of sections of proximal tubuli from a control mouse 
kidney (a) and a 24h cisplatin-treated mouse (b), showing cisplatin-induced 
mitochondrial swelling (mit) and loss of brush border. Original magnification 
2,500X.
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Figure 5.6: Effect of human AFS cells on renal function impairment
Renal function, assessed as BUN, in control (n=ll) and in cisplatin-treated 
mice given saline (n=ll) or hAFS cells (n=ll) at 4 days. Data are mean±SE. 
*p<0.01 vs Control; °p<0.01 vs Cisplatin+saline (ANOVA, followed by Tukey 
Cicchetti test).
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Table5.2: Effect of hAFS cells on renal histology of AKI mice at 4 days
Casts
(n/HPF)
Tubular Necrosis
(n/HPF)
Control (n=6) 0 0
Cispltin+saline (n=6) 8.6±1.2* 5.2±0.8*
Cisplatin+hAFS (n=6) 2.1±0.8° 2.1±0.8°
hAFS cells, human amniotic fluid stem cells.
Data are mean±SE 
HPF: high-power field
*p<0.01 vs Control; °p<0.01 vs Cisplatin+saline (Kruskal Wallis test)
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Figure 5.7: Human AFS cell infusion protects NOD-SCID mice with AKI 
from tubular injury
Renal histology at 4 days of cisplatin-treated mice receiving saline (a) or hAFS 
cells (b). Original magnification 400x.
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T able 5.3: Q uantification of hAFS PKH-26+ cells in  renal tissue of 
cisplatin mice.
hAFS cells/105 % hAFS cells
rena l cells in  p e ritu b u la r areas
hAFS 24h (n=3) 2.9±0.2° 93±4%
hAFS 4 days (n=6) 0.9±0.3 90±7%
hAFS cells, hum an  am niotic fluid stem  cells.
Data are mean±SE
*p<0.05 vs hAFS 24h; °p<0.01 vs hAFS 4gg (M ann-W hitney test)
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Figure 5.8: Human AFS cells engraft the kidney in cisplatin mice.
(a) Representative micrograph of kidney tissue from cisplatin-treated mouse 
injected with PKH-26 labeled hAFS cells (red) at 4 days. Hum an AFS 
PKH-26+ cells were localized in peritubular area. Original magnification 
630X. The sections were stained with FITC-labeled lectin WGA (green), and 
DAPI for nuclei (blue), (b) Representative images of hAFS cells co-stained 
with PKH-26 (red) and (c) human antigen CD105 (white). Nuclei were stained 
with DAPI (blue). Original magnification 630X.
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Figure 5.9: Human AFS cells don't differentiate towards a renal phenotype.
Frozen kidney sections were incubated overnight at 4°C with anti-human 
cytokeratin (1:100) or with anti-human aquaporin-1 (1:50) antibodies. Then 
sections were incubated with secondary antibody, donkey anti-mouse Cy5 
and goat anti rabbit Cy5 (1:50), respectively. Slides were counterstained with 
FITC-labeled lectin WGA (green) and nuclei were stained with DAPI (blue).
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Table 5.4: Quantification of hAFS PKH-26+ cells in different organs of 
cisplatin-mice with AKI
PKH-26+ cells/105 cells
liver lung heart spleen
hAFS 24h (n=3) 0 0 0 0
hAFS 4 days (n=3) 0 0.8 ±0.1 0 0
hAFS, human amniotic fluid stem cells. 
Data are mean±SE
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Figure 5.10: Human AFS cell treatment reduces tubular cell apoptosis in 
mice with AKI at 4 days.
(a) TUNEL positive cells quantified in kidney sections of control mice (n=3), 
cisplatin-treated mice given saline (n=3) or hAFS cells (n=3). *p<0.01 vs 
Control; °p<0.01 vs Cisplatin+saline (ANOVA followed Tukey Cicchetti test), 
(b-d) Representative images of apoptotic tubular cells labeled with TUNEL 
(green), rhodamine-labeled lectin LCA (red) and DAPI (blue) in kidney 
sections of control mice, cisplatin-mice given saline or hAFS cells. Original 
magnification 630X
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Figure 5.11: Human AFS cells enhance Akt phosphorylation in mice with 
AKI at 4 days.
(a) Percentage of pAkt positive tubules in control mice (n=3), cisplatin-treated 
mice receiving saline (n=3) or hAFS cells (n=3). *p<0.01 vs Control; °p<0.01 vs 
Cisplatin+saline (ANOVA followed Tukey Cicchetti test), (b-d) Representative 
images of pAkt staining (red) with FITC-labeled lectin WGA (green) and 
DAPI (blue) in kidney sections of control, cisplatin-mice given saline or hAFS 
cells. Original magnification 630X.
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Figure 5.12: Human AFS cell treatment prolongs survival in mice with AKI.
At 7 days all mice receiving saline died (n=9), while 56% of NOD-SCID mice 
given hAFS cells (n=7) survived. *p<0.005 vs Cisplatin+saline (Log Rank 
Test).
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Table 5.5: Comparison between hAFS cells and hBM-MSCs on survival of 
cisplatin-mice with AKI.
Survival (%)
0 day 5 days 7 days 31 days
Cisplatin+saline (n=6) 100 50 0 0
Cisplatin+ hAFS (n=6) 100 100 50 33*
Cisplatin+ hBM-MSCs (n=6) 100 83 33 33*
hAFS, human amniotic fluid stem cells. 
hBM-MSCs, human bone marrow mesenchymal stem cells 
*p<0.009 vs Cisplatin+saline. (Kaplan-Meier analysis and Log-Rank 
test).
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24h
Figure 5.13: Localization of hAFS cells preconditioned with GDNF
Representative micrographs of kidney tissue from cisplatin-mice injected with 
PKH-26-labelled hAFS cells preconditioned with GDNF at 24h (a) and 4 days
(b). The sections were stained with FITC-labeled lectin WGA (green), and 
DAPI for nuclei (blue). PKH-26 fluorescent cells (red) were localized in 
peritubular area (arrow). Original magnification 630X.
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Figure 5.14: Preconditioning with GDNF increases renoprotection of hAFS 
cells in mice with AKI.
Renal function, measured as BUN, in cisplatin-treated mice given saline 
(n=9), untreated hAFS cells (n=10) or GDNF-preconditioned hAFS cells 
(n=10) at 4 days. Data are mean±SE. °p<0.01 vs Cisplatin+saline; #p<0.05 vs 
Cisplatin+hAFS cells (ANOVA followed by Tackey Cicchetti test).
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Figure 5.15: GDNF-preconditioned hAFS cells ameliorate renal structure in 
mice with AKI at 4 days
Histological changes in kidneys from cisplatin-treated mice receiving saline 
(n=6), untreated hAFS cells (n=6) or GDNF-preconditoned hAFS cells (n=6) at 
4 days. Data are mean+SE. °p<0.01 vs Cisplatin+saline; #p<0.01 vs Cisplatin+ 
hAFS cells (Kruskal-Wallis test).
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Figure 5.16: Preconditioning with GDNF enhances the ability of hAFS cells 
to induce tubular cell regeneration
(a) Quantification of Ki-67 positive tubular cells at 4 days after cisplatin 
treatment in mice receiving saline (n=3), hAFS (n=3) and GDNF/hAFS (n=3). 
Data are mean±SE. °p<0.01 vs Cisplatin+saline; #p<0.01 vs Cisplatin+ hAFS 
cells (ANOVA followed by Tukey Cicchetti test).
(b-d) Representative images of Ki-67 positive tubular cells (red) co-stained 
with FITC-labelled lectin WGA (green) and DAPI (blue) in kidney sections of 
cisplatin-mice given saline, untreated hAFS cells or GDNF-preconditioned 
hAFS cells. Original magnification 630X.
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Figure 5.17: GDNF increases in vitro hAFS cell motility
Representative micrographs of scratch-wound-closure assays in hAFS cells 
untreated (a) or treated for 24 h with GDNF (100 ng/ml) (b). Preconditioned 
hAFS cells with GDNF showed a more rapid capacity to cover the wound 
area after 7 h in respect to untreated hAFS cells.
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Figure 5.18: GDNF increases in v itro  hAFS expression of CD44, CXCR4 and 
CX3CR1 receptors
Representative fluorescence histograms show the expression of CD44, CXCR4 
and CX3CR1 in untreated hAFS cells (green) and GDNF-conditioned hAFS 
cells (blue) by FACs. The negative controls are shown as red line.
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Figure 5.19: GDNF increases in vitro hAFS production of pro-regenerative 
factors
Percentage of increased production of IL-6, VEGF and SDF-1 by hAFS cells 
treated with GDNF (GDNF/hAFS) for 48 h in respect to untreated hAFS cells. 
*p<0.05 and **p<0.01 vs untreated hAFS cells (unpaired t test). The 
experiments were performed in triplicate and repeated 3 times.
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In the last decade, several studies have widely demonstrated the 
important role of stem cells, not only in the physiological cell turnover, 
but also in the repair of the damaged tissues. These discoveries have 
opened a new branch of medicine. Where the traditional medicine has 
not been able to offer therapeutic opportunities, stem cells used as 
vehicles, have represented a great challenge that has lead to profound 
effects on regenerative medicine. Despite this, therapeutic applications 
of stem cells to injured organs are still largely a matter of experimental 
investigation in order to prove the real efficacy and safety of such 
approaches.
Organs, like kidney, showing minimal cell turnover and limited 
capacity for self-repair after injury, could benefit from the stem cell 
treatment. Following damage, renal tubular cells have capacity to 
regenerate, although regeneration is limited by the extent of the injury 
and the number of surviving cells. Cell therapy, based on the used of 
stem cells, could represent a valid alternative to pharmacological 
therapies, that up to now are characterized by poor success rates. 
Therefore, we decided to address our efforts to investigating the 
possibility that stem cells could help in regenerating the kidney after 
AKI. In particular, we focused on the possible therapeutic effect of stem 
cells isolated from fetal tissues in order to bypass the limits of adult 
stem cells.
In the last years, several researches focused on the renoprotective 
effect of BM-MSCs, given their paracrine, anti-inflammatory and
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immunomodulatory properties. In particular our group have 
demonstrated that the intravenous administration of BM-MSCs in mice 
with AKI induced by cisplatin, protected renal function and structure 
through the local release of anti-apoptotic and mitogenic growth 
factors, like IGF-1 (Morigi et ah, 2004, Imberti et ah, 2007). Although 
bone marrow represents the first identified tissue source of MSCs, 
harvesting these stem cells is invasive and their number, frequency, 
differentiation potential, and life span decline with the age of the donor. 
Therefore, in the clinical perspective to cure AKI, the search for new 
sources of MSCs, is of significant value. It has been reported that stem 
cells with similar surface expression patterns of MSCs can be isolated 
from alternative sources as umbilical cord blood, placenta, adipose 
tissue, amniotic fluid, peripheral blood, and other tissues (Liu et ah, 
2009).
Since the first successful transplantation of umbilical cord blood in 
1988, the cord blood has proved a fetal rich source of stem cells, and in 
particular of mesenchymal stem cells with morphological 
characteristics, immunophenotypic markers and differentiation ability 
similar to BM-MSCs (Kern et ah, 2006; Panepucci et ah, 2004; Wagner et 
ah, 2005). Moreover, unlike the invasive harvesting of bone marrow, the 
collection of cord blood is relatively simple and lacks of risks to mother 
or infant and of ethical barrier. Early clinical evidence documented both 
safety and efficacy of CB progenitors cell infusion in hum ans for the 
treatment of haematological (Pinto et ah, 2008; Locatelli et ah, 2008),
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neurological disorders (Sanchez-Ramos et at., 2006; Escolar et ah, 2005) 
and Burger's disease (Kim et ah, 2006). Furthermore, for future therapies 
it will be possible to use the established cord blood bank to construct a 
cord blood-MSC bank network system. Altogether, these findings 
prompted us to investigate whether hCB-MSCs could represent a new 
option to cure AKI. We chose to induce acute kidney injury, treating 
immunodeficient (NOD-SCID) mice with the cytotoxic drug cisplatin. 
This compound is one of the most effective for the treatment of several 
solid tumours; unfortunately, its administration is associated with 
severe nephrotoxicity in 10-15% of patients (Madias et al., 1978). In this 
model of AKI, we transplanted hCB-MSCs 1 day after cisplatin 
treatment, when an ultrastructural damage was already present, and 
we observed that stem cells were able to ameliorate renal function and 
structure compared to cisplatin-mice treated with saline. Another 
significant finding of the present study regards the capacity of this 
population of stem cells to affect the critical outcome of AKI, the 
survival. The renoprotective effect of hCB-MSCs was so strong that 
these stem cells were able to prolong animal survival to a more 
significant extent than that observed in cisplatin mice treated with 
hBM-MSCs. The reasons for this difference still remain to be elucidated. 
A possible explanation may rest on the evidence of the immaturity of 
hCB-MSCs that could produce large amount of growth factors that are 
more active in the mitogenic and pro-survival pathways than that 
produced by hBM-MSCs. Moreover, the fetal nature of these stem cells
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makes them more prone to escape immune rejection than adult stem 
cells.
The positive effect of hCB-MSCs was due to their renotropic 
capacity that allows them to home to injured kidney, following the 
inflammatory cytokines released from the damaged renal cells. Indeed, 
we observed hCB-MSCs exclusively localized in the peritubular areas 
and not in the context of the tubular epithelial lining, excluding the 
transdifferentiation into renal cells. These data are in support of a 
paracrine action of hCB-MSCs once engrafted in the damaged kidney, 
as already described for BM-derived stem cells in experimental AKI by 
other and our laboratories (Imberti et ah, 2007; Togel et ah, 2005; Togel et 
ah, 2007). Relevant to the former interpretation are data that hCB-MSCs 
in culture constitutively produce pro-survival, anti-inflammatory and 
mitogenic proteins (Liu et ah, 2005; Kogler et ah, 2005) as also 
demonstrated by our in vitro experiments, showing a remarkable 
amounts of growth factors as FGF, HB-EGF, VEGF and HGF produced 
by hCB-MSCs in co-cultured with cisplatin -dam aged tubular cells.
In this study, we observed that the differentiative capacity of hCB- 
MSCs toward renal phenotype during kidney repair seems to be very 
confined. Therefore, the sources of stem cells with higher plasticity 
would add value to the employment of cell therapy in terms of 
supporting tissue regeneration via a differentiation-mechanism. To this 
purpose, we tested the effect of hAFS cells in a cisplatin-induced AKI 
model. In the last 10 years, the amniotic fluid, obtained from
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amniocentesis, has been extensively studied as a non-controversial 
source of a population of stem cells with intermediate characteristics 
between embryonic and adult stem cells (De Coppi et al., 2007). Human 
AFS cells, immunoisolated for c-Kit, express embryonic and 
mesenchymal stem cell markers, can be readily expanded and possess 
immunomodulatory properties (De Coppi et al., 2007; Cananzi et al., 
2009). Moreover, hAFS cells show potential to differentiate into 
hematopoietic, neurogenic, osteogenic, chondrogenic, adipogenic, renal, 
hepatic and various other lineages (In't Anker et al., 2003; Tsai et al., 
2004, 1450; Bossolasco et al., 2006; Kim et al, 2007; De Coppi et al., 2007; 
Prusa et al., 2004; Rehni et al., 2007; Kolambkar et al., 2007; Orciani et al., 
2008; Rosner et al., 2011, 1). Therefore, based on the high plasticity of 
this stem cell population, we investigated whether hAFS cells afford 
protection through differentiation into renal cells or through local 
paracrine effect. The injection of hAFS cells in NOD-SCID mice with 
cisplatin-induced AKI showed a partial renoprotective effect. Indeed, 
BUN values were higher than those observed in control animals. Partial 
renoprotective effect of hAFS cells became complete when hAFS cells 
were preconditioned with GDNF, suggesting a contribution of this 
growth factor in the enhancement of the therapeutic effect of these stem 
cells. Moreover, comparing the efficacy of hAFS cells with that of hBM- 
MSCs, we observed that the effect on animal lifespan observed with 
hAFS cells and hBM-MSCs was comparable.
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One possibility of the partial therapeutic effect of hAFS cells could 
be their lower renotropic capacity. Indeed, hAFS cells engrafted the 
injured kidney of cisplatin mice with a low frequency. GDNF pre­
conditioning increased the number of hAFS cells homing the damaged 
tissue, because, as we observed in in vitro experiments, GDNF was able 
to enhance the surface expression of receptors known to be involved in 
cell mobilization and engraftment within damaged tissue. As reported 
in literature for MSCs (Shi et al, 2008), also in this case GDNF was 
necessary to enhance migration a n d / or survival of hAFS cells.
It is widely demonstrated that MSCs facilitate kidney regeneration 
predominantly through a differentiation-independent mechanism 
characterized by the delivering of growth factors and cytokines to the 
site of the injury. The same occurred for hAFS cells, even if, given the 
high plastic capacity of these stem cells, we would expect to observe a 
differentiation-dependent mechanism of action. Our results differ from 
the recent study of Perin et al. (Perin et al., 2010), who showed that 
lx l0 6 hAFS cells directly injected into the renal tissue of n u /n u  mice 
with AKI were able to differentiate, contributing to kidney 
regeneration. This discrepancy may depend on the amount of cells 
transplanted and the route of administration.
To date MSCs isolated from bone marrow are the favoured 
population of stem cells in the clinical practice. However, for future 
application in humans, we have to consider that, since acute kidney 
injury is a sudden phenomenon and there is possibility of donor site
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morbidity, there is no chance of using the patient's own MSCs because 
it takes too long to isolate and in vitro expand the MSCs. It means that 
there is need to use populations of allogeneic stem cells, which, 
however, may pose the significant problem of immune response. As 
fetal cells, hCB-MSCs and hAFS cells, might have an immunoprivileged 
status, as they likely possess mechanism to avoid destruction by the 
maternal immune system during development (Betz, 2010). Moreover, 
given the extensive self-renewal capacity in respect to hBM-MSCs, hCB- 
MSCs and hAFS cells represent ideal sources for cell banking and 
allogeneic transplantation. As allogeneic cell sources, hCB-MSCs and 
hAFS cells may raise the issue of a possible adverse reaction or ultimate 
rejection by the recipient. However, both populations of stem cells, 
similarly to BM-MSCs, expressed MHC I but not MHC II and are 
negative for costimulatory molecules as CD80, CD86, CD40 and CD40 
ligands, which are mainly expressed on antigen presenting cells and 
tissue cells (Wang et al, 2009; Moorefield et al, 2011). Moreover, hCB- 
MSCs were not able to induce allogeneic peripheral blood mononuclear 
cell (PBMC) proliferation and can suppress in vitro the function of 
mature dendritic cells (Wang et al, 2009). Human AFS cells, through the 
release of soluble factors, inhibited lymphocyte activation, suppressing 
inflammatory responses in vitro (Moorefield et al, 2011).
In conclusion, this study suggests a therapeutic effect of foetal 
stem cells in a model of AKI, through a local paracrine mechanism of 
action rather then cell differentiation. In the future, the safety and
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efficacy of hCB-MSCs and hAFS cells should be investigated in the 
prospective of the clinical use of these new potential stem cell sources 
for organ regeneration. Moreover, starting from the data obtained in 
this thesis, future studies should study how stem cells can communicate 
with adult or progenitor cells in order to maintain the integrity of renal 
structure. The sharing of proteins and mRNA through exosomes and 
microvesicles will be the next step to better clarify the mechanism of 
communication between cells.
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7.1 Non-communicable diseases
The end of the 20th century was characterised by significant 
demographic changes, particularly prominent in the developing 
nations. This has been the result of different factors including advances 
in medical practice and technology related to communicable disease, 
reduction of nutritional deficiency disorders, economic improvement 
and development of public health programmes. Life expectancy has 
lengthened, increasing the exposure to the risk factors of non- 
communicable diseases, (NCDs) like tobacco use, unhealthy diet, lack 
of physical activity and alcohol abuse (Codreanu et al., 2006). To date 
NCDs are the largest cause of death in the world, and cardiovascular 
disease, cancer, chronic lung disease, and diabetes mellitus are 
considered NCDs (Perico et al., 2012). Actually, the prevalence of these 
chronic diseases is projected to increase over the next decades. 
According to WHO, the worldwide number of patients with diabetes in 
2000 was estimated to be 171 million, in 2030 will be estimated 366 
million (Wild et al., 2004).
In all countries, the increased burden of NCDs is also an ever­
growing economic cost. For example, it has been anticipated that in the 
United States, cardiovascular disease and diabetes together cost $750 
billion annually (Narayan et al., 2010). As observed by the World 
Economic Forum's 2009 report, NCDs are among the most severe 
threats to global economic development.
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7.1.1 Chronic kidney disease
Chronic kidney disease (CKD) is a key determinant of the poor 
health outcome for major NCDs. CKD is a general term for 
heterogeneous disorders that affect the structure and function of the 
kidney but also include some complications such as hypertension, 
anemia, malnutrition, bone and mineral disorders, and neuropathy as 
well as increased risk of cardiovascular disease. The definition of CKD 
is based on the presence of kidney damage (ie. albuminuria) or 
decreased kidney function (ie. glomerular filtration rate [GFR] below 60 
m l/m in  per 1.73 m2) for 3 months. Because of the central role of GFR in 
the pathophysiology of complications, the disease is classified into five 
stages on the basis of GFR: >90 m l/m in  per 1.73 m2 (stage 1), 60-89 
m l/m in  per 1.73 m2 (stage 2), 35-59 m l/m in  per 1.73 m2 (stage 3), 15-29 
m l/m in  per 1.73 m2 (stage 4), less then 15 m l/m in  per 1.73 m2 (stage 5). 
The U.K. National Institute of Health and Clinical Excellence (NICE) 
has modified in 2008 the KDOQI CKD classification by subdividing 
CKD stage 3 into 3A and 3B, estimated GFR of 45 to 59 m l/ min per 1.73 
m2 and 30 to 44 m l/m in  per 1.73 m2, respectively. The NICE CKD 
guidelines also stipulated that the suffix p be added to the stages in 
proteinuric patients (National Kidney Foundation, 2002; Vassalotti et al., 
2007; Stevens et al., 2009).
CKD is a worldwide threat to public health, but the true 
dimension of this problem is not fully appreciated. On potential 
outcome of CKD is end-stage renal disease (ESRD), requiring costly
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renal replacement therapy, which consists primarily of kidney 
transplantation, haemodialysis and peritoneal dialysis. In developed 
countries, ESRD is a major cost for health-care system, with annual 
growth of dialysis programs ranging between 6% and 12% over the past 
two decades and continuing to grow (Couser et al., 2011).
Approximately 2 million people are currently treated with renal 
replacement therapy (RRT), but this likely represents less than 10% of 
those who need (Eggers, 2011). More than 90% of these individuals live 
in industrialized countries, while available RRT in developing countries 
is scarce, and null in underdeveloped areas. Indeed, 112 countries, with 
a combined population of over 600 million people, cannot afford renal 
replacement at all-resulting in the death of over 1 million people 
annually from untreated kidney failure (Couser et al., 2011).
The most obvious social effect of CKD is the enormous financial 
cost and loss of productivity associated with advanced kidney disease. 
Many developed nations spend more than 2-3% of their annual health­
care budget to provide treatment for ESRD, while the population with 
ESRD represents approximately 0.02-0.03% of the total population 
(Couser et al., 2011).
According to the 2010 US Renal Data System Annual Data Report, 
the leading causes of CKD leading to kidney failure in the United States 
are diabetes, hypertension and glomerulonephritis (Collins et al., 2009). 
A conceptual model for the course of CKD has been identified (Figure
7.1). This model describes, how the kidney disease tends to worsen over
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time through a sequence of risk factors like susceptibility, initiation, 
progression factors and end-stage factors. Susceptibility factors can be 
genetic, developmental or demographic factors. Initiation factors are 
conditions that can cause kidney damage, as diabetes, hypertension and 
autoimmune diseases. Progression factors include elevate blood 
pressure, higher level of proteinuria, poor glycemic control in diabetes, 
and smoking, while end-stage factors influence the risk for the 
development of adverse outcome in patients with kidney failure. Once 
established, CKD progression is influence by a number of non- 
modifiable and modifiable risk factors (Taal et al., 2008). The non- 
modifiable progression risk factors include age; gender: the ESRD 
occurs more frequently in men than in women; race: the incidence and 
prevalence of diabetic and hypertensive CKD are higher in African and 
Hispanic Americans compared with Caucasians (Traver-Carr et al, 
2002); and genetics: recent technologic advancements in genome-wide 
association studies are likely to uncover new CKD susceptibility genes. 
The modifiable progression risk factors include systemic hypertension, 
proteinuria and metabolic factors. Moreover, cigarette smoking, alcohol 
consumption and drug use can influence the progression of CKD 
(Floege J et al, 2010).
The progression of CKD is associated with the appearance of 
progressive scarring that lead to loss of kidney function and ESRD. 
Scarring is characterized by loss of intrinsic renal cells and their 
replacement with fibrous tissue made of collagenous extracellular
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matrix (ECM) that affects the glomeruli (glomerulosclerosis), tubules 
and interstitium (tubulointerstitial fibrosis), and vessels (vascular 
sclerosis) (Floege J et al., 2010). This fibrotic process is preceded by 
kidney cell loss through apoptosis or necrosis, phenotypic changes 
towards embryonic phenotype (epithelial-mesenchymal transition), and 
proliferation of myofibroblasts with subsequent increased ECM 
synthesis.
In the past decades, ample evidence from clinical trials and meta­
analysis has shown the efficacy of several treatments for CKD, to 
reduce risk of progression to ESRD. These treatments are based on the 
control of hypertension with inhibitors of the rennin-angiotensin 
system which slowing the progression of diabetic and non-diabetic 
CKD (Remuzzi et ah, 2002). In addition, lifestyle intervention (wight 
loss, smoking cessation), tight diabetes control, and treatment of other 
cardiovascular risk factors as dyslipidemia are associated with a slow 
progression to ESRD (Couser et al., 2011).
7.2 Adriamycin toxicity
In literature different experimental model of CKD are described. 
In this study, we chosen ADR-induced nephropathy as it is universally 
considered the prototypical experimental model of hum an primary 
focal segmental glomerulosclerosis (FSGS). So, in this animal model we
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studied the effect of bone marrow derived mesenchymal stem cells. 
This section of the introduction focuses on features of adriamycin 
nephrotoxicity and goes deeper inside the mechanisms underlying 
toxicity.
7.2.1 Metabolism of adriamycin
Adriamycin (ADR; doxorubicin) is an anthracycline antibiotic, a 
class of anti-tumour drugs used for the treatment of solid tumors 
including breast cancer and childhood leukemias (Lee V et al., 2011). 
Unfortunately, this broadly successful antineoplastic agent has also 
been shown to be cardiotoxic and nephrotoxic (Berthiaume et ah, 2007; 
Bertani et ah, 1982).
Detailed pharmacokinetic studies have been performed in hum an 
and animals. Adriamycin is not significantly metabolized; indeed, it is 
rapidly cleared from the plasma after intravenous administration, 
deposited in the tissue, and slowly excreted into urine and bile. 
Adriamycin accumulates mainly in the kidney but also in liver, heart 
and small intestine (Lee V et ah, 2011).
Different mechanisms have been proposed for the cytostatic and 
cytotoxic action of ADR, including intercalation into DNA, inhibition of 
topoisomerase II, free radical formation and lipid peroxidation (Figure
7.2). Cells in the S phase of the cell cycle appear to be most sensitive to 
the cytotoxic action of ADR, the antibiotic inhibits both cellular DNA 
and RNA synthesis, presumably by binding to nucleic acid (Gewirtz,
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1999; Momparler et al., 1976). Intercalation of ADR into DNA inhibits 
the progression of the topoisomerase II, which is a nuclear enzyme that 
regulates the overwinding or underwinding of DNA and it is essential 
for cell replication. ADR stabilizes the topoisomerase II complex 
preventing the DNA double helix from being resealed and thereby 
stopping the process of replication (Gewirtz, 1999; Bodley et al., 1989).
Another toxic effect of ADR is due to the capacity of this antibiotic 
to form free radicals. The quinone structure permits ADR to act as an 
electron acceptor. The addition of free electron, converts the quinone to 
semiquinone free radicals, which may induce DNA damage or form 
superoxides, hydroxyl radicals and peroxides if they interact with 
molecular oxygen (Gewirtz, 1999). There is further evidence for free- 
radical generation due to the formation of complexes between ADR and 
iron formation with consequent induction of DNA damage or lipid 
peroxidation (Gewirtz, 1999; Eliot et al., 1984; Gianni et al., 1985). All 
these cytotoxic and cytostatic effect of ADR, result in the induction of 
apoptotic cell death, which is the final cellular response to upstream 
events such as inhibition of topoisomerase II (Gewirtz, 1999; Ling et al., 
1993).
7.2.2 Pathophysiology of ADR-induced nephropathy
ADR-induced nephropathy in rats is universally considered to be 
the prototypical experimental model of human primary focal segmental 
glomerulosclerosis (FSGS). In both experimental models and affected
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humans, the podocytes are the site of the initial injury in the 
development of FSGS (Pippin et ah, 2009). Adriamycin exerts oxidative 
damage on cell structure through a direct reduction to a semiquinone 
radical or by producing ROS via the xanthine oxidase system. The ROS- 
mediated injury is associated with down-regulation and shift in polarity 
of a-3 and a-5 integrin expression, key molecules for maintenance of 
podocyte shape and adhesion. Changes in these integrins, may 
underlie podocyte foot process fusion and alteration in the cell-cell and 
cell-matrix interactions, with consequent podocyte loss (Fogo, 2003; 
Pippin et al., 2009).
The loss of podocytes has been linked to an altered expression of 
numerous factors, as vascular endothelial growth factor and its 
receptors, which decreasing in glomerular endothelial cells cause 
adverse effects on capillary growth and permselectivity. All resulted in 
the formation of segmental glomerulosclerosis, followed by global 
sclerosis and interstitial fibrosis (Fogo, 2003; Pippin et ah, 2009). The 
tubulointerstitial fibrosis is strongly linked to macrophage infiltration 
and ongoing proteinuria.
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7.3 Stem cell therapy in chronic kidney disease
As discussed in section 1.3, kidney has an intrinsic capacity to 
undergo repair after acute damage, and this is best illustrated by the 
capacity of tubular cells to replace damaged ones. The same does not 
occur in chronic kidney disease. This is probably due to the complexity 
of the chronic kidney damage, which involves different populations of 
renal cells. Moreover, glomeruli have rather limited capacity for repair 
and once the damage has reached a certain point, the ability to 
recuperate from the injury is compromised and may primarily 
dependent on extrarenal cellular sources. Several studies have shown 
that bone marrow treatment may lead to improvement of renal function 
in several diseases, including IgA nephropathy and Alport's syndrome. 
Imasawa and co-workers showed in a mouse model of spontaneous 
presentation of IgA nephropathy an amelioration of disease after bone 
marrow transplantation from an unaffected donor (Imasawa et ah, 
1999). Whole BM transplantation has been reported to induce a 
significant improvement in renal function and histological damage in 
the collagen4a3 defective model of Alport syndrome (Sugimoto et ah, 
2006; Prodromini et al., 2006). These positive results are also 
accompanied by conflicting findings. Using chimeric mice transplanted 
w ith enhanced green fluorescent protein (EGFP)-expressing BM, Li et al. 
have demonstrated that BM may also act as a source of a-SMA-positive 
interstitial myofibroblasts, which have been shown to participate in the
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production of extracellular matrix in renal fibrosis (Li et al., 2007).
Accumulating evidence suggests that MSCs are efficacious in 
acute kidney injury. Conversely stem cells in models of CKD is a new 
area of investigation with many open questions as whether CKD, which 
has different many causes, has a complex pathophysiology and is 
associated with different segments of the nephron, can be repaired by 
using stem cell treatment (Table 1). In a mouse model of Alport 
syndrome, Ninichuk and coworkers have observed that multiple 
intravenous injections of MSCs reduced interstitial renal fibrosis but not 
glomerulosclerosis, and also had no effect on functional and 
physiological parameters as proteinuria (Ninichuk et al., 2006). In the 
rat remnant kidney model (5/6 nephrectomy), Semedo et al. have 
observed that a single injection of MSCs was sufficient to reduce 
interstitial fibrosis and glomerulosclerosis. However, functional 
restoration was only temporary achieved with a single dose of MSCs, 
while frequent and continuous MSC treatments effectively ameliorated 
renal functional parameters (Semedo et al., Dec 2009). Conflicting 
results were also observed in an Adriamycin model of nephropathy. 
Magnasco and co-workers have observed the protective effect of MSCs 
on adriamycin-damaged podocytes in vitro. However, in vivo 
experiments showed that MSCs failed to ameliorate proteinuria and 
progression of renal failure (Magnasco et al, 2008).
In order to identify a most adequate method to deliver MSCs, 
Cavaglieri et al. have tested the effect of subcapsular injection of MSCs
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in the rat remnant kidney model. The Authors observed a migration of 
these cells into renal parenchyma, resulting in a significant reduction of 
albuminuria and serum creatinine and glomerulosclerosis. These results 
could suggest that locally implanted MSCs into the kidney could 
represent an effective route for MSC delivery (Cavaglieri et al, 2009).
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Figure 7.1: Conceptual model for chronic kidney disease (Modified from Levey A. et alv 2009)
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Figure 7.2: Main biological effects of Adriamycin (ADR))
236
CH A P TE R  7; I N T R O D U C T I O N - C K D
Table 7.1. Summary of studies using mesenchymal stem cells (MSCs) isolated from bone marrow to treat chronic kidney disease
Reference Model Number and 
Cell Type
Functional Outcome Delivery
Method
Histology
Ninichuk et al., 2006 COL4A3KO MSC (1 x 106) No change in renal function Tail vein I Interstitial fibrosis
Kunter et al., 2006 Anti-Thyl.l(GN)
MSC (2 x 106) Improved renal function 
and decreased proteinuria
Intra-
arterially J, Glomerulosclerosis
Choi et al., 2009 5 /6nephrectomy j
MSC (1 x 106) No change in creatinine and 
decreased proteinuria Tail vein
i  Glomerulosclerosis
Cavaglieri et al., 2009 5 /6nephrectomy
MSC (2 x 106) Increased albuminuria and 
serum creatinine
Subcapsul
e
I Glomerulosclerosis
Semedo et al., 2009 5 /6  nephrectomy :
MSC (2 x 105) Amelioration of renal 
function Tail vein
J, Lymphocytic infiltration, 
J, Interstitial fibrosis,
J. Glomerulosclerosis
Prodromidi et al., 2006 COL4A3KO MSC (5 x 105) N o amelioration of renal function Tail vein
No improvement in glomerular 
histology and interstitial fibrosis
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7A  Aim of the study
Given the extensive amount of literature related to the 
renoprotective effect of BM-MSCs in experimental model of AKI, we 
wanted to test the possible therapeutic effect of this population of stem 
cells in an experimental model of CKD. In a model of spontaneously 
progressive glomerular injury, we have previously shown that 
podocyte loss, abnormal migration, and proliferation of glomerular 
parietal epithelial progenitor cells contributed to the formation of 
synechiae and crescentic lesions. Here, we have aimed to investigate 
whether a similar sequence of events could be extended to rats with 
adriamycin (ADR)-induced nephropathy. Moreover, we wanted to 
evaluate the regenerative potential of BM-MSCs on glomerular resident 
cells as progenitor cells. Another important goal of this study was to 
clarify in vitro the mechanisms underlying the renoprotective effect of 
this population of stem cells. We have investigated which kind of 
regenerative pathways are activated or blocked by BM-MSCs.
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CHAPTER 8
MATERIALS
239
C H A P T E R  8: M A T E R I A L S - C K D
8.1 Mice and Rats
C57BL6/J male mice and Lewis male rats were purchased from 
Charles River Italia s.p.a., Calco, Italy.
8.2 Cells
Rat MSCs. Rat mesenchymal stem cells were isolated from bone 
marrow of 2 month-old male Lewis rats.
M urine MSCs. Murine mesenchymal stem cells were isolated 
from bone marrow of 2 month-old male C57BL6/J.
M urine Podocytes. Immortalized mouse podocyte line was kindly 
given by Dr. Peter Mundel of "Department of Medicine" at Mount Sinai 
School of Medicine, New York, USA.
8.3 Media, supplem ents and cell culture reagents
Penicillin-Streptomycin, liquid containing 10,000 units of penicillin and 
10,000 pg of streptomycin, GIBCO-Invitrogen, S. Giuliano Milanese 
(MI), Italy, was used at 1% (lml/lOOml).
L-Glutamine-200 mM, liquid, GIBCO-Invitrogen.
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"Isolation m edium " for rat MSCs 
Alpha-MEM, GIBCO-Invitrogen.
+ 1% penicillin -streptomycin
+ 2% Foetal Calf Serum (FCS), selected lot. Euroclone. 
+ 2 mM L-Glutamine, GIBCO-Invitrogen.
"Growth m edium " for rat MSCs
Alpha-MEM, GIBCO-Invitrogen.
+ 1 % penicillin -streptomycin
+ 20% Foetal Calf Serum (FCS), selected lot. Euroclone. 
+ 2 mM L-Glutamine, GIBCO-Invitrogen.
"Inductive m edium " for rats MSCs
Alpha-MEM, GIBCO-Invitrogen.
+1% penicillin-streptomycin
+ 20% Foetal Calf Serum (FCS), selected lot. Euroclone. 
+ 2 mM L-Glutamine, GIBCO-Invitrogen.
Adipogenic supplements:
5 pg/m l insulin, Sigma-Aldrich, St Louis, MO, USA.
+ 10-6 M dexamethasone, Sigma-Aldrich.
+ 0.5 pM isobutylmethylxanthine, Sigma-Aldrich.
+ 50 pM indomethacin, Sigma-Aldrich.
Osteogenic supplements:
10 mM P-glycero-phosphate, Sigma-Aldrich.
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+ 0.2mM ascorbic acid 2-phosphate, Sigma-Aldrich.
+ 10*8 M dexamethasone, Sigma-Aldrich.
"Growth medium" for podocytes
RPM I1640, Sigma-Aldrich 
+1% penicillin -streptomycin 
+10% FCS, GIBCO-Invitrogen 
+ 2 mM L-Glutamine, GIBCO-Invitrogen
+ 10 U /m l recombinant murine y-interferon (permissive conditions), 
Peprotech, Rocky Hill, NJ, USA.
"Isolation medium" for murine MSCs
DMEM, Sigma-Aldrich
+1% penicillin -streptomycin, GIBCO-Invitrogen.
+ 2% Foetal Calf Serum (FCS), selected lot from Euroclone.
+ 2 mM L-Glutamine, GIBCO-Invitrogen.
"Growth medium" for murine MSCs
DMEM, Sigma-Aldrich 
+1% penicillin -streptomycin
+ 20% Foetal Calf Serum (FCS), selected lot. Euroclone.
+ 2 mM L-Glutamine, GIBCO-Invitrogen.
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"Test m edium " (for in vitro experiments)
RPMI, Sigma-Aldrich 
+ 2 mM L-Glutamine, GIBCO-Invitrogen 
+ 10% FCS, GIBCO-Invitrogen 
+ 1 % penicillin -streptomycin, GIBCO-Invitrogen
Trypsin
Trypsin for MSCs: 0.25% Trypsin-EDTA (IX) in Hanks' Balanced Salt 
and phenol red was purchased from GIBCO-Invitrogen.
Trypsin for podocytes: 0.5% Trypsin-EDTA (10X) was purchased from 
GIBCO-Invitrogen.
8.4 Growth factors
Recombinant mouse VEGF-A was purchased from Immunotools, 
Germany.
8.5 Chemicals
Adriamycin (ADR) was purchased from Pfeizer Italia s.r.l, Latina, Italy. 
Alizarin Red S (sodium alizarin sulfonate) was purchased from Sigma- 
Aldrich. 2% Solution was prepared by dissolving the powder in
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distilled water. Solution was stirred and centrifuged at 4000 rpm  for 10 
minutes. The supernatant was collected and filtered. pH was adjusted 
at 4.1 with 0.5% ammonium hydroxide.
Coomassie brilliant blue dye was purchased from Sigma-Aldrich. 
Ethanol was purchased from Carlo Erba, Milan, Italy.
Formalin solution, ready to use was purchased from Bio-Optica.
Harris haematoxylin and eosin was purchased from Bio-Optica, Milan, 
Italy.
Isofluorane was purchased from Abbot.
M ounting m edium  was purchased from DakoCytomation, Glostrup, 
Denmark.
Oil Red O was purchased from Sigma-Aldrich. We prepared a 0.5% 
solution in methanol. Solution was stirred and centrifuged at 4000 rpm  
for 10 minutes. The supernatant was collected and filtered. 
Orthophosphoric acid was purchased from Merck, Milan, Italy. 
Paraffin, Bioplast Plus, was purchased from Bio Optica. 
Paraformaldehyde was purchased from Electron Microscopy Sciences 
(Hatfield, PA, USA). In order to prepare a 4% solution, we diluted 8% 
aqueous solution in PBS 2X under a fume hood.
Periodic acid, Diapath, Martinengo, Bergamo, Italy 
Schiff's reagent, Kaltek srl, Padova, Italy
Streptavidin-alkaline phosphatase conjugated was purchased from 
Roche Diagnostic and used at final concentration of 1:50.
Toluene was purchased from Sigma-Aldrich.
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Trypan blue (4% solution) was purchased from Sigma-Aldrich. This 
solution was diluted 1:2 with saline and filtered (0.4 pm filters).
8.6 Buffers and solutions
"Blocking buffer "
Bovine serum albumin (BSA) (Sigma-Aldrich) was added to PBS to 
obtain a final BSA concentration of 1%. The solution was maintained on 
ice for few minutes to facilitate albumin solubilisation. The solution was 
then filtered with a 0.2 pm sterile filter.
"Buffer" for im m unodepletion
PBS IX have been added with:
EDTA 2 mM 
BSA 0.5%
The solution was then filtered with a 0.4 pm filter.
Citrate buffer 10% concentrated pH 6.0, was diluted 1:10 in PBS IX and 
was purchased from DiaPath .
3,3'-diaminobenzidine (DAB)
One tablet of DAB was put into 25 ml of distilled water. Solution was 
mixed and 6.5 pi of 30% H2O2 was added.
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DAB was purchased from Merck.
Duboscq-Brazil solution ready to use, was purchased from DiaPath, 
Martinengo (BG), Italy.
Fast Red
One tablet was dissolved into 2 ml of 0.1 M TRIS-HC1 (pH 8.2) and then 
filtered with a 0.45 pm filter. It was purchased from Roche.
Paraformaldehyde-lysine-periodate (PLP) fixative
Solution A: 8% paraformaldehyde, purchased from Electron Microscopy 
Sciences (Hatfield, PA, USA).
Solution B: 0.05 M Phosphate buffer Stock (pH 7.4)
- Dissolve 0.69 gr of Sodium Phosphate Monobasic Monohydrate in 100 
ml of dH20 (solution I)
-Dissolve 4.45 gr of Sodium Phosphate in 500 ml of dH20 (solution II)
- Add 95 ml of solution I and 405 ml of solution II.
Solution C:
-Dissolve 9.13 gr of L-Lysine (Sigma-Aldrich) and 1.425 gr of Sodium 
m-Periodate (Sigma-Aldrich) in 500 ml of Solution B.
Solution D: PLP fixative
- Add 10 ml of solution A and 30 ml of solution C 
"Perm eabilizing solution"
TRITON X100 was purchased from Sigma-Aldrich and was diluted to a
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final concentration of 0.5% in PBS IX.
Phosphate buffer saline (PBS) 10X (for cell culture and 
immunohistochemistry) was purchased from Ambion-Invitrogen. 
Finally, PBS IX is prepared diluting 1:10 PBS 10X in water.
Vector Red substrate, Vector Laboratories Inc.
One tablet was dissolved (and kept in the dark) in 2 ml of TRIS-HC1 
immediately before using and filtered with a 0.45 pm filter.
8.7 Materials and buffers for W estern blotting
30% acrylamide/bis solutions, liquid, 99.9% pure acrylamide and bis- 
acrylamide at the concentration of 30%, crosslinker ratio 37.5:1, 
purchased from Bio-Rad.
Ammonium persulfate (NH4)2S20 8 (APS), powder, purchased from 
Sigma-Aldrich. A 10% stock solution was prepared in water.
Bio-Rad protein assay reagent, purchased from Bio-Rad.
Bicinchoninic acid assay, purchased from Thermo Scientific, Rockford, 
IL, USA.
Filter paper 3MM, purchased from Whatman.
Glycine, 0.2% Glycine solution was prepared by dissolving 0.2 g 
glycine in PBS 2X. Glycine was purchased from Sigma-Aldrich.
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Halt protease inhibitor cocktail, purchased from Thermo Scientific.
Hyperfilm™  ECL, high performance chemiluminescent film, 
purchased from Amersham Biosciences.
N,N,N',N '-tetramethylethylenediamine (TEMED), liquid, purchased 
from Sigma-Aldrich.
Non fat dry milk, purchased from Sigma-Aldrich. 
Phenylmethylsulfonyl fluoride (PMSF), powder, purchased from 
Sigma-Aldrich. A stock solution (200 mM) was prepared in isopropyl 
alcohol.
Protran® Nitrocellulose membrane, purchased from Whatman.
SeeBlue® Plus2 Pre-stained Standard, purchased from GIBCO- 
Invitrogen. It contains eight blue-dyed and two with contrasting 
colours providing easier band identification.
Sodium dodecyl sulfate (SDS), liquid, purchased from Sigma-Aldrich. 
Sodium orthovanadate (NasVO^, powder, purchased by Sigma- 
Aldrich. A stock solution of 1 mM was constituted in distilled water 
and adjusted to pH 10. To ensure the presence of monomers, the 
solution was boiled until translucent and the pH readjusted. 
Supersignal west pico chemiluminescent substrate working solution: 
chemiluminescent detection system composed by luminol/enhancer 
solution and stable peroxidase solution, was purchased from Pierce, 
Rockford, Illinois, USA.
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Supersignal chemiluminescent substrate purchased from GE 
Healthcare, UK
Tris-HCl was purchased from Sigma-Aldrich. A solution of 50mM was 
prepared by solubilising 0.3028 g TRIS-HC1 into 50 ml of distilled water. 
The pH  was adjusted to 8.
Tween 20, purchased from Sigma-Aldrich.
X-ray Developer and Fixer solutions, purchased from Kodak Industry.
- Rabbit anti mouse Akt antibody, purchased from Cell Signaling 
Technology, Danvers, MA, USA, and used at the concentration of 
1:1000.
- Rabbit anti mouse p-Akt Ser473 antibody, purchased from Cell 
Signaling Technology, and used at the concentration of 1:1000.
- Horseradish peroxidase (HRP) conjugated goat anti rabbit antibody 
was purchased from Sigma-Aldrich, and used at the concentration of 
1:4000.
- Goat anti rat anti-VEGFi64 antibody was purchased from R&D System 
and used at the final concentration of 1:200.
- Mouse anti rat a -tubu lin  antibody was purchased from Sigma- 
Aldrich and used at the final concentration of 1:4000.
- Horseradish peroxidase (HRP) conjugated rabbit anti goat antibody 
was purchased from Sigma-Aldrich, and used at the concentration of 
1:20000.
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- Horseradish peroxidase (HRP) conjugated goat anti mause antibody 
was purchased from Sigma-Aldrich, and used at the concentration of 
1:20000.
Scraping buffer
A cold solution of PBS IX containing 2 mM EDTA (Sigma-Aldrich) 
and the protease inhibitor phenylmethylsulfonyl fluoride PMSF (1 mM) 
was used to mechanically detach the cells using a scraper.
Lysis buffer
For frozen kidney section, lysis buffer was composed by 50 mM 
Tris-HCl (pH 8; Sigma-Aldrich), 150 mM NaCl (Merck), 1% Triton X- 
100, 0.5% Sodium deoxycholate, 0.1% SDS) containing the Halt protease 
inhibitor cocktail (Thermo Scientific, Rockford, IL, USA) at the final 
concentration of IX.
For podocytes, lysis buffer was composed by 20 mM Tris-HCl (pH
7.5), l%Triton X-100, 25 mM NaCl, 1.5 mM EDTA, 50 mM NaF and 15 
mM Na4P2C>7 containing protease inhibitor (Complete, Roche 
Diagnostic).
Sample Buffer 3X
Sample buffer 3X was composed by Tris-HCl 0.24 M at pH 6.8, 6% 
SDS (Sigma-Aldrich), 15% p-mercaptoethanol (Merck), 30% glycerol 
(Fischer Scientific), 0.03% bromophenol blue (Sigma-Aldrich) in water.
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TANK buffer 10X
TANK buffer was composed by 250 mM Tris base (Sigma-Aldrich) 
and 2M glycine (Sigma-Aldrich) in water.
8.8 Antibodies
For all antibodies, preliminary experiments were performed following 
manufacturer's suggestions in order to identify the most appropriate 
concentration.
- Rabbit anti-Wilm's tum or 1 (SC-192), purchased from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA. Final concentration: 2 |ig/m l.
- Mouse anti-Nestin (611658), purchased from BD Biosciences, Milan, 
Italy. Final concentration: 1:100.
- Rabbit anti-CD2AP (SC-9137), purchased from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA. Final concentration: 0.2 (ig/ ml.
- Goat anti-Nephrin (SC-32530), purchased from Santa Cruz 
Biotechnology, Santa Cruz. Final concentration: 0.2 pg/m l.
- Rabbit anti-claudinl (PA5-13332), purchased from Thermo Scientific, 
Rockford, IL, USA. Undiluted.
- Mouse anti-NCAM (5B8), purchased from Developmental Studies 
Hybridoma Bank, University of Iowa, USA. Final concentration: 1:2.
- Mouse anti-rat endothelial cell antigen (RECA-1; MCA970R),
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purchased from AbD Serotec, Kidlington, Oxford, UK. Final 
concentration 1:100.
- Monoclonal anti rat monocytes/macrophages (ED-1; MAB1435) 
antibody, purchased from Chemicon. Final concentration 1:100.
- Goat anti-rat VEGF antibody (AF564) was purchased from R&D 
Systems and used at the final concentration of 1:10.
- Biotinilated-horse anti-goat IgG antibody (BA-9500) purchased from 
Vector Labs and used at the concentration of 1:150.
- Cy3-conjugated goat anti rabbit IgG (111-165-003), purchased from 
Jackson ImmunoResearch Laboratories and used at final concentration 
of 1:50.
- FITC-conjugated goat anti mouse IgG (115-095-003), purchased from 
Jackson ImmunoResearch Laboratories and used at final concentration 
of 1:50.
- FITC-conjugated rabbit anti goat IgG (305-095-003), purchased from 
Jackson ImmunoResearch Laboratories and used at final concentration 
of 1:50.
- Cy3-conjugated donkey anti mouse IgG (715-165-150), purchased 
from Jackson ImmunoResearch Laboratories and used at final 
concentration of 1:50.
- Cy5-conjugated donkey anti mouse IgG (715-175-150), purchased 
from Jackson ImmunoResearch Laboratories and used at final 
concentration of 1:50.
- Biotinylated sheep anti-mouse IgG (AP302B), purchased from
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Chemicon and used at final concentration of 1:50.
For immunodepletion of murine MSCs:
-Rat anti-mouse CD45 antibody (550539), purchased from Beckton 
Dickinson and used at a concentration of 0.2 pg/106 cells diluted in 
buffer.
- MACS goat anti-rat IgG magnetic microbeads (130-048-501), 
purchased from Miltenyi Biotec.
For in vitro experiments:
- Functional blocking anti-VEGF antibody (AF471) was purchased 
from R&D System and used at final concentration of 10 pg/m l.
- Mouse anti-cytochrome C antibody (556432) was purchased from BD 
Biosciences and diluted 1:100 in blocking buffer.
- Rabbit anti-cleaved caspase-3 antibody (9661) was purchased from 
Cell Signaling ( Beverly, MA, USA) and used at the final concentration 
of 1:400.
- FITC-conjugated donkey anti rabbit antibody (711-095-152) 
purchased from Jackson ImmunoResearch Laboratories and used at 
final concentration of 1:50.
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8.9 Other reagents
Collagenase IV was purchased from W orthington Biochemical 
Corporation, Lakewood, NJ, USA.
Collagen Rat Tail Type I was purchased from BD Biosciences. It was 
used at the final concentration of 0.1 m g/m l.
Dapi: 4/,6/-diamidino-2-phenylindole dihydrochloride hydrate was 
purchased from Sigma-Aldrich.
FITC-labeled lectin W heat Germ Agglutinin (WGA) was purchased 
from Vector Lab., Burlingame, CA, USA. Final concentration 1/400. 
Hoechst 33258 was purchased from Sigma-Aldrich.
In Situ Cell Death Detection Kit (TUNEL), Fluorescein was purchased 
from Roche.
Nanoparticles: negative poly-methyl-methacrylate (PMMA)-based 
nanoparticles of 200nM (200-) was kindly provided by Dr. Davide 
Moscatelli, Politecnico di Milano, Italy.
PKH-26: Red Fluorescent Cell Linker Kit for general cell membrane 
labeling was purchased from Sigma-Aldrich.
Rhodamine-labelled Lectin Lens Culinaris Agglutinin (LCA) was 
purchased from Vector Laboratories Inc., and used at the final 
concentration of 25 pg/m l.
Vectastain ABC kit purchased from Vector Laboratories, Burlingame, 
CA, USA.
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8.10 Disposable material
Sterile filters: 100 pm nylon mesh, purchased from BD Biosciences, 
Bedford, MA, USA
8.11 Instrum ents
Confocal laser-scanning microscope LS 510 Meta; Zeiss, Jena, 
Germany.
FACS Canto II Becton Dickinson, BD Bioscience, Milan, Italy.
MACS Separator: Miltenyi Biotec, Bergisch Gladbach, Germany. 
Reflotron analyser purchased from Roche, Basel, Switzerland .
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CHAPTER 9
METHODS
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Methods for in vivo  studies
9.1 Isolation and characterization of rat MSCs
Rat MSCs were obtained from bone marrow (BM) of 2 month-old 
male Lewis rats (Materials, section 8.2). Rats were sacrificed by 
exposure to C02 for a few minutes. Under a laminar flow hood, femurs 
and tibias were aseptically removed from the posterior legs by using 
sterilized surgical instruments. BM was flushed from the shaft of each 
bone by using a syringe filled with "Isolation medium" (Materials, 
section 8.3). Each bone was washed twice with 2 ml of medium. BM 
obtained from each rat was collected in different tubes and maintained 
on ice. Tubes were centrifuged at 1200 rpm  for 10 min at 4 °C and then 
the pellet was suspended by using a 2 ml pipette in a volume of 2 ml 
alpha-MEM serum-free. Several passages into pipette were needed in 
order to disaggregate bone marrow and to obtain a single cell 
suspension. Eight ml of medium were added and cells were dissociated 
by aspirating through a syringe needle (21Gxl 9/16"). Thereafter, the 
cell suspension was filtered through a 100-pm sterile nylon mesh filter 
(Materials, section 8.10) to eliminate bone fragments and to produce a 
single cell suspension. Cells were counted by a haemocytometer and 
cells obtained from one rat (4 bones) have been seeded in complete 
medium onto one flask (75 cm2), left to adhere for 24 hours and 
maintained at 37 °C in a CO2 incubator with 5% CO2 .
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Mesenchymal stem cells (MSCs) were recovered from BM by 
their tendency to tightly adhere to plastic culture dishes. After 24 hours, 
non-adhered cells have been transferred to a new flask and left to 
adhere for other 48 hours. After 48 hours, all the flasks have been 
washed with PBS IX to remove unadhered cells (mainly haematopoietic 
cells). Adhered MSCs have been added with freshly prepared "growth 
medium" (Materials, section 8.3) that was changed every three days. 
After 2 to 3 weeks, subconfluent cells were detached by adding 500 pi 
trypsin-EDTA (Materials, section 8.3) and by incubating for 2 minutes 
at 37°C. Trypsin was blocked by addition of 5 ml "growth medium". 
Detached MSCs were combined, counted by haemocytometer and 
stored in liquid nitrogen for in vivo experiments. The MSCs preparation 
used for the in vivo experiments derived from a pool of MSCs obtained 
by bone marrow collected from 12 Lewis rats.
BM-derived cells obtained by plastic adhesion, as described 
above, were studied in order to verify their mesenchymal potential to 
differentiate towards adipocytes and osteoblasts. MSCs were grown to 
confluence and the growth medium was replaced with the "Inductive 
medium" (Materials, section 8.3) supplemented with specific 
differentiation reagents (Materials, section 8.3).
Adipogenesis: cells were incubated for 3 weeks with "Inductive 
medium" plus adipogenic supplements. Adipogenic differentiation was 
visualized by phase contrast microscopy by the presence of highly
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refractive intracellular lipid vacuoles during this period of time in 
which the cells can differentiate and images were acquired by a digital 
camera. To further confirm the accumulation of lipid droplets in these 
vacuoles, cells were rinsed with PBS IX, fixed with 10% formalin 
(Materials, section 8.5) and incubated with Oil Red O for 25 minutes at 
room temperature (Materials, section 8.5). After extensive rinsing with 
PBS IX, cells were observed under phase contrast microscopy and 
images were acquired by a digital camera.
Osteogenesis: MSCs were fed twice a week for three weeks with 
"Inductive medium" plus osteogenic supplements. The cells were then 
washed with PBS IX and fixed in 10% formalin for 20 minutes at room 
temperature. Fixed cells were rinsed with PBS IX and stained for 20 
minutes with 2% w /v  Alizarin Red S solution (Materials, section 8.5) to 
evaluate the presence of calcium rich hydroxyapatite of the extracellular 
matrix. Images of mineral deposits were acquired by a digital camera.
9.2 Rat model of adriamycin-induced nephropathy
Male Lewis rats (Materials, section 8.1), with initial body weights 
of 200-250 g, were used. Animal care and treatment were in accordance 
with institutional guidelines in compliance with national (D.L. n.116, 
G.U., suppl 40, 18 February 1992, Circolare No. 8, G.U., 14 July 1994) 
and international laws and policies (EEC Council Directive 86/609, OJL
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358, Dec 1987; NIH Guide for the Care and Use of Laboratory Animals, 
U.S. National Research Council, 1996). Animal studies were submitted 
to and approved by the Institutional Animal Care and Use Committee 
of "Mario Negri" Institute, Milan, Italy. Animals were housed in a 
constant temperature room with a 12-hour dark 12-hour light cycle and 
fed a standard diet.
9.2.1 Adriamycin preparation and injection
CKD was induced by a single dose of adriamycin (ADR; Materials, 
section 8.5) by tail-vein infusion. To test the effect of rat MSCs, ADR 
was administered to rats based on their weight, at a concentration 
(chosen by preliminary experiments) of 5 m g/kg. We used an ADR 
already diluted, commonly used in patients undergoing chemotherapy. 
To facilitate the injection, rats were anesthetized for a few minutes in a 
container containing Isofluorane (Materials, section 8.5). A total volume 
of 500 pi of ADR was intravenously injected by using 1 ml syringe 
(needle 30Gxl/2").
9.3 Rat MSC administration
Rat MSCs were administered to Lewis rats 36, 60 hours, 3, 5, 7,14, 
and 21 days after receiving ADR. Cells were suspended in 500 pi of
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sterile saline. Before injection, rats were exposed to an infrared lamp to 
induce vasodilatation and facilitate injection into the tail vain. To study 
the effect of rat MSCs, Lewis rats were intravenously (i.v.) injected with 
saline (n=16), or MSCs (2 x 106 cells) (n=16) at different times after ADR 
in order to ensure the presence of MSCs in the kidney during time. 
Before injection, MSCs were labeled with PKH-26 red fluorescence cell 
linker (Materials, section 8.9). In selected experiments, ADR-treated rats 
(n=3) were injected with MSCs labeled with polymeric large 
nanoparticles (fluoNP; Materials, section 8.9). Six normal rats injected 
with saline, served as controls. Twenty-four-hour urine samples were 
collected using metabolic cages, and proteinuria was determined by the 
Coomassie protein assay (Materials, section 8.5). Serum creatinine was 
measured by the Reflotron test (Materials, section 8.11). Rats were 
sacrificed at 3, 9,16 and 30 days after ADR, and kidneys were removed 
for histology and immunohistochemistry analysis.
9.4 Renal function measurement
To assess renal function, we measured total urinary protein 
excretion rate by using the Coomassie brilliant blue dye-binding assay. 
Coomassie brilliant blue (50 mg; Materials, section 8.5) was dissolved in 
50 ml orthophosphoric acid 99% 16 M (Materials, section 8.5) and 46.7 
ml absolute ethanol (Materials, section 8.5) then diluted to 1 L with
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water. The solution was filtered through Whatman paper and stored in 
dark-colour glass bottles, maintaining rigorous cleanliness. The half- 
life of the solution is several weeks, but refiltering may be required if 
precipitation of dye occurs. The assay was performed in plastic 
cuvettes. Coomassie brilliant blue dye-reagent (2 ml) was added to 50 pi 
of urine samples. In each evaluation 1 sample of water alone and 3 
samples with bovine serum albumin (BSA) at known concentrations 
(50,100 and 200 pg/m l) were included to obtained the standard curve. 
Samples were always assayed in triplicate. The colour development is 
essentially complete at 5 minutes and remains stable for a period of 2 
hours. The absorbance at 578 nm was measured at the 
spectrophotometer. The concentration of proteins present in the 
samples of interest was obtained taking into account the absorbance 
values derived from the standard curve in which the BSA 
concentrations were known.
9.5 Sacrifice and tissue collection
Rats were sacrificed by exposure to CO2 at 3, 9, 16 and 30 days 
after ADR. Kidneys were weighed and in order to take samples 
representative of the different structural components of the kidney, 
sections were cut in the axial coronal plane. Depending on the type of
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procedure that would have been applied (light microscopy, electron 
microscopy, immunohistochemistry), samples were differently fixed as 
described in each specific chapter.
9.6 Renal morphology
Procedure for light microscopy was the same described in chapter 
3, section 3.6.1.
At least 15-20 glomeruli were examined for each rat, and the extent of 
synechiae was expressed by giving a score from 0 to 4 related on the 
percentage of glomerular tuft occupied by the lesions (0: no lesions; 1: 
lesions affecting <25% of the glomerulus; 2: lesions affecting >25 to 50% 
of the glomerulus, 3: lesions affecting >50 to 75% of the glomerulus, 4: 
lesions affecting >75 to 100% of the glomerulus). Data were expressed 
as percentage of glomeruli with different degree of lesions (synechiae 
and more extensive adhesions). To evaluate the extent of glomerular 
sclerosis, an average of 35 glomeruli was examined and data were 
expressed as glomerular sclerosis index. Each glomerulus was scored 
according to the extension of sclerotic changes as follows: 0 = absence of 
sclerosis; 1 = sclerotic changes affecting less than 25% of glomerular tuft 
area; 2 and 3 = lesions affecting >25 to 50% and >50 to 75% of the tuft, 
and 4 = lesions exceeding 75% of the tuft. The indices for 
glomerulosclerosis was calculated by using the following formula:
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GS= (1 x ni)+ (2 x 112)+ (3 x 113)+ (4 x m )/ no+ n i+ 112+ n3+114  
Where nx = number of glomeruli in each grade of glomerulosclerosis 
(Davis et al., 2004). The same pathologist, who was unaware of the 
nature of the experimental groups, analyzed all renal biopsies.
9.7 Staining and quantification of labelled MSCs
9.7.1 PKH-26 labelling
To study intrarenal localization of stem cells, rat MSCs were 
labelled with PKH-26 (Materials, section 8.9) before injection into ADR- 
treated rats, as previously described (see chapter 3, section 3.7). After 
staining, PKH-26 positive cells were resuspended in saline (500 pi/rat) 
and intravenously injected.
At different times, rats were sacrificed and kidney samples were 
fixed in paraformaldehyde-lysine-periodate (PLP) (Materials, section
8.6) overnight at 4°C then infiltrated with 30% sucrose/phosphate 
buffer saline (PBS), embedded in Tissue-Tek OCT Compound and 
frozen in liquid nitrogen. Eight-micrometer-thick sections were stored 
at -80°C. Sections were fixed 10 minutes in acetone and incubated for 10 
minutes at room temperature with FITC-labeled lectin Wheat Germ 
Agglutinin (WGA, Materials, section 8.9). Nuclei were stained with 
DAPI for 15 minutes at room temperature (Materials, section 8.9). Slides
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were analysed for PKH-26 positive cells. Data were expressed as 
number of PKH-26 positive cells/105 renal cells. A number of 9 
sections/rat (n=3 rats) were analyzed and PKH-26 positive cells were 
counted.
9.7.2 Nanoparticles staining
These experiments were performed in collaboration with the 
group of Dr. Paolo Bigini, Laboratory of Biochemistry and Protein 
Chemistry at "Mario Negri" Institute for Pharmacological Research. 
The presence of MSCs into the damaged kidney was also evaluated by 
tracking MSCs with polymeric 200 nm  large nanoparticles (fluoNP, 
Materials, section 8.9) (Lazzari et ah, 2012) in which the dye rhodamine- 
B was covalently bounded to the polymer to avoid the risk of leakage of 
the fluorescent compound once injected in animals. Briefly, MSCs were 
incubated for 72 hours with polymeric nanoparticles (35 pg/ml). At the 
end of the incubation, MSCs were resuspended in sterile saline and 
injected into the tail vein of ADR-treated rats (n=3). To verify the 
efficiency of the labeling, a small aliquot of MSCs was fixed with 4% 
paraformaldehyde in PBS, co-stained with Hoechst 33258 (Materials, 
section 8.9) and visualized with Confocal laser-scanning microscope LS 
510 Meta (Materials, section 8.11). FACS analysis was used to quantify 
the number of fluoNP-labeld MSCs in the kidneys of ADR-treated rats 
sacrificed at 3 days. Kidneys were minced and digested with 
collagenase IV (300U/ml, Materials, section 8.9) for 45 min at 37°C. The
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cell suspension was filtered through a 100-jrm sterile filter, washed with 
PBS IX and red emission for nanoparticles was analyzed by using BD 
FACSCanto II (Materials, section 8.11). Kidneys isolated from ADR- 
treated rats that did not receive fluoNP-labeled MSCs were used as 
negative control. The threshold used for the negative control was set at 
2%.
9.8 Im munohistochemistry
9.8.1 Immunofluorescence
For all immunofluorescence experiments, sections (3-pm) from 
PLP-fixed kidney specimens were fixed 10 minutes in acetone at 4°C. 
The antigen retrieval was performed in citrate buffer (Materials, section
8.6) 10 m m ol/L  (pH 6.0) at boiling temperature for 20 minutes, 
followed by incubation with citrate buffer (20 minutes) at room 
temperature to enhance the reactivity of antibodies to antigens. To 
block nonspecific sites, sections were treated with "blocking buffer" 
(Materials, section 8.6) for 30 minutes at room temperature and then 
incubated with the following primary antibodies.
WT1. Sections were incubated overnight with rabbit anti-Wilm's tumor 
1 antibody (Materials, section 8.8) at 4°C. Subsequently, kidney samples 
were treated with goat anti rabbit-Cy3 antibody (Materials, section 8.8) 
for 1 hour at room temperature. Renal structure was stained w ith FITC-
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WGA lectin for 10 minutes (Materials, section 8.9), while nuclei with 
DAPI for 15 minutes at room temperature.
In some experiments, some sections were co-incubated with anti-WTl 
and anti-nestin antibodies.
Nestin. Slides were incubated overnight with mouse anti-nestin 
antibody (Materials, section 8.8) at 4°C. Subsequently, kidney samples 
were treated with goat anti mouse-FITC antibody for 1 hour at room 
temperature. Nuclei were stained with DAPI for 15 minutes. In some 
experiments, some sections were co-incubated with anti-claudinl 
antibody.
CD2AP. PLP-fixed kidney sections, were incubated with rabbit anti- 
CD2AP antibody (Materials, section 8.8) at 4°C. Subsequently, kidney 
samples were treated with goat anti rabbit-Cy3 antibody for 1 hour at 
room temperature.
Nephrin. Slides were incubated overnight with goat anti-nephrin 
antibody (Materials, section 8.8) at 4°C. Subsequently, kidney samples 
were treated with rabbit anti goat-FITC antibody for 1 hour at room 
temperature.
C laudinl. Sections were incubated overnight with rabbit anti-claudinl 
antibody (Materials, section 8.8) at 4°C. Subsequently, kidney samples 
were treated with goat anti rabbit-Cy3 antibody for 1 hour at room 
temperature. Then, slides were co-incubated with anti-nestin antibody. 
NCAM. PLP-fixed kidney sections, were incubated overnight with 
mouse anti-NCAM antibody (Materials, section 8.8) at 4°C and then
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treated with donkey anti mouse-Cy3 antibody for 1 hour at room 
temperature.
RECA-1. Slides were incubated 2 hours at room temperature with 
mouse anti-rat endothelial cell antigen (RECA-1) antibody (Materials, 
section 8.8) at 4°C and then treated with donkey anti mouse-Cy5 
antibody for 1 hour at room temperature.
After each step, slides were washed with PBS IX (two times for 5 
minutes) and finally mounted with the mounting medium DAKO 
(Materials, section 8.5). Double and triple fluorescence labeling were 
analyzed by an inverted confocal laser-scanning microscope (Materials, 
section 8.11). Glomerular expression of the podocyte-associated 
proteins nephrin, CD2AP and nestin was estimated by calculating the 
proportion of area occupied by the staining within each glomerulus, 
using NIH image J software and a Mac OS PC (Apple computer, 
Cupertino, CA, USA). At least 30 randomly chosen glomeruli per 
section were analyzed.
9.8.2. Differentiative potential of MSCs
To evaluate whether MSCs acquired a podocyte phenotype, some 
PLP-fixed kidney sections (twenty sections/ rat, n=3) from ADR-treated 
rats injected with PKH-26 labeled MSCs (day 16) were stained with 
anti-WTl antibody. Slides were fixed 10 minutes in acetone at 4°C, 
followed by boiling in citrate buffer (Materials, section 8.6) 10 m m ol/L  
(pH 6.0) for 20 minutes and then incubation with citrate buffer (20
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minutes) at room temperature. To block nonspecific sites, sections were 
treated with "blocking buffer" (Materials, section 8.6) for 30 minutes at 
room temperature and then incubated overnight with mouse anti- 
W ilm's tumor 1 antibody (Materials, section 8.8) at 4°C. Subsequently, 
kidney samples were treated with donkey anti mouse-Cy5 antibody 
(Materials, section 8.8) for 1 hour at room temperature. Renal structure 
was stained with FITC-WGA lectin for 10 minutes, while nuclei with 
DAPI for 15 minutes at room temperature. After each step, slides were 
washed with PBS IX (two times for 5 minutes) and finally mounted 
with the mounting medium DAKO (Materials, section 8.5). 
Fluorescence was analyzed by an inverted confocal laser-scanning 
microscope (Materials, section 8.11).
9.8.3 ED-1 staining
Renal tissue was fixed overnight in Dubosq Brazil, dehydrated in 
alcohol, and embedded in paraffin. EDI staining was detected by 
alkaline phosphatase-Fast Red technique. Microwave and citrate buffer 
treatment was performed to increase the reactivity of antibody to 
antigen. The sections were blocked " blocking buffer" (Materials, 
section 8.6), and incubated overnight at 4°C with monoclonal anti rat 
monocytes/macrophages (ED-1) (Materials, section 8.8). After washing 
in PBS IX, slides were incubated with biotinylated sheep anti-mouse 
IgG (Materials, section 8.8) for 30 minutes at room temperature. Then 
the sections were incubated with streptavidin-alkaline phosphatase
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conjugated (Materials, section 8.5) for 30 min at room temperature. 
After washing in PBS IX, Fast Red substrate (Materials, section 8.5) was 
applied for 5 min at room temperature. The sections were 
counterstained with Harris haematoxylin (Materials, section 8.5). 
Negative controls were obtained by omitting the primary antibody. 
EDl-labeled cells were counted in at least 30 randomly selected high- 
power microscopic fields (x400) per each animal.
9.8.4 VEGF staining
For the immunohistochemical detection of VEGF, kidneys were 
fixed in Dubosq-Brazil (Materials, section 8.6) and then embedded in 
paraffin. Three pm sections were deparaffinized and after washing with 
PBS IX, endogenous peroxidases was inactivated by incubation in 3% 
H2O2 in methanol for 30 minutes. Slides were treated with "blocking 
buffer" (Materials, section 8.6) and then incubated with goat anti-rat 
VEGF antibody (Materials, section 8.8) overnight at 4°C followed by 
biotinylated-horse anti-goat IgG antibody (Materials, section 8.8) for 1 
hour. Sections were incubated for 30-min with avidin-biotin complex 
solution (ABC) (Materials, section 8.9), and the staining was visualized 
using diaminobenzidine (DAB) (Materials, section 8.6).
Intensity of glomerular VEGF signal was graded on a scale of 0 to 3 (0, 
no staining; 1, weak staining, 2, staining of moderate intensity; 3, strong 
staining). Negative controls were obtained by omitting the primary 
antibody on adjacent sections.
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9.8.5 Apoptosis
Apoptosis was detected by enzymatic labelling of DNA strand 
breaks using a terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick end-labelling (TUNEL) assay 
(Materials, section 8.9). PLP-fixed sections were treated in citrate buffer 
10 m m ol/L  (pH 6.0) at boiling temperature for 20 minutes, followed by 
incubation with citrate buffer (20 minutes) at room temperature to 
enhance the reactivity of antibodies to antigens. To block nonspecific 
sites, sections were treated with "blocking buffer" for 15 minutes at 
room temperature and then incubated for 80 minutes at 37°C with 
TUNEL reaction mixture, that was prepared add 50 pi of Enzyme 
Solution to 450 pi of Label Solution. As negative controls PLP-fixed 
slides were incubated only with Label Solution, while as positive 
controls slides were treated with DNase I recombinant for 20 minutes at 
37°C. Subsequently, sections were rinsed in PBS IX and then 
counterstained with Rhodamine-labeled lectin Lens Culinaris 
Agglutinin (LCA, Materials, section 8.9) and DAPI for 15 minutes. 
Podocytes were identified by WT-1 staining, as described above. Triple 
fluorescence labeling was analyzed by an inverted confocal laser- 
scanning microscope, and 30 random images for each sample were 
acquired.
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9.9 Morphometrical analysis
Glomerular podocytes were identified as cells positive for WT1, as 
described above (see section 9.8.1). Using fluorescence microscopy with 
appropriate filters, images of single wavelength will be acquired, and 
digitally merged. In the merged image, podocytes will be then 
identified and counted.
Estimation of glomerular volume (VG) was performed using a 
computer-based image analysis system (Mac OS 09, Apple Computer, 
Cupertino CA). Histological sections of fluorescein WGA-labeled 
glomeruli were digitized from the fluorescence microscope and stored 
on 696 x 520 pixel images. Exact enlargement in pm /pixel of digital 
images was calculated from images of a reference grid digitized at the 
same resolution. The outline of the minimal polygon around the 
glomerular tuft area was manually traced, and its surface area 
automatically measured, in the same glomeruli examined for counting 
WTl-positive cells in each tissue section. Mean value of VG will be then 
calculated using the formula
VG =(p/k)(Am)3/2
where k = 1.01 is a size distribution coefficient, and p = 1.38 is the shape 
coefficient for spheres, which is the assumed shape of glomeruli.
The estimation of the average number of podocytes per glomerulus 
(NP) was determined by the stereological method of particle density
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proposed by Weibel (Weibel, 1979). Briefly, the volume density of the
podocytes (NV) in glomerular tuft volume is estimated as NV = NA/D 
where NA, the podocyte nuclear profile area density, is estimated by 
the ratio between the numbers of podocyte nuclear profiles and the 
glomerular profile area in each glomerulus. D is the average diameter 
of podocyte nuclei that we estimate from major and minor axis of cell 
nuclear sections. To calculate D the average volume of podocyte nuclei 
(V) is first calculated based on the assumption that podocyte nuclei 
have an ellipsoidal shape. The average diameter of an equivalent 
sphere having the same volume of the ellipsoid is then determined. The 
mean number of podocytes per glomerular tuft (NP) is calculated for 
each animal by multiplying podocyte volume density NV in the 
capillary tuft by the mean value of VG previously calculated.
Volume density (Vv) of glomerular endothelial cells was 
estimated as area density occupied by RECA-1 staining. Twenty renal 
sections per rat were digitalized using an inverted confocal laser 
microscopy (original magnification, x630). Each image (512x512 pixels) 
was digitally overlapped with an orthogonal grid composed of 2500 
points (ImageJ; NIH, Bethesda, MD, USA). The volume density (Vv) of 
endothelial cells was calculated as the ratio of the number of grid points 
hitting RECA-1 staining to the total number of grid points falling into 
the total area occupied by the glomerulus.
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9.10 W estern blot analysis
These experiments were performed in collaboration with Dr. 
Cristina Zanchi Laboratory of Pathophysiology of Experimental Renal 
Disease and Interaction with other Organ systems at "Mario Negri" 
Institute for Pharmacological Research, Bergamo, Italy. Frozen kidney 
tissues were homogenized in lysis buffer (50 mM Tris-HCl (pH 8), 150 
mM NaCl, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS) 
containing the Halt protease inhibitor cocktail (Materials, section 8.7). 
Protein concentration was determined using the bicinchoninic acid 
assay (Materials, section 8.7) following the manufacturer's instructions. 
The samples (50 jug) were resolved on 7-15% SDS-polyacrylamide gel 
(Materials, section 8.7) and transferred to nitrocellulose membrane. 
After blocking, membranes were incubated 4°C overnight with anti- 
VEGFi64 antibody (Materials, section 8.7) or anti-a-tubulin antibody 
(Materials, section 8.7) and with an appropriate secondary antibody 
(Materials, section 8.7). Protein bands were detected by supersignal 
chemiluminescent substrate (Materials, section 8.7) and quantified 
using NIH Image J software. The amount of VEGF protein was 
calculated relative to the level of a-tubulin.
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Methods for in vitro studies
9.11 Cells and cell culture
M urine podocytes. Immortalized mouse podocyte line was kindly 
given by Dr. Peter Mundel (Materials, section 8.2). The group of Dr. 
Mundel has originally isolated murine podocytes (Mundel et al., 1997) 
using standard procedures and grown in medium at 37°C on collagen-I 
(Materials, section 8.9) coated dishes as previously described (Mundel 
et al., May 1997).
Medium. "Growth medium" (Materials, Section 8.3).
Cell density. For routine cell culturing, murine podocytes were seeded 
on collagen-I coated dishes at the dilution of 1:6 (1:8 in the week-end) 
and maintained at 33°C in a 5% CO2 humidified atmosphere. The cells 
were sub-cultured every second day by using trypsin (Materials, 
section 8.3) for 1 minute at room temperature. In order to perform in 
vitro experiments, murine podocytes (23000 cells/cm2) were induced to 
differentiate along podocyte lineages by shifting them to 37°C for 14 
days and culturing in "growth medium" without y-interferon.
Cell storage. Murine podocytes were preserved for long-term storage in 
liquid nitrogen. Cell pellets were suspended in FCS plus 7.5% DMSO in 
cryovials. To guarantee a gradual freezing, the vials were left in 
isopropanol-filled containers overnight at -80°C and then transferred to 
liquid nitrogen tanks for storage.
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Thawing frozen cells. The cells were thawed rapidly by placing the vial in 
a water bath at 37°C with a gentle agitation. The cells were then slowly 
resuspended in 9 ml of complete medium and DMSO traces were 
remove by centrifugation at 1200 rpm  for 7 minutes.
MSCs. Murine MSCs were obtained from BM of 2-month-old 
male C57BL6/J mice with the same procedure used for isolation of rat 
MSCs (see section 9.1). Briefly, BM was flushed from the shaft of the 
bone by using the "isolation medium" (Materials, section 8.3), and 
filtered through a 100 pm sterile filter. Filtered BM cells were plated in 
the "growth medium" (Materials, section 8.3) and allowed to adhere for 
24 hours. After 2 to 3 weeks, subconfluent (80%-90%) cells were 
detached by trypsin-EDTA (Materials, section 8.3), immunodepleted 
and used for in vitro experiments (23000 cells/cm2).
9.12 Depletion of CD45 positive cells from mesenchymal stem cell
preparation
Murine MSCs were immunodepleted of CD45 positive cells. MSCs 
grown for two weeks, as described in methods, section 9.11, were 
trypsinized counted and incubated in "Buffer" for immunodepletion 
(Materials, section 8.6) for 15 minutes. After centrifuging, cells were
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incubated at 4°C for 20 min with a rat anti-mouse CD45 antibody 
(Materials, section 8.8), at a concentration of 0.2 pg/106 cells diluted in 
buffer. After washing with buffer, the pellet was suspended in 80 pi of 
buffer per 107 total cells plus 20 pi of MACS goat anti-rat IgG magnetic 
microbeads (Materials, section 8.8), and incubated for 15 minutes. By 
passage on LS columns assembled on a MACS separator (Materials, 
section 8.11), cells were magnetically sorted by exposure to a magnetic 
field. Before adding cells, columns were filled and washed with 
"buffer" for immunodepletion. Cells that did not express the CD45 
(CD45- MSCs) antigen were eluted from the column, collected after 
washing the columns several times, and used for in vitro experiments.
9.13 Co-culture experiments
For co-culture experiments, podocytes were seeded in growth 
m edium with y-interferon, at the concentration of 23x103 cells/cm2 and 
14 days later were incubated with RPMI plus 10% FCS (test medium) 
(Materials, section 8.3) alone or in the presence of 1.5 pM ADR 
(Materials, section 8.5) for 6 hours. After drug withdrawal, podocytes 
were incubated with test medium or with MSCs at the density of 23x103 
cells/cm 2 (1:1) for 72 hours, and then total viable cells were counted by 
Trypan blue dye exclusion (Materials, section 8.5). Number of adherent 
podocytes was obtained by counting total viable cells in co-culture
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subtracted of MSC number. The percentage of viable podocytes in each 
sample was calculated versus control podocytes imposed as 100%. The 
role of VEGF was studied by adding to ADR-treated podocytes co­
cultured with MSCs, functional blocking anti-VEGF antibody 
(Materials, section 8.8) for 72 hours. In additional samples, exogenous 
recombinant mouse VEGF-A (Materials, section 8.4) was added to 
podocytes treated with ADR.
9.14 Apoptosis assay
Apoptosis was assessed by studying the expression of cytocrome 
C at 3, 15 and 24 hours after ADR incubation. Cells, seeded on glass 
slides, were treated with "permeabilized solution" containing Triton 
0.5% (Materials, section 8.6) for 5 minutes at room temperature. After 
washing in PBS IX (Materials, section 8.6), sections were treated with 
blocking buffer (Materials, section 8.6) for 30 minutes at room 
temperature, followed by incubation 1 hour with anti-cytochrome C 
antibody (Materials, section 8.8) at room temperature. Subsequently, 
cells were treated with goat anti mouse-FITC antibody for 1 hour at 
room temperature as secondary antibody. Nuclei were counter-stained 
with DAPI and slides were mounted with the mounting medium. 
Apoptotic podocytes were expressed as percentage of cells with 
cytocrome C in the cell cytosol/total cells.
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Apoptosis was also evaluated by assessment of cleaved caspase-3 
at 3 and 15 hours after ADR incubation. Cells were detached with 
Trypsin/EDTA, centrifuged and resuspended in the "permeabilized 
solution" for 5 minutes at room temperature. Then, after rinsed in PBS 
IX the cells were centrifuged, incubated with "blocking buffer" for 15 
minutes at 4°C and then incubated with anti-cleaved caspase-3 
antibody (Materials, section 8.8), followed by donkey anti rabbit-FITC 
antibody Cells were analyzed by FACS at 488 nm excitation, green 
emission for cleaved caspase-3. Data were expressed as percentage of 
apoptotic cells.
9.15 W estern blot analysis
The expression of Akt and pAkt was studied in control podocytes 
exposed to medium, in ADR-treated podocytes incubated with 
medium, exogenous VEGF-A (40 ng/m l) or with MSC-conditioned 
medium (24-hour conditioned medium) for 72 hours. Podocytes were 
lysed with lysis buffer (20 mM Tris-HCl (pH 7.5), l%Triton X-100, 25 
mM NaCl, 1.5 mM EDTA, 50 mM NaF and 15 mM Na4P20z) containing 
protease inhibitor (Materials, section 8.7). Protein lysates were 
separated on 10% polyacrylamide gel by SDS-PAGE (Materials, section
8.7) and transferred to nitrocellulose membrane. After blocking, 
membranes were incubated overnight with primary antibodies against
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Akt or p-Akt Ser473 (Materials, section 8.8) and with an appropriate 
secondary antibody (Materials, section 8.8). Protein bands were 
detected by supersignal chemiluminescent substrate (Materials, section
8.7).
9.16 Statistical analysis
Results are expressed as means ±SE. Data were analyzed by non- 
parametric Mann-Whitney test or Kruskal-Wallis test for multiple 
comparisons followed by Ryan's procedure, or by Anova test coupled 
with Bonferroni post-hoc analysis, as appropriate. The statistical 
significance level was defined as P<0.05.
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Principles of the main techniques and instruments
9.17 Flow cytometer
See Chapter 3, section 22.
9.18 MACS cell separation system
MACS technology is based on MACS microbeads, magnets and 
columns. Microbeads are tiny superparamagnetic particles of 
approximately 50 nanometers in diameter. They are composed of 
biodegradable matrix, and it is therefore not necessary to remove them 
after the separation process. Usually, microbeads do not alter structure, 
function or activity status of labelled cells and are not known to 
interfere with subsequent experiments. Cell separation takes place 
within the columns that retain magnetically labelled cells. When 
columns are placed in a MACS separator, the column matrix provides a 
magnetic field strong enough to retain cells labelled with minimal 
amounts of magnetic material. Therefore, microbeads used for labelling 
the cells can be so small and only a few are needed to separate a cell. 
The magnetically labelled cells are separated over a column placed in a 
separator. They are retained on the column, while unlabeled cells pass 
through. These cells can be collected as the unlabeled fraction. We have
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used LS columns that are useful for the isolation of up to 108 
magnetically labelled cells. Up to 2xl09 total cells can be processed. The 
column matrix is composed of ferromagnetic spheres, which are 
covered with a cell-friendly plastic coating allowing fast and gentle 
selection of cells. The columns are packed in a sterile way and can be 
used to separate eukaryotic cells, bacteria, viruses, or subcellular 
material less than 30 pm in size.
For obtaining lineage negative MSCs (CD45-), we have 
performed a negative selection. It means that the non-target cells 
(lineage positive cells and CD45 positive cells) are magnetically labelled 
and eliminated from the starting mixture of cells. With this strategy, the 
target cells remain non-magnetical (or "untouched"). Single depletion 
can remove nearly all of the magnetically labelled cells, resulting in a 
very pure fraction of unlabeled cells. By this procedure, first non-target 
cells are recognized by labeling with specific antibodies (i.e rat anti- 
CD45), and then magnetical microbeads, able to target the antibody 
(beads coated with anti-rat IgG) are added. Cells labelled with MACS 
are the non-target cells and are retained on MACS column.
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9.19 W estern blotting
Western blotting is a method to detect a specific protein in a given 
sample of tissue homogenate or cell extract. It uses gel electrophoresis 
to separate native or denaturated proteins by the length of the 
polypeptide (denaturing conditions) or by 3-D structure of the protein 
(native/non-denaturing conditions).
Sample preparation
Sample may be taken from the whole tissue or from cell culture that 
should be first broken down mechanically with a blender or by 
sonication. The latter acts by applying ultrasound energy to disrupt cell 
membrane and release cellular content. In laboratory, it usually 
performed by using an ultrasonic bath or an ultrasonic probe. 
Detergents, salts, and buffers may be employed to encourage lysis of 
cells and to solubilize proteins whereas protease inhibitors are often 
added to prevent the digestion of the sample by it own enzymes.
Protein concentration detection
Protein concentration was determined by using the Bio-Rad 
protein assay reagent (Materials, section 8.7). First, a series of BSA serial
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solutions of known concentrations were prepared starting from a stock 
solution of 10 m g/m l as follows:
BSA final concentration
10 pi of 10 m g / ml + 10 pi of H20 5 m g/m l
15 pi of 5 m g/m l + 15 pi of H20 2.5 m g / ml
21 pi of 2.5 m g / ml + 9 pi of H2O 1.75 m g/m l
15 pi of 1.75 m g / ml + 6 pi of H2O 1.25 m g/m l
15 pi of 1.25 m g / ml + 5 pi of H2O 0.938 m g / ml
10 pi of 0.938 m g/m l + 5 pi of H2O 0.625 m g / ml
10 pi of 0.625 m g/m l + 10 pi of H2O 0.312 m g / ml
Then, 200 pi of Bio-Rad dye reagent diluted 1 /5  was added to a 96- 
multiwell plate followed by the addition of the above described BSA 
dilutions or samples (2 pi). The absorbance was read at the wavelength 
of 620 nm using a spectrophotometer. The standard curve, created by 
plotting the absorbance versus the concentration of each standard, was 
used to calculate the concentration for an unknown sample given its 
absorbance.
Gel electrophoresis
The most common type of gel electrophoresis employs 
polyacrylamide gels and buffer containing sodium dodecyl sulphate
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(SDS) (Materials, section 8.7). The SDS polyacrylamide gel 
electrophoresis (SDS-PAGE) maintains polypeptides in a denatured 
state once they have been treated with strong reducing agents to 
remove secondary and tertiary structure (e.g. S-S disulphide bonds to 
SH and SH) and thus allows separation of proteins by their molecular 
weight. Sampled proteins become covered in the negatively charged 
SDS and move to the positively charged electrode through the 
acrylamide mesh of the gel. Smaller proteins migrate faster through this 
mesh and the proteins are thus separated according to the size. 
Polyacrylamide gels are composed of chains of polymerized acrylamide 
that are cross-linked by a bifunctional agent such as N,N'- 
methylenebisacrylamide. Polyacrylamide gels form as a result of 
polymerization of the monomeric acrylamide into polymeric 
polyacrylamide chains with cross-linking of the chains by 
bisacrylamide. The polymerization reaction is initiated by addition of 
ammonium persulfate (Materials, section 8.7) and accelerated by 
addition of TEMED (Materials, section 8.7), which catalyzes the 
formation of the free radicals from ammonium persulfate.
The effective range of separation of SDS-polyacrylamide gels 
depends on the concentration of polyacrylamide used to cast the gel 
and the amount of cross-linking formed from bisacrylamide that add 
rigidity and tensile strength to the gel and form pores through which 
the SDS-polypeptide complexes must pass. When samples are loaded 
into wells in the gel, one line is usually reserved for a marker or ladder,
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a commercially available mixture of proteins having defined molecular 
weights, typically stained so as to form visible, coloured bands. By 
using a marker of known molecular weight, it is possible to estimate the 
molecular weight of the polypeptide chain(s).
The most common buffer system used for protein electrophoresis is 
the Tris-glycine buffer system (Materials, section 8.7), where glycine is 
the trailing ion. During electrophoresis, a sharp zone, usually visible as 
change of refractive index, forms a boundary between the slower 
trailing ion (glycine) and the faster leading ion (chloride). When the 
protein sample is applied in a stacking gel, in which proteins can move 
faster than the trailing ion, the proteins stack up between the leading 
and trailing ion fronts. Once the proteins enter the higher percentage 
separating gel, they are passed by trailing ion, and separation of the 
proteins begins based on their mobility through the pores of the 
separating gel. Thus, freed from the moving boundary, the SDS- 
polypeptide complexes move through the resolving gel in a zone of 
uniform voltage and pH and are separated according to size by sieving. 
When voltage is applied along the gel, proteins migrate into it at 
different speeds. These different rates of advancement (different 
electrophoretic mobilities) separate into bands within each lane.
Electroblotting
Electroblotting is a method applied to transfer proteins onto a 
membrane (generally PVDF or nitrocellulose) after gel electrophoresis.
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The proteins can then be analyzed using specific antibodies. This 
technique relies upon a current and a transfer buffer solution to drive 
proteins onto a membrane. Following electrophoresis a standard tank 
or semi-dry blotting transfer system is set-up. A stack is put together in 
the following order from cathode to anode: sponge | three sheets of 
filter paper soaked in transfer buffer | gel | PVDF or nitrocellulose 
membrane | three sheets of filter paper soaked in transfer buffer | 
sponge. The membrane is located between the gel and the anode, as the 
current and sample will be moving in that direction.
Protein binding is based upon hydrophobic interactions, as well as 
charged interactions between the membrane and protein.
Protein detection
Since the membrane has been chosen for its ability to bind protein, 
and both antibodies and the target are proteins, steps must be taken to 
prevent interactions between the membrane and the antibody used for 
detection of the target protein. Blocking of non-specific binding is 
achieved by placing the membrane in a dilute solution of protein - 
typically bovine serum albumin (BSA) or non-fat dry milk-(Materials, 
section 8.7) in the presence of a detergent such as 0.1% Tween 20 
(Materials, section 8.7). Proteins in the dilute solution attach to the 
membrane in all places where the target proteins have not attached. 
Thus, when the antibody is added, it can only attach to the binding sites 
of the specific target protein.
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To detect target protein, the membrane is "probed" w ith a primary 
antibody specific for the protein of interest. After blocking, a dilute 
solution of primary antibody is incubated with the membrane under 
gentle agitation. The solution is comprised of buffered saline solution 
with a small percentage of detergent, and sometimes with BSA. After 
rinsing the membrane to remove unbound primary antibody, the 
membrane is exposed to another antibody, directed at a species-specific 
portion of the primary antibody. This secondary antibody is usually 
linked to biotin or to a reported enzyme such as alkaline phosphatase or 
horseradish peroxidase. Most commonly, a horseradish peroxidase- 
linked secondary is used in conjunction with a chemiluminescent agent, 
and the reaction product produces luminescence in proportion to the 
amount of protein. Chemiluminescent detection methods depend on 
incubation of the western blot with a substrate that will luminesce 
when exposed to the reporter on the secondary antibody. A sensitive 
sheet of photographic film is placed against the membrane, and 
exposure to the light from the reaction creates an image of the 
antibodies bound to the blot. The image is analysed by densitometry, 
which evaluates the relative amount of protein staining and quantifies 
the results in terms of optical density.
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9.20 Microscopy
9.20.1 Light microscopy
See Chapter 3, section 3.24.
9.21 Immunofluorescence technique and confocal microscopy
See Chapter 3, section 3.25.
9.22 Haemocytometer
See Chapter 3, section 3.26.
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CHAPTER 10
BONE MARROW-MESENCHYMAL STEM CELL 
THERAPY PRESERVES GLOMERULAR  
PODOCYTES AN D  PROGENITOR CELLS IN  
ADRIAMYCIN-INDUCED NEPHROPATHY
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10.1 Introduction
Chronic kidney disease (CKD) is a worldwide threat to public 
health, with an estimated prevalence of 11% of the adult population in 
Western industrialized nations (Hallan et al, 2006), but the true 
dimension of this problem is not fully appreciated. Approximately, 
over 2 million people are currently treated with renal replacement 
therapy (RRT), which consist primarily of kidney transplantation, 
haemodialysis and peritoneal dialysis (Remuzzi et al., 2006; Couser et 
al., 2011). More than 90% of these individuals live in industrialized 
countries, while in developing countries, available RRT is scarce, and 
null in underdeveloped areas (Remuzzi et al., 2006). Moreover, in the 
next decade, the cost for dialysis will become unbearable even in the 
most developed countries (Just et al., 2008).
Although considerable gains have been obtained in retarding 
progression of CKD by renin-angiotensin system blockade in a 
significant proportion of patients, the therapeutic goal of arresting CKD 
progression to end-stage renal disease remains unfulfilled. At this 
purpose, stem cell-based therapy exploiting stem cell peculiar 
properties of renal tropism and regenerative capability, may also 
contribute to kidney repair and could represent an innovative strategy 
as cure for CKD.
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In this contest, bone marrow-derived mesenchymal stem cells 
(BM-MSCs) are a source of multipotent cells having the potential of 
tissue regeneration in experimental models of myocardial infarction 
(Laflamme et al., 2005; Nagaya et ah, 2004; Tang et al., 2006), 
neurological disease (Torrente et al., 2008) and acute kidney injury 
(Morigi et al., 2004; Imberti B et al., 2007; Morigi et al., 2008; Herrera et 
al., 2004). We showed that infusion of murine (Morigi et al., 2004; 
Imberti et al., 2007) and hum an BM-MSCs (Morigi et al., 2008) in mice 
with acute kidney injury decreased renal tubular injury and 
ameliorated renal function impairment reducing animal mortality. The 
mechanism underlying renoprotection was due to a paracrine action of 
these stem cells, with production of regenerative, prosurvival, anti- 
apoptotic and angiogenic factors including IGF-1 and VEGF (Imberti et 
al, 2007; Togel et al, 2005; Togel et al, 2007).
In experimental models of acute kidney injury, the renoprotective 
effect of BM-MSCs is well established, unfortunately, the therapeutic 
potential of these stem cells in animal models of chronic nephropathies 
has not been completely demonstrated so far. In literature there are 
reported some conflicting results. Ninichuk et al. have observed that 
BM-MSC treatment improved interstitial fibrosis and loss of peritubular 
capillaries, but it failed to prevent the progression of CKD in mice with 
Alport disease (Ninichuk et al, 2006). Infusion of MSCs in rats w ith 5 /6  
nephrectomy partially preserved renal function and attenuated
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glomerulosclerosis (Cavaglieri et al, 2009) and interstitial fibrosis 
(Semedo et al, 2009). Early treatment with MSCs blunted 
glomerulosclerosis in adriamycin model of nephropathy, while it failed 
to modify proteinuria and progression of renal failure (Magnasco et al, 
2008).
So based on these evidences the aim of this study was to 
investigate whether BM-MSCs could ameliorate renal function and 
glomerular architecture in a model of chronic kidney disease. To this 
aim, we set up a model of adriamycin-induced nephropathy and we 
evaluated if treatment of nephrotic rats with ex-vivo expanded bone 
marrow-derived MSCs, a cell source of pro-survival and angiogenic 
factors, had regenerative effects on cells of distinct glomerular 
compartments as podocytes, parietal epithelial cells (PECs) and 
endothelial cells.
10.2 Model of ADR nephropathy
In order to evaluate the renoprotective effect of BM-MSCs, we set 
up an experimental model of nephropathy induced by adriamycin 
(ADR) in rats. Renal function assessed as proteinuria, was evaluated at 
different time points from ADR treatment.
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Since podocytes are target of injury in a variety of kidney diseases, 
we evaluated whether podocyte number was reduced following ADR 
treatment. Using WT-1, a podocyte-specific marker that localizes in 
nuclei, we observed a decrease in the number of podocytes in ADR- 
treated rats in respect to control rats (Figure 10.1 a and b). By 
morphometric analysis a significant decrease in the number of WT-1- 
positive cells was observed after ADR injection, starting from 3 days, 
with respect to control rats (ADR, day 3 :129.57±3.56; day 9 :127.01±2.83; 
day 16: 122.84±5.37 vs control, 221.99±5.66 podocytes/glomerulus, 
p<0.01). Podocyte loss in response to ADR was confirmed by 
immunostaining with nestin, a specific marker of podocytes 
(glomerular area percentage: ADR, day 3: 10.25±4.16% vs control, 
16.00± 0.75%, P<0.01). Loss of podocytes, was coupled to slit diaphragm 
protein alterations including nephrin and CD2AP. We observed that 
nephrin, a key component of the slit diaphragm, which functions to 
maintain slit pore integrity and renal filtration capacity (Tryggvason et 
al., 2001), was reduced and the staining was discontinuous (glomerular 
area percentage: ADR, day 9 :1.69±0.05 vs control 10.84±0.41%, p<0.05) 
(Figure 10.2 a and b). Also CD2AP, a protein associated to nephrin (Shih 
et al., 2001), shown a decreased expression in ADR-treated rats in 
respect to control (Figure 10.2 c and d) (glomerular area percentage: 
ADR, day 9: 2.85±0.43 vs control, 15.06± 0.23%, p<0.05).
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Since the cytotoxic and cytostatic effect of ADR results in the 
induction of apoptotic cell death, we observed whether the loss of 
podocytes observed starting from 3 days, was due to apoptosis. Using 
double-staining for TUNEL and WT-1, we observed in the renal tissue 
of ADR-rats given saline, a high number of apoptotic podocytes, at 
variance with kidneys from control rats where no apoptotic podocytes 
were detected (ADR, day 3: 17.8±0.54; day 9: 16.79±0.78; day 16: 
15.34±0.61 vs control 0 TUNEL/WT-1 positive podocytes/glomerulus).
As a consequence of ADR-induced podocyte injury, we observed 
starting from 16 days, glomerular adhesions of the capillary tuft to the 
Bowman's capsule (synechiae), followed by crescents-like lesions at 30 
days (Figure 10.3 a and b). The phenotype of cells contributing to early 
lesions of ADR-treated rats was then assessed by studying the 
expression of claudinl, an intercellular tight junction protein 
constitutively expressed by all glomerular parietal epithelial cells 
(PECs) lining the Bowman's capsule (Ohse et al., 2008) and of nestin, a 
marker of podocytes (Perry et al., 2007). As shown in Figure 10.4, co- 
staining of claudinl and nestin revealed that PECs and podocytes both 
participated to the formation of early cellular bridges at 16 days (Figure
10.4 a and b). At the same time, parietal progenitor cells expressing the 
metanephric mesenchymal marker NCAM (Metsuyanim et al., 2009; 
Bard et al., 2002), contributed to the formation of the early lesions 
(Figure 10.5 a and b). With time (30 days), multilayers of cells
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accumulated at the site of synechiae resulting in more severe crescentic- 
like lesions (Figure 10.3 c and d).
All resulted in a mild degree of glomerulosclerosis characterized 
by accumulation of the extracellular matrix material and obliteration of 
the capillary filter. We observed glomerulosclerosis starting from 16 
days after ADR, which became more evident at 30 days 
(glomerulosclerosis index, control rats: 0; ADR, day 16: 0.15±0.06; day 
30: 0.39±0.09).
10.3 Characterization of mesenchymal stem cells isolated from bone
marrow
MSCs were obtained from bone marrow of 2 month-old male 
Lewis rats. After 2 to 3 weeks, subconfluent cells were detached and 
used for in vivo experiments. The ability of BM-MSCs to differentiate 
into adipocytes and osteocytes, after exposure to appropriate inductive 
media, was observed by lipid droplet formation and by extended area 
of mineralization (Figure 10.6 a and b).
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10.4 Localization of bone marrow-mesenchymal stem cells
Because of the severity of the disease, we decided to maintain a 
constant number of BM-MSCs in the kidney during the study. At this 
purpose, repeated infusions of MSCs were applied to ADR-treated rats. 
To assess the ability of MSCs to engraft the kidney in response to injury, 
we labelled before in vivo injection MSCs with PKH-26, a red 
fluorescent membrane dye. We found that the frequency of PKH-26 
positive-MSCs homing the kidney averaged 4.33±0.38, 4.85±0.43 and 
5.73±2.85 cells/105 renal cells, respectively, at day 3,9 and 16 after ADR, 
as assessed 15 hours after MSC injection. Thirty-four % of PKH-26- 
labeled MSCs were found in the glomeruli at 3 days (Figure 10.7 a), but 
the amount of MSCs localized in the glomeruli declined over time. The 
labeled MSCs localized in the glomeruli did not show positivity for the 
podocyte marker WT-1 (Figure 10.7 b). Moreover, FACS analysis of 
dissociated renal tissue of ADR-treated rats receiving MSCs labeled 
with another tracer, rhodamine-B-conjugated nanoparticles, was also 
performed. Kidney samples of ADR- rats receiving fluoNP-labeled 
MSCs, showed 1.6±0.2% positive cells for rhodamine B-fluoNP above 
the negative control set at 2%.
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10.5 Effect of bone marrow mesenchymal stem cells on renal function 
parameters in ADR-treated rats
With the aim to study the renoprotective effect of BM-MSCs, we 
performed repeated injection of MSCs into the tail vain of ADR-treated 
rats, starting 36 hours after ADR treatment. As reported in Figure 10.8, 
rats injected with a single dose of 5m g/kg ADR exhibited proteinuria 
within 6 days (133±8 vs basal, 19±1 m g/day, p<0.01). Proteinuria 
progressively increased during time averaging 1004±33 m g / day at day 
30 in ADR-rats given saline. Unfortunately, the repeated infusions of 
MSCs did not affect the development of proteinuria at any time of the 
study (Figure 10.8).
In parallel, we observed that serum creatinine levels tended to 
increase during time in ADR-rats given saline in respect to controls, 
although a statistical significance was not achieved (ADR, day 9: 0.60± 
0.09; day 16: 0.73±0.01, day 30: 0.86±0.02 versus controls:
0.58±0.01mg/dl). Serum creatinine levels, of ADR-rats that received 
MSC therapy, were not different from those of rats given saline 
(ADR+MSC, day 16: 0.80±0.03; day 30: 0.81±0.06 m g/dl).
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10.6 Bone marrow mesenchymal stem cell treatm ent preserves
glomerular architecture
As noted by the set up of ADR-induced nephropathy, the targets of 
ADR toxicity are podocytes, so we focus on the effect of BM-MSCs on 
podocyte loss. As shown in Figure 10.9, repeated injections of BM-MSCs, 
significantly limited (p<0.01) podocyte depletion. Indeed, at day 3, 9 and 
16, we observed a higher number of podocytes per glomerulus in the 
group of ADR-treated rats receiving MSCs as compared to saline (Figure 
10.9). The preservation of podocyte number was also confirmed by nestin 
expression (glomerular area percentage: ADR+MSCs, day 3: 18.19±2.6%, 
P<0.01 vs ADR). Associated with limited podocytes depletion, we 
observed at day 9 in ADR-treated rats receiving MSCs, a partial, 
although, significant preservation of both nephrin and CD2AP expression 
as compared to ADR-rats given saline (nephrin, glomerular area 
percentage: ADR+MSC, 3.81±0.34%, P<0.05 vs saline; CD2AP, glomerular 
area percentage: ADR+MSC, 5.24±0.24%, p<0.05 vs saline).
In vivo and in vitro model of ADR-induced toxicity (Magnasco et al., 
2008) have demonstrated that podocytes depletion is due to an induction 
of apoptotic pathway, therefore we have investigated whether BM-MSCs 
were able to exert an anti-apoptotic effect. As shown in Figure 10.10, BM- 
MSCs infusions, significantly (p<0.01) reduced apoptotic podocytes, as 
indicated by the lower number of TUNEL+ WT1+ podocytes in renal
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tissue of MSC-treated rats compare to ADR-rats given saline, at the 
corresponding times (Figure 10.10).
Protective effect of BM-MSCs on podocytes depletion resulted in a 
significant reduction of glomerular podocyte-PEC bridges. We 
observed in ADR-rats given saline a significant (p<0.01) increase of 
percentage of glomeruli with area occupied by more than 50% 
adhesions of the tuft to the Bowman's capsule (Figure 10.11). In ADR- 
rats receiving BM-MSCs, the percentage of glomeruli w ith area 
occupied by more than 50% adhesions of the tuft to the Bowman's 
capsule was significantly lower than that observed in rats given saline 
(Figure 10.11). In control animals, no glomeruli with adhesions more 
than 50% were found (Figure 10.11).
In the set up model, we observed in ADR-rats given saline, that 
NCAM positive cells contributed to the formation of early synechiae 
(Figure 10.12). Following MSC injections, the distribution of NCAM 
positive progenitor cells was restored along the Bowman's capsule to a 
pattern similar to controls (Figure 10.12).
Since BM-MSCs were able to restore glomerular architecture, we 
tested whether BM-MSCs treatment could exert a protective effect on 
glomerulosclerosis, a serious outcome of ADR nephropathy. As shown 
in Figure 10.13, ADR-rats given saline revealed at 30 days sclerotic 
lesions which were significantly reduced (p<0.01) in ADR-rats treated 
with BM-MSCs (Figure 10.13).
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10.7 Role of bone marrow mesenchymal stem cells on glomerular 
VEGF level and endothelial cell damage
Looking for factors possibly involved in MSC-mediated 
renoprotection in ADR-rats, we focused on VEGF, highly produced by 
rat MSCs (Figliuzzi et al., 2009) and known to exert pro-survival and 
angiogenic activity (Togel et al., 2007; Togel et al., 2009). As shown in 
Figure 10.14, glomeruli of ADR-rats given saline showed, starting from 
3 days, a decrease of VEGF staining in respect to control rats. Infusions 
with BM-MSCs, significantly (p<0.05) enhanced glomerular VEGF 
expression at days 9 and 16. Consistently, Western blot experiments 
performed in renal tissue of all the experimental groups showed that at 
days 9 and 16, MSC treatment almost normalized renal levels of VEGF 
protein (Figure 10.15).
In parallel, we observed that BM-MSC infusions translated into 
preservation of glomerular endothelial cells. By morphometric analysis 
of the glomerular endothelium labelled with RECA, a marker of rat 
endothelial cells, we observed a marked reduction in volume density 
(Vv) of endothelial cells in ADR-treated rats given saline compared 
with control rats (Figure 10.16). The degree of microvessel rarefaction 
was significantly reduced in glomeruli of ADR-rats infused with MSCs 
versus glomeruli of ADR-rats given saline, confirming a key role of 
VEGF on glomerular endothelial cell integrity and function.
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10.8 Anti-inflammatory effect of bone marrow derived 
mesenchymal stem cells
Consistent with the data reported in literature, we observed in the 
glomeruli of ADR rats given saline, an increased number of ED1- 
positive monocytes/macrophages as compared to control rats (ADR, 
day 9: 4.31±0.22; day 16: 4.78+0.23 vs control 1.11±0.14 ED-1+ 
cells/ glomerulus, p<0.05). ADR-rats treated with BM-MSCs, showed a 
significant (p<0.05) reduction of glomerular cell infiltrates w ith respect 
to ADR-rats given saline (ADR+MSC, day 9 :1.87±0.06; day 16: 2.78±0.31 
ED-1+ cells/glomerulus), suggesting a marked anti-inflammatory effect 
of BM-MSCs.
10.9 Bone marrow mesenchymal stem cells protect podocytes
from
adriamycin-induced toxicity via VEGF: in vitro studies
In order to better explain the capability of BM-MSCs to exert 
protective effects on podocytes, we performed in vitro experiments 
using a co-culture system whereby BM-MSCs were in co-culture with 
podocytes pre-treated with ADR. Murine differentiated podocytes were 
exposed for 6 hours to ADR, and 72 hours after drug withdrawal, cell
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count was performed. As shown in Figure 10.17 exposure to ADR 
significantly (P<0.01) reduced the number of viable podocytes 
compared to control podocytes (Figure 10.17). Co-culture of damaged 
podocytes with murine BM-MSCs completely prevented podocyte loss 
caused by ADR (p<0.01) (Figure 10.17). BM-MSCs seeded alone did not 
proliferate.
Since BM-MSCs produce high levels of VEGF (Figliuzzi et al., 2009) 
that, as shown by our in vivo results, played important role on 
glomerular endothelial integrity, we tested in the co-culture system the 
contribution of VEGF in MSC-induced podocyte survival. Using a 
specific antibody against VEGF, we observed, an abrogation of BM- 
MSC protective effects on ADR-treated podocytes (Figure 10.18). In 
order to provide further evidence on the role of VEGF, we added 
exogenous VEGF to ADR-treated podocytes, and we observed that 
VEGF was able to prevent cell loss at a similar extent as MSCs did 
(Figure 10.18).
To study whether MSCs could counteract podocyte apoptosis 
induced by ADR, we evaluated the expression of cytochrome C (Cyt C), 
a marker of intrinsic apoptosis when released from mitochondria into 
the cell cytosol (Lebrecht et al., 2004; Gewirtz et al., 1999; Park et al, 
2002; Brooks et al., 2009). As shown in Figure 10.19, we found that ADR 
caused apoptosis in a high number of podocytes at 3,15 and 24 hours 
(p<0.01 vs control podocytes) after ADR (Figure 10.19). BM-MSCs co­
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cultured with ADR-treated podocytes, significantly (p<0.01) reduced 
the percentage of apoptotic podocytes at all times considered (Figure 
10.19). The anti-apoptotic effect exerted by MSCs was abrogated by the 
addition of a specific functional blocking anti-VEGF antibody to the co­
culture system, while using exogenous VEGF on damaged podocytes, 
we observed a percentage of apoptotic cells comparable to that 
observed with BM-MSCs (Figure 10.19 and 10.20). The anti-apoptotic 
activity of MSCs was further confirmed by evaluating cleaved caspase-3 
in cells exposed to ADR at different times. ADR-treated podocytes 
exposed to MSCs showed a significant (P<0.01) decrease in the 
percentage of cells positive for cleaved caspase-3 at 3 hours (control 
podocytes: 4.7±0.4; ADR: 15.3±2.1 and ADR+MSCs: 6.0±0.7 % apoptotic 
cells) and at 15 hours (ADR: 26.0± 1.0 and ADR+MSCs: 8.7±1.1 % 
apoptotic cells) in respect to ADR-treated podocytes exposed to 
medium alone. Exposure to VEGF markedly reduced the percentage of 
apoptotic cells in response to ADR at 3 hours (10.5±2.6%) and at 15 
hours (8.0±1.4%, PO.01 vs ADR).
The serine threonine kinase Akt is a critical factor in the regulation 
of pro-survival signals (Datta et ah, 1999). By Western blot analysis, in 
control podocytes, we observed a constitutively expression of the 
phosphorylated form of Akt (pAkt), while in ADR-damaged podocytes, 
we reported a markedly reduction of pAkt (Figure 10.21). Conversely, 
addition of exogenous VEGF and conditioned medium from BM-MSCs
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markedly stimulated activation/phosphorylation of Akt in podocytes 
72 hours after ADR incubation (Figure 10.21).
Since the intracellular serine/threonine protein kinase integrin- 
linked kinase (ILK), plays an important role in mediating podocyte 
adhesion to matrix, migration and survival (Yang et ah, 2005; Dai et al., 
2006), we investigated whether changes in ILK expression in ADR- 
treated podocytes were restored by BM-MSCs. As shown in Figure 
10.22, damaged podocytes exhibited a marked redistribution and 
decrease of ILK staining with respect to control cells. When ADR- 
treated podocytes were co-cultured w ith BM-MSCs the granular pattern 
of ILK was almost normalized (Figure 10.22).
10.10 Conclusions
In order to study the effect of BM-MSCs in a model of chronic 
kidney disease, we set up a model of nephropathy induced by ADR. 
The results presented in this Chapter, can be summarized as follows. 
We found that:
• Early podocyte injury and subsequent chaotic migration of parietal 
epithelial progenitor cells lead to crescents-like lesions and 
glomerulosclerosis in ADR nephropathy.
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• Repeated injections of BM-MSCs, created a glomerular pro- 
regenerative environment able to restored glomerular architecture, 
limiting podocyte and endothelial dysfunction and moderating 
progenitor cell activation.
• The protective effect of BM-MSCs could be due to VEGF, produced 
by large amount from BM-MSCs, which acts limiting podocyte 
apoptosis, endothelial rarefaction and inducing podocyte survival.
10.11 Discussion
Several studies have suggested the therapeutic effect of BM-MSCs 
in experimental model of acute kidney injury (Morigi et ah, 2004; 
Imberti et al., 2007; Morigi et al., 2008; Herrera et al, 2004), 
unfortunately, only limited data are available on the role of BM-MSCs 
in models of chronic kidney disease. In this contest, we studied the 
capability of BM-MSCs to promote renal repair in a rat model of 
adriamycin-induced nephropathy, analysing the ability of these stem 
cells to regenerate different cellular components of glomeruli.
First of all, we characterized the model of adriamycin-induced 
nephropathy. We observed starting at 3 days, podocyte loss due to 
ADR-induced apoptosis, accompanied by slit diaphragm protein 
alterations. Moreover, for the first time, we demonstrated that podocyte
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depletion was followed by intercellular bridges between nestin+ 
podocytes and claudinl+ PECs and by more extensive areas of 
adhesions between the Bowman's capsule and the tuft. More 
importantly, claudinl+ PECs present at the adhesion sites expressed 
also the metanephric mesenchymal marker NCAM (Metsuyanim et al., 
2009; Bard et al., 2002). The presence of NCAM+ cells in such lesions 
implied that progenitor cells of parietal origin, in response to ADR- 
induced podocyte damage, acquired a migratory phenotype and 
invaded the glomerular tuft participating to the formation of crescents­
like lesions and glomerular sclerosis. In human adult kidney, along the 
Bowman's capsule, has been identified a hierarchical population of 
progenitor cells organized in a precise sequence, that contributed to the 
turnover of senesced or injured podocytes (Ronconi et al, 2009). 
However, in glomerular disease in response to a severe podocyte 
damage an aberrant repair may take place, with an excessive 
proliferative response of renal progenitor cells from the Bowman's 
capsule, that contribute to hyperplastic lesions of podocytopathies and 
crescentic glomerulonephritis (Smeets et al., 2009; Lasagni et al, 2010). 
In adult rat kidney, we recently provided the evidence for the presence 
of renal progenitor cells along the Bowman's capsule by showing that 
the sternness markers NCAM and CD24 (Challen et al, 2004; Ronconi et 
al, 2009)} were expressed by the large majority of claudinl+ PECs 
(Benigni et al, 2011). In the MWF rat model characterized by
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spontaneous podocyte loss, extracapillary crescents and 
glomerulosclerosis, a high percentage of claudinl+ PECs expressing 
NCAM, and to a lesser extent WT1+ podocytes were found in 
hyperplastic lesions during disease progression, suggesting that renal 
injury in this model could be the consequence of progenitor cell 
dysfunction (Benigni et ah, 2011).
Subsequently, once characterized the damage induced by 
adriamycin, we addressed the capacity of BM-MSCs to induce renal 
repair. We showed that repeated BM-MSC injections limited podocyte 
depletion by exerting a remarkable anti-apoptotic effect, and partially 
restored nephrin and CD2AP expression. The protective effect of BM- 
MSCs on podocyte dysfunction and loss resulted in a significant 
reduction of adhesions between PECs and podocytes, with the re­
establishment of a normal localization of NCAM+ PECs along the 
Bowman's capsule. Thus, stem cell therapy by reducing podocyte injury 
and progenitor cell activation, ameliorated glomerular architecture and 
prevented glomerular sclerotic lesions. The fact that BM-MSC treatment 
failed to reduce proteinuria in ADR-rats could be ascribed to the limited 
recovery of the slit diaphragm proteins in the preserved podocytes.
We than studied the mechanisms underlying the BM-MSC- 
mediated glomerular protection in ADR-rats. VEGF, a factor that 
critically regulates and maintains podocyte and glomerular endothelial 
cell integrity and function {Sugimoto et ah, 2003; Eremina et ah, 2003), is
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highly produced in vitro and in vivo by rat BM-MSCs (Figliuzzi et al., 
2009; Togel et al, 2007) and by podocytes (Eremina et al, 2003; Eremina 
et al, 2006; Guan et al, 2006). So, based on these evidences, we 
investigated whether the positive BM-MSC effect on glomerular 
compartments was possibly mediated by VEGF. We observed in ADR- 
treated rats a reduction of glomerular VEGF staining with consequent 
loss of endothelial integrity. These results were consistent with studies 
that documented that alterations in VEGF expression were associated 
with glomerular diseases (Kim et al, 2000; Ostendorf et al, 1999; 
Eremina et al, 2003). BM-MSC treatment recovered glomerular VEGF 
levels restoring endothelial integrity as confirmed by a significant 
limitation of capillary rarefaction in ADR rats infused with BM-MSCs.
It is plausible to hypothesize that BM-MSCs homing the glomeruli 
could locally release VEGF that acting on podocytes would activate 
pro-survival pathways that render podocytes again metabolically active 
to synthesize great amount of the pro-regenerative growth factor itself. 
That VEGF may exert a beneficial effect on podocytes is supported also 
by data showing that nephrin and CD2AP -target proteins regulated by 
VEGF (Sugimoto et al, 2003; Guan et al, 2006) - were partially preserved 
in renal tissues of BM-MSC-treated animals.
Finally, the regenerative effect of BM-MSC-derived VEGF on 
ADR-damaged podocytes was explored in in vitro studies. In agreement 
w ith the in vivo data, BM-MSCs significantly enhanced viability and
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limited apoptosis of podocytes in response to ADR. A neutralizing anti- 
VEGF antibody markedly abrogated such a prosurvival effect, thereby 
indicating a cytoprotective action of BM-MSC-derived VEGF on 
podocytes. The hypothesis that VEGF could activate pro-survival 
pathways in ADR-treated podocytes was confirmed by our finding that 
showed activation/ phosphorylation of Akt, a key factor in the 
regulation of pro-survival signals, in ADR-treated podocytes exposed to 
BM-MSC-conditioned m edium or directly to exogenous VEGF. 
Similarly, previous studies showed that VEGF induced the activation of 
Akt signalling pathway in several cell types, thus reducing apoptosis 
(Foster et a l, 2005, F48-57; Cai et al., 2003; Gerber et al, 1998).
Consistent with the view that alterations of ILK expression -an  
important intracellular kinase regulating cell binding and migration- 
are associated with podocyte dysfunction (Dai et al, 2006) here we 
found that ILK protein distribution was partially restored when ADR- 
injured podocytes were co-cultured with MSCs.
In summary, our findings indicate that early podocyte injury and 
subsequent chaotic migration of parietal epithelial progenitor cells lead 
to crescents-like lesions and glomerulosclerosis in ADR nephropathy. 
Treatment with BM-MSCs creates a glomerular pro-regenerative 
environment possibly via VEGF, and restores glomerular architecture 
by limiting podocyte and endothelial dysfunction and by m oderating 
progenitor cell activation.
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Figure 10.1: Adriamycin causes loss of podocytes
Representative micrographs of renal sections from (a) control and (b) ADR- 
treated rats showing podocytes (WT-1 positive nuclei in red), glomerular 
capillaries (lectin, green) and cell nuclei (DAPI in blue). Original 
magnification, x400.
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Figure 10.2: Adriamycin reduces the expression of the podocyte-associated 
proteins nephrin and CD2AP
Representative images of renal sections showing nephrin (green; a,b) and 
CD2AP (red; c,d) expression in glomeruli from control (a, c) and ADR-rats (b, 
d). Original magnification, x400.
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Control ADR 16 days
Figure 10.3: Glomerular lesions in rats with ADR nephropathy at 16 and 
30 days.
Representative micrographs of kidney tissue from control (a) and ADR-rats 
(b-d). Synechiae (b) and more extensive adhesions or crescents-like lesions 
(c,d) were observed during time in ADR-treated rats. Original 
magnification, x400.
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Figure 10.4: Formation of early synechiae in rats with ADR nephropathy at 
16 days.
Representative images of claudin-1 (red) and nestin (green) in control (a) and 
ADR-rats (b). Inset shows claudin-1 and nestin positive cells that participated 
to the formation of early cellular bridge. Cells were co-stained w ith DAPI. 
Original magnification, x400.
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Figure 10.5: NCAM positive cells contributed to the formation of early 
lesions in ADR nephropathy at 16 days
Representative images of NCAM (red) in control (a) and ADR-rats (b). Cells 
were co-stained with DAPI. Original magnification, x400.
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Figure 10.6: Differentiation potential and staining of MSCs
Representative micrographs of rat MSCs showing differentiation into 
adipocytes as visualized by intracellular lipid vacuoles detected with Oil Red 
O staining (a). The differentiation toward osteocytes is indicated by the 
formation of calcium-rich hydroxy apatite detected with Alizarin red (b). 
Representative image of fluo-NP labeled MSCs (red) co-stained with Hoechst 
33258 for cell nuclei (blue) (c). Original magnification, x400.
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Figure 10.7: Localization of MSCs in renal tissue
Representative micrographs of kidney tissue from ADR-treated rats injected 
with PKH26-labeled MSCs (red) at 3 days (a). Representative micrograph of 
kidney section of ADR-treated rats injected with PKH-26-labeled MSCs (red) 
stained with the podocyte marker WT1 (white) at 16 days (b). Section were 
co-stained with lectin WGA and DAPI. Original magnification, x400.
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Figure 10.8: Effect of MSCs on proteinuria
Time course of urinary protein excretion in control (n=6) and ADR-rats 
treated with saline (n=16) or MSCs (n=16) . Data are mean ± SE. *P<0.01 vs 
control rats at corresponding time (Mann- Whitney test).
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Figure 10.9: MSC treatment reduces podocyte loss in ADR-rats
Morphometrical estimation of average number of podocytes per glomerulus 
from 3 to 16 days in ADR-rats treated with saline (n=4 at each time point) or 
MSCs (n=4 at each time point), and in control rats (n=6). Values are expressed 
as mean+SE. *P<0.01 vs ADR+saline at corresponding time (ANOVA 
corrected with Bonferroni coefficient).
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Figure 10.10: Effect of MSC injection on apoptotic podocytes in ADR-rats.
Quantification of apoptotic podocytes, double positive for TUNEL and WT-1 
in glomeruli of ADR-rats given saline (n=4 at each time point) or MSCs (n=4 
at each time point) at day 3, 9 and 16 and in control rats (n=6). Values are 
expressed as mean±SE. *P<0.01 vs ADR+saline at corresponding time 
(ANOVA corrected with Bonferroni coefficient).
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Figure 10.11: MSCs reduce formation of glomerular podocyte-PEC bridges 
in ADR-rats.
Percentage of glomeruli (meaniSE) affected by different degree of synechiae 
at 16 days in control (n=4) and ADR-rats receiving saline (n=4) or MSCs (n=4). 
°p<0.01 vs CTR.*P<0.01 vs ADR+saline (ANOVA corrected with Bonferroni 
coefficient).
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Figure 10.12: MSC treatment restores along the Bowman's capsule, the 
distribution of NCAM positive cells
Representative images of NCAM+ cells (red) in ADR-rats receiving saline (a) 
or MSCs (b) at 16 days. Cells were co-stained with DAPI. Original 
magnification, x400.
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Figure 10.13: MSC treatment reduces glomerulosclerosis in ADR-rats at 30 
days
Glomerulosclerosis index evaluated at 16 and 30 days in ADR-rats, receiving 
saline (n=4), MSCs (n=4) and in control rats (n=4). Original magnification, 
x400. Score values are mean±SE. *P<0.01 vs ADR+saline at corresponding 
time (Mann-Whitney).
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Figure 10.14: E ffect o f M SC  treatm ent o n  g lom eru lar VEG F ex p ression
(a) Scores of glomerular VEGF expression evaluated at 3, 9 and 16 days after 
ADR in rats receiving saline (n=4), MSCs (n=4) or in control rats (n=4). Score 
values are mean±SE. *P<0.05 vs ADR+MSCs at corresponding time (t test), (b- 
d) Representative micrographs of VEGF expression at day 9 in control, ADR- 
rats receiving saline or MSCs. Original magnification, x400.
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Figure 10.15:Effect of MSC treatment on glomerular VEGF expression
Western blot analysis of VEGF in kidney tissue of ADR-rats receiving saline 
(n=4) or MSCs (n=4), and control rats (n=4) at 3, 9, 16 days (top). The 
expression levels of VEGF are quantified relative to levels of (X-tubulin 
(bottom). Data are means±SE. °P<0.01 vs. control; **P<0.01 vs. ADR+saline at 
corresponding time (ANOVA corrected with Bonferroni coefficient).
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Figure 10.16: Effect of MSC treatment on volume density of endothelial 
cells.
Estimation of volume density (Vv) of glomerular endothelial cells stained for 
RECA during time (a). Score values are mean±SE. *P<0.01 vs ADR+saline at 
corresponding time (ANOVA followed Tuckey-Cicchetti). Representative 
micrographs at 9 days of glomerular RECA staining in control (n=4), ADR- 
rats receiving saline (n=4) or MSCs (n=4) (b-d). Original magnification, x400.
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Figure 10.17: Effect of MSCs on ADR-treated podocytes : in vitro studies.
MSCs protected podocytes from ADR-induced damage after 72 hours of co­
culture. Podocytes were incubated with 1.5 pM ADR for 6 hours, and after 
drug withdrawal, were co-cultured with murine MSCs. After 72 hours viable 
cells were counted. Data are expressed as mean±SE. °P<0.01 versus Podo, 
*P<0.01 versus Podo/ ADR (ANOVA corrected with Bonferroni coefficient). 
The experiments were performed in triplicate and repeated 3 times.
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Figure 10.18: MSCs exert protective effect on ADR-damaged podocytes via 
VEGF
Percentage of viable ADR-treated podocytes alone or co-cultured with murine 
MSCs in the presence or absence of anti-VEGF antibody (10 mg/ml) for 72 
hours. In additional samples, ADR-treated podocytes were incubated with 
exogenous VEGF (40 ng /ml) for 72 hours. Data (mean ± SE) are expressed as 
percentage of viable podocytes in each sample versus control podocytes imposed 
as 100%. °P<0.01 versus control, *P<0.01 versus Podo/ADR, #P<0.01 versus 
Podo/ADR+MSCs (ANOVA corrected with Bonferroni coefficient).
The experiments were performed in triplicate and repeated 3 times.
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Figure 10.19: Effect of MSCs on podocyte apoptosis at different time 
intervals.
ADR-treated podocytes alone or co-cultured with MSCs in the presence or 
absence of functional blocking anti-VEGF antibody. In additional samples, 
ADR-treated podocytes were incubated with exogenous VEGF. Apoptosis 
was expressed as the percentage of podocytes with cytocrome (Cyt C) 
released into cell cytosol. *P<0.01 versus Podo, °P<0.01 versus Podo/ADR 
(ANOVA corrected with Bonferroni coefficient).
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Figure 10.20: Effect of MSCs on Cyt C released on cytosol
Representative images of Cyt C expression in podocytes 3 hours after ADR 
incubation. Cyt C expression was also shown in ADR-treated podocytes co­
cultured with MSCs with or w ithout anti-VEGF antibody and in ADR-treated 
podocytes incubated w ith exogenous VEGF. Cells were co-stained w ith DAPI. 
Original magnification, x630.
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Figure 10.21: Effect of MSCs on Akt activation in ADR-damaged podocytes
Western blot analysis of Akt at 3 days. Expression level of phosphorylated 
(p)-Akt Ser437 and total Akt in control podocytes, ADR-treated podocytes, 
ADR-treated podocytes incubated with VEGF or with MSC conditioned 
medium (c.m. MSCs)
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Figure 10.22: MSC treatment restores ILK staining in ADR-damaged 
podocytes
R epresentative im ages of ILK staining in  un trea ted  podocytes (a) or in 
cells exposed to ADR alone (b) or in co-culture w ith  MSCs (c) for 24 
hours. Cells w ere co-stained w ith  DAPI. O riginal m agnification, x630.
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The kidney has been regarded as an organ with minimal cell 
turnover and limited capacity for repair. However, after acute damage, 
the kidney maintains a significant ability to undergo repair, and this is 
best illustrated by the power of tubular cells to replace damaged ones. 
The same, though, does not occur with glomeruli, their capacity for 
repair is rather limited, and once the damage has reached a certain 
point, the ability to recover from the injury may primarily depend on 
extrarenal stem cell sources. In experimental model of AKI, the 
renoprotective effect of BM-MSCs is well established, unfortunately, the 
therapeutic potential in CKD has not been completely demonstrated so 
far. This is probably due to the complexity of the chronic kidney 
damage, which involves different populations of renal cells.
In order to establish a therapeutic effect of BM-MSCs, we set up a 
model of nephropathy induced by adriamycin (ADR), an anthracycline 
antibiotic, used for the treatment of solid tumors. ADR-induced 
nephropathy is considered an accurate experimental model that mimics 
the primary focal segmental glomerulosclerosis (FSGS). To study the 
renoprotective effect of BM-MSCs, repeated intravenous injections of 
stem cells were performed, in order to maintain a constant number of 
MSCs into the damaged kidney.
The first important evidence of this study is that BM-MSCs are 
able to create a glomerular pro-regenerative environment in the 
glomerulus possibly by producing large amount of growth factors 
including VEGF. It is well established that VEGF regulates and
j
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maintains podocyte and glomerular endothelial cell integrity and 
function (Sugimoto et al., 2003; Eremina et al., 2003). Moreover, VEGF is 
able to activate Akt, a kinase upstream target of anti-apoptotic and pro­
survival pathways in podocytes.
It is plausible to hypothesize that BM-MSCs homing the glomeruli 
locally release VEGF that activates pro-survival pathways, thus 
rendering podocytes again metabolically active. Podocytes, in response 
to these pro-survival signals, start to synthesize again great amount of 
the pro-regenerative growth factor itself, through a self-repair process.
The second important finding is the preservation of the Bowman's 
capsule architecture with consequent reduction of formation of PEC- 
podocyte bridges and crescents. PECs response to injury by 
d e / transdifferentiated into a mesenchymal/ embryonic phenotype. This 
change leads to lose their polarity, microvilli and tight junctions (Le Hir 
et al., 2001). As result of damage, podocytes undergo foot process 
effacement and prominent microvillus transformation that represents 
extensive membrane dynamics (Le Hir et al., 2001). It is tempting to 
speculate that these changes enable podocytes to disjoin junction 
between PECs. This junctional instability could be provoked also by 
inflammatory environment present during the progression of CKD (Le 
Hir et al., 2001). The rupture of junctions in the parietal epithelium at 
the site of intrusion by podocytes might play a central role in the 
proliferation of PECs and the organization of crescents. The restoration 
of podocyte number and function mediated by BM-MSC treatment,
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limit migration and proliferation of parietal progenitor epithelial cells 
of the Bowman's capsule thereby reducing the early formation of PEC- 
podocyte bridges. In the future, it will be necessary to understand how 
podocytes and PECs communicate, and how PECs are activated by the 
damage in order to better understand the formation of cellular bridges.
The fact that BM-MSC treatment failed to reduce proteinuria could 
be ascribed to the limited recovery of the slit diaphragm proteins in the 
preserved podocytes. Future studies must investigate the reasons for 
this failure. Moreover, based on data described in literature, it becomes 
evident that potentiating renal migration, engraftment, survival and 
paracrine effects of administered stem cells through preconditioning or 
genetic modifications, may be possible to contribute to enhance the 
MSC local effect in the damaged kidneys thus improving also 
proteinuria and renal functional parameters. In particular, gene- 
modified and pre-conditioned BM-MSCs have shown enhanced 
therapeutic effects in preclinical model of AKI. BM-MSCs genetically 
modified with the serine protease kallikrein by adenovirus transduction 
were more resistant to oxidative stress-induced apoptosis and secreted 
high levels of VEGF in culture medium (Hagiwara et al, 2008). Injection 
of kallikrein-modified BM-MSCs in rat with ischaemia/reperfusion 
injury enhanced renal function inhibiting apoptosis and inflammation 
(Hagiwara et al, 2008). Other strategies to improve the ability of stem 
cells to survive and produce paracrine factors can be achieved by in 
vitro pretreatment with melatonin. Mias and coworkers have observed
340
C H A P T E R  11: G E N E R A L  D 1S CU SS1 0N -C K D
that melatonin was able to increase the resistance of BM-MSCs to 
hydrogen peroxide-induced apoptosis by promoting overexpression of 
the antioxidant enzyme catalase and superoxidase dismutase (Mias et 
al, 2008). Moreover, in a rat model of AKI, melatonin preconditioning 
allowed the long-term survival of BM-MSCs within the damaged 
kidney improving angiogenesis, proliferation and recovery of renal 
function (Mias et al, 2008). Of note, the glial cell line-derived 
neurotrophic growth factor (GDNF), increased motility and survival of 
cultured MSCs and ameliorated acute renal damage (Shi et al, 2008).
Another important finding of this study is the anti-inflammatory 
effect of BM-MSC therapy that markedly reduced glomerular 
macrophage infiltration and local release of chemo-attractants, possibly 
involved in PEC-podocyte activation. The role of inflammation in the 
progression of chronic kidney disease is well known and there is broad 
agreement that fibrosis often follows inflammation and that both 
associate with a decline of renal function in CKD. The relationship 
between inflammation and fibrosis remains under debate. However, it 
is now becoming clear the impact of distinct macrophage phenotypes 
on "inflammation", "epithelial healing", "mesenchymal healing" and 
the "resolution of fibrosis" (Anders et al, 2011). At least four different 
types of macrophages should exist: proinflammatory macrophages, 
anti-inflammatory macrophages, profibrotic macrophages and fibrolytic 
macrophages (Anders et al, 2011). However, as the histomorphological 
abnormalities in CKD are complex, it remains difficult to dissect their
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presence in renal biopsies or their functional contribution to single 
disease. Much more work remains to be done to more clearly define 
functionally important macrophage phenotypes in the different stages 
of CKD. Equally, much work needs to be done to understand the effect 
of MSCs on macrophage-mediated inflammation.
In spite the BM-MSCs failed to improve renal function, our results 
demonstrated that BM-MSCs are able to create a pro-regenerative 
environment that restored glomerular architecture, limiting podocyte 
loss, endothelial dysfunction and moderating progenitor cell activation. 
Therefore, this study contributes to the advancement of knowledge in 
stem cell biology and provides a basis for a new therapeutic concept for 
the treatment of chronic kidney disease. Moreover, given the role of 
progenitor cells in the progression of the disease in chronic kidney 
injury future studies should investigate which mechanisms are induced 
by BM-MSCs to modulate renal progenitor cell activation.
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13.1 Contribution to the thesis by other researchers
Part of the thesis project was carried on with the collaboration of 
other researchers of the "Mario Negri" Institute in Bergamo that 
contributed to the research as follows:
- Real Time PCR experiments were performed together with Dr. Lorena 
Longaretti, Laboratory of Gene Therapy and Cellular Reprogramming, 
"Mario Negri" Institute.
- Animal care and treatments were conducted in collaboration with 
Daniela Coma, Unit of Experimental Models of Kidney Diseases, 
"Mario Negri" Institute.
- Technical assistance for electron microscopy was given by Daniela 
Rottoli, Unit of Pathologhy and Immunopathology, "Mario Negri" 
Institute.
- Western Blotting experiments were conducted in collaboration with 
Dr. Cristina Zanchi, Laboratory of Pathophysiology of Experimental 
Renal Disease and Interaction with other Organ systems, "Mario Negri" 
Institute.
- A great contribute to the project was given by Dr. Marina Morigi, 
head of the Laboratory of Cell Biology and Regenerative Medicine, the 
laboratory of Mario Negri Institute where the thesis was carried on. Dr. 
Morigi contributed to the work addressing research and supervising the 
progress of the study.
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All the other techniques and experiments described in this thesis were 
performed by the PhD student, Cinzia Rota.
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